+

US20060116395A1 - 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease - Google Patents

1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease Download PDF

Info

Publication number
US20060116395A1
US20060116395A1 US11/329,475 US32947506A US2006116395A1 US 20060116395 A1 US20060116395 A1 US 20060116395A1 US 32947506 A US32947506 A US 32947506A US 2006116395 A1 US2006116395 A1 US 2006116395A1
Authority
US
United States
Prior art keywords
azabicyclo
carboxamide
oct
pyrazole
pyrrole
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
US11/329,475
Inventor
David Piotrowski
Eric Jacobsen
Brad Acker
Daniel Walker
Donn Wishka
Vincent Groppi
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pfizer Inc
Original Assignee
Pfizer Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer Inc filed Critical Pfizer Inc
Priority to US11/329,475 priority Critical patent/US20060116395A1/en
Publication of US20060116395A1 publication Critical patent/US20060116395A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D453/00—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids
    • C07D453/02—Heterocyclic compounds containing quinuclidine or iso-quinuclidine ring systems, e.g. quinine alkaloids containing not further condensed quinuclidine ring systems

Definitions

  • Nicotinic acetylcholine receptors play a large role in central nervous system (CNS) activity. Particularly, they are known to be involved in cognition, learning, mood, emotion, and neuroprotection. There are several types of nicotinic acetylcholine receptors, and each one appears to have a different role in regulating CNS function. Nicotine affects all such receptors, and has a variety of activities. Unfortunately, not all of the activities are desirable. In fact, one of the least desirable properties of nicotine is its addictive nature and the low ratio between efficacy and safety.
  • the present invention relates to molecules that have a greater effect upon the ⁇ 7 nAChRs as compared to other closely related members of this large ligand-gated receptor family. Thus, the invention provides compounds that are active drug molecules with fewer side effects.
  • the invention also concerns the synthesis of and isolation of intermediates and final compounds. Specifically, the present invention concerns the preparation of 1H-pyrazole and 1H-pyrrole-azabicyclic compounds and pharmaceutically acceptable salts thereof.
  • U.S. Pat. No. 6,255,490 discloses 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands.
  • U.S. Pat. No. 6,117,889 discloses discloses 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents.
  • U.S. Pat. No. 6,060,473 discloses 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands.
  • U.S. Pat. No. 6,054,464 discloses azabicyclic esters of carbamic acids useful in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders, as well as intermediates and use of intermediates in synthesis.
  • U.S. Pat. No. 5,977,144 discloses compositions for benzylidene- and cinnamylidene-anabaseines and methods for using these compositions for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors. These compositions target the ⁇ 7 receptor subtype with little or no activation of the ⁇ 4 ⁇ 2 or other receptor subtypes.
  • U.S. Pat. No. 5,712,270 discloses a group of 2-aroylaminothiazole derivatives which bind to and stimulate central muscarinic acetylcholine receptors and are useful agents for treating symptoms of cognitive disorders, specifically the impaired memory associated with a decrease in the neurotransmitter, acetylcholine. Some of the compounds of this invention also bind to 5HT 1A receptors and dopamine D 2 receptors, making them useful as antipsychotic agents.
  • U.S. Pat. No. 5,624,941 discloses pyrazole derivatives useful in pharmaceuticals in which cannabis is known to be involved.
  • U.S. Pat. No. 5,561,149 discloses the use of a mono or bicyclic carbocyclic, or heterocyclic carboxylic, acid ester or amide or an imidazolyl carbazol in the manufacture of a medicament suitable for the treatment of stress-related psychiatric disorders, for increasing vigilance, for the treatment of rhinitis or serotonin-induced disorders and/or coadministration with another active agent to increase the bioavailability thereof, or for nasal administration.
  • U.S. Pat. No. 5,510,478 discloses a group of 2-aroylaminothiazole derivatives which bind to and stimulate central muscarinic acetylcholine receptors and are useful agents for treating symptoms of cognitive disorders, specifically the impaired memory associated with a decrease in the neurotransmitter, acetylcholine. Some of the compounds of this invention also bind to 5HT 1A receptors and dopamine D 2 receptors, making them useful as antipsychotic agents.
  • U.S. Pat. No. 5,342,845 discloses indole derivatives and drugs effective as gastrointestinal motor activity regulator, antimigraine, antipsychotic or antianxiety drugs.
  • U.S. Pat. No. 5,237,066 discloses enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their use as medicinal products having activity in respect of gastric movements and antiemetic activity.
  • U.S. Pat. No. 5,217,975 discloses azabicyclic compounds for treating dementia.
  • U.S. Pat. No. 5,206,246 discloses anxiolytic-R-N-(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof.
  • a preferred compound is R-(+)-4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.
  • U.S. Pat. No. 5,106,843 discloses heterocyclic compounds useful as 5-HT 3 antagonists.
  • U.S. Pat. No. 5,057,519 discloses 5-HT 3 antagonists as being useful in reducing opiate tolerance.
  • U.S. Pat. No. 5,039,680 discloses 5-HT 3 antagonists in preventing or reducing dependency on dependency-inducing agents.
  • U.S. Pat. No. 5,025,022 discloses a method of treating or preventing schizophrenia and/or psychosis using S-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof.
  • a preferred compound is S( ⁇ )-4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.
  • U.S. Pat. No. 5,017,580 discloses memory enhancing R-N-(1-azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof.
  • a preferred compound is R-(+)-4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.
  • U.S. Pat. No. 4,988,691 discloses isoxazole-containing compounds exhibiting anti-serotonin activity.
  • U.S. Pat. No. 4,835,162 discloses agonists and antagonists to nicotine as smoking deterrents.
  • U.S. Pat. No. 4,803,199 discloses pharmaceutically useful heterocyclic acid esters and amides or alkylene bridged peperidines as serotonin M antagonists.
  • U.S. Pat. No. 4,798,829 discloses 1-azabicyclo[3.2.2]nonane derivatives having gastric motility enhancing activity and/or anti-emetic activity and/or 5-HT receptor antagonist activity.
  • U.S. Pat. No. 4,789,673 discloses dicarboxylic, heterocyclic and substituted benzoic acid alkylene-bridged piperidyl amides and esters as being serotonin M antagonists.
  • U.S. Pat. No. 4,721,720 discloses a method of treating emesis, anxiety and/or irritable bowel syndrome.
  • U.S. Pat. No. 4,657,911 discloses 3-amino quinuclidine derivatives and the application thereof as accelerators of gastro-intestinal motor function and as medicament potentiators.
  • U.S. Pat. No. 4,605,652 discloses a method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes, and the pharmaceutically acceptable acid addition salts, hydrates and alcoholates thereof.
  • WO 01/76576 discloses a pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines.
  • WO 01/60821 discloses biarylcarboxamides.
  • WO 01/36417 A1 discloses N-azabicyclo-amide derivatives and use in therapy, especially in the treatment of prophylaxis of psychotic disorders and intellectual impairment disorders.
  • WO 01/29304 discloses quinuclidine acrylamides.
  • WO 00/73431 A2 discloses two binding assays to directly measure the affinity and selectivity of compounds at the ⁇ 7 nAChR and the 5-HT 3 R. The combined use of these functional and binding assays may be used to identify compounds that are selective agonists of the ⁇ 7 nAChR.
  • WO 92/15579 discloses multicyclic tertiary amine polyaromatic squalene synthase inhibitors and method of treatment for lowering serum cholesterol levels using the compounds.
  • WO 90/14347 A as abstracted in chemical abstract 1991:143,158 discloses N-quinuclidinyl-indolecarboxamide derivatives as being antiemetics.
  • FR 2 625 678 discloses N-(quinuclidin-3-yl)-benzamides and thiobenzamides useful as diet-control agents.
  • the brain ⁇ 7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease using DMXBA which is known as GTS-21.
  • nAChRs comprise a large family of ligand-gated ion channels that control neuronal activity and brain function. These receptors have a pentameric structure. In mammals, this gene family is composed of nine alpha and four beta subunits that co-assemble to form multiple subtypes of receptors that have a distinctive pharmacology. Acetylcholine is the endogenous regulator of all of the subtypes, while nicotine non-selectively activates all nAChRs.
  • the ⁇ 7 nAChR is one receptor system that has proved to be a difficult target for testing. Native ⁇ 7 nAChR is not routinely able to be stably expressed in most mammalian cell lines (Cooper and Millar, J. Neurochem., 1997, 68(5):2140-51). Another feature that makes functional assays of ⁇ 7 nAChR challenging is that the receptor is rapidly (100 milliseconds) inactivated. This rapid inactivation greatly limits the functional assays that can be used to measure channel activity.
  • Eisele et al. has indicated that a chimeric receptor formed between the N-terminal ligand binding domain of the ⁇ 7 nAChR (Eisele et al., Nature, 366(6454), p 479-83, 1993), and the pore forming C-terminal domain of the 5-HT 3 receptor expressed well in Xenopus oocytes while retaining nicotinic agonist sensitivity.
  • Eisele et al. used the N-terminus of the avian (chick) form of the ⁇ 7 nAChR receptor and the C-terminus of the mouse form of the 5-HT 3 gene.
  • ⁇ 7 nAChR is a calcium channel while the 5-HT 3 R is a sodium and potassium channel.
  • Eisele et al. teaches that the chicken ⁇ 7 nAChR/mouse 5-HT 3 R behaves quite differently than the native ⁇ 7 nAChR with the pore element not conducting calcium but actually being blocked by calcium ions.
  • WO 00/73431 A2 reports on assay conditions under which the 5-HT 3 R can be made to conduct calcium. This assay may be used to screen for agonist activity at this receptor.
  • the present invention discloses compounds of the Formula I: wherein Azabicyclo is W is wherein W 1 is N or CH;
  • X is O or S
  • R 0 is H, lower alkyl, substituted lower alkyl, or halogenated lower alkyl
  • R 1 is H, alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl;
  • R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
  • k 1 , k 2 , k 5 , k 6 , and k 7 are independently 0, or 1;
  • k 3 , and k 4 are independently 0, 1, or 2;
  • Each R 3 is independently F, Cl, Br, I, —CN, —NO 2 , alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocyloalkyl, substituted heterocycloalkyl, lactam heterocyclcoalkyl, aryl, R 7 , R 9 , —OR 10 , —SR 10 , —SOR 10 , —SO 2 R 10 , —SCN, —S(O)N(R 10 ) 2 , —S(O) 2 N(R 10 ) 2 , —C(O)R 10 , —C(O) 2 R 10 , —C(O)
  • n 0, 1, or 2;
  • R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR 8 , —SR 8 , —S(O) 2 R 8 , —S(O)R 8 , —OS(O) 2 R 8 , —N(R 8 ) 2 , —C(O)R 8 , —C(S)R 8 , —C(O)OR 8 , —CN, —C(O)N(R 8 ) 2 , —NR 8 C(O)R 8 , —S(O) 2 N(R 8 ) 2 , —NR 8 S(O) 2 R 8 , —NO 2 , —N(R 8 )C(O)N(R 8 ) 2 , substitute
  • Each R 5 is independently H, alkyl, or substituted alkyl
  • R 6 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, 1, —OH, —CN, —NH 2 , —NH(alkyl), or —N(alkyl) 2 ;
  • R 7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of —O—, ⁇ N—, —N(R 14 )—, and —S—, and having 0-1 substituent selected from R 15 , and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R 7 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula wherein A 1 is O, S, or NR 14 , wherein A is CR 17 or N, and each A 2 or A 3 is independently selected from CR 17 , O, S, N, or NR 14 , or wherein A is CR 17 or N, and each A 2 or A 3 is independently selected from CR 17 , O, S, N, or NR 14 , and, each 9-membered fused-ring moiety having 0-1 substituent selected from R 15
  • Each R 8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R 15 ;
  • R 9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from ⁇ N— and having 0-1 substituent selected from R 15 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R 9 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from ⁇ N—, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R 15 , and 0-3 substituent(s) independently selected from F, Cl, Br, or I and having a bond directly or indirectly attached to the core molecule where valency allows;
  • Each R 10 is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R 13 , cycloalkyl substituted with 1 substituent selected from R 13 , heterocycloalkyl substituted with 1 substituent selected from R 13 , halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;
  • Each R 11 is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;
  • R 12 is —NO 2 , —CN, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —C(O)N(R 11 ) 2 , —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , or —NR 11 S(O) 2 R 11 ;
  • R 13 is —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —SOR 11 , —SO 2 R 11 , —C(O)N(R 11 ) 2 , —CN, —CF 3 , —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , —NR 11 S(O) 2 R 11 , or —NO 2 ;
  • R 14 is independently H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;
  • R 15 is alkyl, substituted alkyl, halogenated alkyl, —OR 11 , —CN, —NO 2 , —N(R 10 ) 2 ;
  • R 17 is H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R 18 , —OR 11 , —SR 11 , —N(R 11 ) 2 , —NR 11 S(O) 2 R 11 , F, Cl, Br, or I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R 18 , —OR 11 , —SR 11 , —NR 11 R 11 , —C(O)R 11 , —NO 2 , —C(O
  • R 18 is alkyl, cycloalkyl, heterocycloalkyl, any of which is substituted with 0-3 substituents independently selected from F, Cl, Br, or I and further substituted with I substituent selected from —NO 2 , —CN, —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)NR 10 R 10 , —NR 10 C(O)R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , phenyl, or phenyl having 1 substituent selected from R 15 and further having 0-3 substituents independently selected from F, Cl, Br, or I;
  • the compounds of Formula I are used to treat any one of or combination of cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.
  • diseases such as Alzheimer's disease
  • Embodiments and aspects of the invention may include the following.
  • An embodiment of the present invention provides a method comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof or pharmaceutical composition containing said compound or salt thereof, to the mammal.
  • the compound of Formula I where any one of k 1 , k 2 , k 3 , k 4 , k 5 , k 6 , or k 7 is 1.
  • the compound of Formula I where any one of k 1 , k 2 , k 3 , k 4 , k 5 , k 6 , or k 7 is 0, this means R 2 is absent.
  • R 0 is H, lower alkyl, substituted lower alkyl, or halogenated lower alkyl
  • R 1 is H, alkyl, or cycloalkyl
  • each R 2 is independently absent, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl, or aryl.
  • the compound of Formula I, where Azabicyclo is any one or more or combination of the following: I, II, III, IV, V, VI, or VII.
  • each R 5 is independently H, lower alkyl, or substituted lower alkyl.
  • R 6 is H, or lower alkyl optionally substituted with up to 3 substituents independently selected from F, Cl, Br, I, —OH, —CN, —NH 2 , —NH(alkyl), or —N(alkyl) 2 .
  • R 5 is H and one R 5 is H or lower alkyl optionally substituted with 1 substituent selected from —CN, —NO 2 , —OR 10 , —SR 10 , —S(O)R 10 , —S(O) 2 R 10 , —OS(O) 2 R 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)OR 10 , —C(S)R 10 , —C(O)NR 10 R 10 , —NR 10 C(O)R 10 , —NR 10 C(O)NR 10 R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , or optionally substituted phenyl, provided that R 10 is H, lower alkyl, or halogenated lower alkyl, and further provided that when said lower alkyl is optionally substituted, said lower alkyl can be further optionally substituted with up to
  • R 10 of said substituents is H, lower alkyl or halogenated lower alkyl: —OR 10 , —SR 10 , —S(O)R 10 , —S(O) 2 R 10 , —OS(O) 2 R 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)OR 10 , —C(S)R 10 , —C(O)NR 10 R 10 , —NR 10 C(O)R 10 , —NR 10 C(O)NR 10 R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 .
  • Optionally substituted phenyl is phenyl optionally substituted with up to 3 substituents independently selected from F, Cl, Br, I, and R 13 and further optionally substituted with up to 1 substituent selected from R 15 .
  • Another group of compounds of Formula I includes compounds where each R 3 is absent.
  • Another group of compounds of Formula I includes compounds where each R 3 independently includes being absent and being any one of F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, substituted phenyl, —OR 10 , —SR 10 , —SOR 10 , —SO 2 R 10 , —NR 10 R 10 , —NO 2 , —C(O)R 10 , —CN, —C(O) 2 R 10 , —C(O)NR 10 R 10 , —SCN, —NR 10 C(O)R 10 , —S(O)NR 10 R 10 , —
  • Another group of compounds of Formula I includes compounds where each R 3 independently includes being absent and being any one of H, F, Cl, Br, I, alkyl, halogenated alkyl, —OR 10 , —SR 10 , —C(O)R 10 , —NO 2 , —CN, or —C(O)NR 10 R 10 .
  • R 4 includes any one of the following: H, F, Cl, Br, I, alkyl, halogenated alkyl, —OR 10 , —C(O)R 10 , —NO 2 , —CN, or —C(O)NR 10 R 10 .
  • Another group of compounds of Formula I includes compounds where W is 1H-pyrazol-1-yl, substituted at the four position with any one of the following: halogen, methyl, cyano, methylthio, aryl, R 7 or R 9 .
  • Another group of compounds of Formula I includes compounds where W is 1H-pyrazol-1-yl, substituted at the four position with phenyl optionally substituted whever valency allows with any one of the following: halogen, lower alkyl, or —O-(lower alkyl).
  • Another group of compounds of Formula I includes compounds where W is 1H-pyrazol-1-yl, substituted at the four position with thienyl or pyridinyl.
  • Another group of compounds of Formula I includes compounds where W is 1H-pyrrol-1-yl, substituted at the three position with any one of the following: halogen, methyl, cyano, methylthio, aryl, R 7 or R 9 .
  • Another group of compounds of Formula I includes compounds where W is 1H-pyrrol-1-yl, substituted at the three position with phenyl optionally substituted whever valency allows with any one of the following: halogen, lower alkyl, or —O-(lower alkyl).
  • Another group of compounds of Formula I includes compounds where W is 1H-pyrrol-1-yl, substituted at the three position with thienyl or pyridinyl.
  • Another group of compounds of Formula I includes any one or more or combination of the following as a free base or pharmaceutically acceptable salt thereof:
  • Another group of compounds of Formula I includes any one or more or combination of the following as a free base or pharmaceutically acceptable salt thereof:
  • the present invention also includes a pharmaceutical composition
  • a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient and optionally an anti-psychotic agent.
  • the pharmaceutical composition is administered rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval.
  • the pharmaceutical composition is administered to deliver a compound of Formula I in an amount of from about 0.001 to about 100 mg/kg of body weight of said mammal per day.
  • the pharmaceutical composition is also administered to deliver a compound of Formula I in an amount of from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
  • the present invention also includes a method to use a compound according to Formula I or pharmaceutically acceptable salt thereof by itself or optionally in combination with an anti-psychotic agent for treating, or preparing a medicament to treat, a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of ⁇ 7 nicotinic acetylcholine receptor agonist.
  • the present invention also includes a method to use a compound according to Formula I or pharmaceutically acceptable salt thereof by itself or optionally in combination with an anti-psychotic agent for treating, or preparing a medicament to treat, a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of ⁇ 7 nicotinic acetylcholine receptor agonist, and wherein the disease, or condition is any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington'
  • the invention also concerns the synthesis of and isolation of stereospecific intermediates and final compounds. Specifically, the present invention concerns the stereoselective synthesis of (3R,5R)-1-azabicyclo[3.2.1]octan-3-amine, or salts thereof. Although there are known procedures for making 1-azabicyclo[3.2.1]octan-3-amine, separation of the different stereoismers as described herein occurs without using a chiral HPLC separation procedure. The procedure within this invention results in an efficient selective synthesis of (3R,5R)-1-azabicyclo[3.2.1]octan-3-amine.
  • the present invention also includes the compounds of the present invention, pharmaceutical compositions containing the active compounds, and methods to treat the identified diseases.
  • the compounds of Formula I where Azabicyclo is I have optically active centers on the quinuclidine ring.
  • the compounds of the present invention include quinuclidines with the 2S, 3R configuration and also includes racemic mixtures and compositions of varying degrees of streochemical purities.
  • compounds of Formula I include compounds with stereospecificity including:
  • the compounds of Formula I where Azabicyclo is VII have optically active centers on the 7-azabicyclo[2.2.1]heptane ring which can exhibit a number of stereochemical configurations.
  • exo and endo are stereochemical prefixes that describe the relative configuration of a substituent on a bridge (not a bridgehead) of a bicyclic system. If a substituent is oriented toward the larger of the other bridges, it is endo. If a substituent is oriented toward the smaller bridge it is exo. Depending on the substitution on the carbon atoms, the endo and exo orientations can give rise to different stereoisomers.
  • the endo orientation gives rise to the possibility of a pair of enantiomers: either the 1S, 2S, 4R isomer or its enantiomer, the 1R, 2R, 4S isomer.
  • the exo orientation gives rise to the possibility of another pair of stereoisomers which are diastereomeric and C-2 epimeric with respect to the endo isomers: either the 1R, 2S, 4S isomer or its enantiomer, the 1S, 2R, 4R isomer.
  • the compounds of this invention exist in the exo orientation. For example, when R 2 is absent and each R 5 is H, the absolute stereochemistry is exo-(1S, 2R, 4R).
  • Stereoselective syntheses and/or subjecting the reaction product to appropriate purification steps produces substantially optically pure materials.
  • Suitable stereoselective synthetic procedures for producing optically pure materials are well known in the art, as are procedures for purifying racemic mixtures into optically pure fractions.
  • the compounds of the present invention have the exo orientation at the C-2 carbon and S configuration at the C-1 carbon and the R configuration at the C-2 and the C-4 carbons of the 7-azabicyclo[2.2.1]heptane ring.
  • the inventive compounds exhibit much higher activity relative to compounds lacking the exo, 1S, 2R, and 4R stereochemistry.
  • the ratio of activities for compounds having the exo, 1S, 2R, and 4R configuration to other stereochemical configurations may be greater than about 100. Although it is desirable that the stereochemical purity be as high as possible, absolute purity is not required.
  • compositions can include one or more compounds, each having an exo, 1S, 2R, and 4R configuration, or mixtures of compounds having exo, 1S, 2R, and 4R and other configurations.
  • those species possessing stereochemical configurations other than exo, 1S, 2R, and 4R act as diluents and tend to lower the activity of the pharmaceutical composition.
  • pharmaceutical compositions including mixtures of compounds possess a larger percentage of species having the exo, 1S, 2R, and 4R configuration relative to other configurations.
  • the compounds of Formula I (Azabicyclo is II) have optically active center(s) on the [2.2.1] azabicyclic ring at C3 and C4.
  • the scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being endo-4S, endo-4R, exo-4S, exo-4R:
  • the endo isomer is the isomer where the non-hydrogen substituent at C3 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges.
  • the exo isomer is the isomer where the non-hydrogen substituent at C3 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges.
  • the compounds of Formula I (Azabicyclo is III) have optically active center(s) on the [3.2.1] azabicyclic ring at C3 and C5.
  • the scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being endo-3S, 5R, endo-3R, 5S, exo-3R, 5R, exo-3S, 5S:
  • the compounds of Formula I (Azabicyclo is TV) have optically active centers on the [3.2.2] azabicyclic ring with one center being at C3 when R 2 is absent.
  • the scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being 3(S) and 3(R):
  • the compounds of Formula I (Azabicyclo V) have optically active center(s) on the [2.2.1] azabicyclic ring at C1, C4 and C5.
  • the scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being (1R,4R,5S), (1R,4R,5R), (1S,4S,5R), (1S,4S,5S):
  • the endo isomer is the isomer where the non-hydrogen substituent at C5 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges.
  • the exo isomer is the isomer where the non-hydrogen substituent at C5 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges.
  • the compounds of Formula I (Azabicyclo VI) have optically active center(s) on the [2.2.1] azabicyclic ring at C1, C4 and C6.
  • the scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being exo-(1S,4R,6S), exo-(1R,4S,6R), endo-(1S,4R,6R), and endo-(1R,4S,6S):
  • the endo isomer is the isomer where the non-hydrogen substituent at C6 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges.
  • the exo isomer is the isomer where the non-hydrogen substituent at C6 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges.
  • the compounds of the present invention having the specified stereochemistry have different levels of activity and that for a given set of values for the variable substitutuents one isomer may be preferred over the other isomers. Although it is desirable that the stereochemical purity be as high as possible, absolute purity is not required.
  • This invention involves racemic mixtures and compositions of varying degrees of streochemical purities when R 2 is absent and when R 2 is present (a substituent rather than H).
  • This invention involves racemic mixtures and compositions of varying degrees of streochemical purities. It is preferred to carry out stereoselective syntheses and/or to subject the reaction product to appropriate purification steps so as to produce substantially optically pure materials. Suitable stereoselective synthetic procedures for producing optically pure materials are well known in the art, as are procedures for purifying racemic mixtures into optically pure fractions.
  • R 2 is absent (k 1 is 0) and where the compound is a racemic mixture, or (ii) R 2 is absent and where the compound is has the R stereochemistry at C-3 as discussed herein.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds where Azabicyclo is: where (i) R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl and where the compound is a racemic mixture;
  • R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl and where the compound is a racemic mixture; or
  • R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl and where the compound has the 3R, 2S stereochemistry as discussed herein, respectively.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds where Azabicyclo is: where (i) R 2 is absent (k 2 is 0);
  • R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, respectively.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds wherein Azabicyclo is where (i) R 2 is absent (k 3 is 0);
  • R 2 is absent and where the Azabicyclo has the stereochemistry of 3R, 5R;
  • R 2 is R 2-a and R 2-b , where R 2-a is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, and where R 2-b is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
  • R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, respectively.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds wherein Azabicyclo is where (i) R 2 is absent (k 4 is 0);
  • R 2 is R 2-a and R 2-b , R 2-a is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl and where each R 2-b is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
  • R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, respectively.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds where Azabicyclo is: where (i) R 2 is absent (k 5 is 0);
  • R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • R 2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, respectively.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds where Azabicyclo is: where (i) R 2 is absent (k 6 is 0);
  • R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, respectively.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds where Azabicyclo is:
  • R 2 is absent (k 7 is 0), and each R 5 may independently be H, alkyl, or substituted alkyl, and where R 6 is any one of H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents independently selected from F, Cl, Br, I, —OH, —CN, —NH 2 , —NH(alkyl), or —N(alkyl) 2 , and where the 7-azabicyclo[2.2.1]heptane ring moiety has the 1S, 2R, 4R stereochemistry; or
  • R 2 is alkyl, or substituted alkyl, and where each R 5 may independently be H, alkyl, or substituted alkyl, and where R 6 is any one of H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, —OH, —CN, —NH 2 , —NH(alkyl), or —N(alkyl) 2 , and where the 7-azabicyclo[2.2.1]heptane ring moiety has the 1S, 2R, 4R stereochemistry, respectively.
  • the azabicyclic moiety of Formula I is connected to W by a urea or thiourea linkage.
  • This type of linkage imparts different physical properties to the compounds compared to the corresponding amide or thioamide.
  • the different physical properties offer advantages in ease of formulation, reduced toxicity or a different metabolism profile.
  • Another group of compounds of Formula I includes compounds where W is any one or more or combination of the following: where R 3 has any definition as described herein.
  • Another group of compounds of Formula I includes compounds where W is any one or more or combination of the following: where R 4 has any definition as described herein, and where n is 0, 1, 2, or 3.
  • Another group of compounds of Formula I includes compounds where W is a three-fused ring moiety and includes any one of the following:
  • the three-fused ring moiety is composed of a five-membered ring fused to a middle 6-membered ring fused to a terminal 6-membered ring.
  • the middle 6-membered ring and the terminal 6-membered ring are each optionally substituted with one substituent selected from Br, Cl, F, I, —CN, —NO 2 , —CF 3 , —N(R 8 ) 2 , —N(R 8 )C(O)R 8 , alkyl, alkenyl, and alkynyl.
  • X is O or S
  • R 0 is H, lower alkyl, substituted lower alkyl, or halogenated lower alkyl
  • Lower alkyl is both straight- and branched-chain moieties having 1-4 carbon atoms
  • Substituted lower alkyl is lower alkyl having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R 7 , R 9 , —NO 2 , —CN, —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)NR 10 R 10 , —NR 10 C(O)R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , phenyl, or phenyl having 1 substituent selected from R 15 and further having 0-3 substituents independently selected from F, Cl, Br, or I;
  • Halogenated lower alkyl is lower alkyl having 1 to (2n+1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • R 1 is H, alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl;
  • Alkyl is both straight- and branched-chain moieties having from 1-6 carbon atoms
  • Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having 1 to (2n+1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms
  • Substituted phenyl is a phenyl either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from R 12 and 0-3 substituents independently selected from F, Cl, Br, or I;
  • Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from R 12 and 0-3 substituents independently selected from F, Cl, Br, or I, where the substitution can be independently on either only one ring or both rings of said naphthalene moiety;
  • R 2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
  • k 1 , k 2 , k 5 , k 6 , and k 7 are independently 0, or 1;
  • k 3 , and k 4 are independently 0, 1, or 2;
  • Substituted alkyl is an alkyl moiety from 1-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R 7 , R 9 , —NO 2 , —CN, —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(S)R 10 , —C(O)OR 10 , —C(O)N(R 10 ) 2 , —NR 10 C(O)R 10 , —NR 10 C(O)R 10 N(R 10 ) 2 , —NR 10 S(O) 2 R 10 , —S(O)R 10 , —S(O)OR 10 , —OS(O) 2 R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , phenyl, or phenyl having 0-3 substituents independently selected from
  • Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl;
  • Each R 3 is independently F, Cl, Br, I, —CN, —NO 2 , alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocyloalkyl, substituted heterocycloalkyl, lactam heterocyclcoalkyl, aryl, R 7 , R 9 , —OR 10 , —SR 10 , —SOR 10 , —SO 2 R 10 , —SCN, —S(O)N(R 10 ) 2 , —S(O) 2 N(R 10 ) 2 , —C(O)R 10 , —C(O) 2 R 10 , —C(O)
  • n 0, 1, or 2;
  • Alkenyl is straight- and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond;
  • Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n ⁇ 1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R 7 , R 9 , —NO 2 , —CN, —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(S)R 10 , —C(O)OR 10 , —C(O)N(R 10 ) 2 , —NR 10 C(O)R 10 , —NR 10 C(O)R 10 N(R 10 ) 2 , —NR 10 S(O) 2 R 10 , —S(O)R 10 , —S(O)OR 10 , —OS(O) 2 R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , phenyl, or phenyl having 0-3
  • Alkynyl is straight- and branched-chained moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond;
  • Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n ⁇ 3) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R 7 , R 9 , —NO 2 , —CN, —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(S)R 10 , —C(O)OR 10 , —C(O)N(R 10 ) 2 , —NR 10 C(O)R 10 , —NR 10 C(O)R 10 N(R 10 ) 2 , —NR 10 S(O) 2 R 10 , —S(O)R 10 , —S(O)OR 10 , —OS(O) 2 R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , phenyl, or phenyl having
  • Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from F, or Cl;
  • Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R 7 , R 9 , —NO 2 , —CN, —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(S)R 10 , —C(O)OR 10 , —C(O)N(R 10 ) 2 , —NR 10 C(O)R 10 , —NR 10 C(O)R 10 N(R 10 ) 2 , —NR 10 S(O) 2 R 10 , —S(O)R 10 , —S(O)OR 10 , —OS(O) 2 R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , phenyl, or phenyl having 0-3 substitu
  • Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being —S—, —N(R 19 )—, or —O—;
  • Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being —S—, —N(R 19 )—, or —O—, and having 1-4 substituents independently selected from F, or Cl;
  • Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being —S—, —N(R 19 )—, or —O— and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R 7 , R 9 , —NO 2 , —CN, —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(S)R 10 , —C(O)OR 10 , —C(O)N(R 10 ) 2 , —NR 10 C(O)R 10 , —NR 10 C(O)R 10 N(R 10 ) 2 , —NR 10 S(O) 2 R 10 , —S(O)R 10 , —S(O)OR 10 , —OS(O) 2 R 10 , —S(O) 2 NR 10 R 10
  • Lactam heterocycloalkyl is a cyclic moiety having from 4-7 atoms with one atom being only nitrogen with the bond to the lactam heterocycloalkyl thru said atom being only nitrogen and having a ⁇ O on a carbon adjacent to said nitrogen, and having up to 1 additional ring atom being oxygen, sulfur, or nitrogen and further having 0-2 substituents selected from F, Cl, Br, I, or R 15 where valency allows;
  • R 4 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR 8 , —SR 8 , —S(O) 2 R 8 , —S(O)R 8 , —OS(O) 2 R 8 , —N(R 8 ) 2 , —C(O)R 8 , —C(S)R 8 , —C(O)OR 8 , —CN, —C(O)N(R 8 ) 2 , —NR 8 C(O)R 8 , —S(O) 2 N(R 8 ) 2 , —NR 8 S(O) 2 R 8 , —NO 2 , —N(R 8 )C(O)N(R 8 ) 2 , substitute
  • Each R 5 is independently H, alkyl, or substituted alkyl
  • R 6 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, —OH, —CN, —NH 2 , —NH(alkyl), or —N(alkyl) 2 ;
  • R 7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of —O—, ⁇ N—, —N(R 14 )—, and —S—, and having 0-1 substituent selected from R 15 , and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R 7 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula wherein A 1 is O, S, or NR 14 , wherein A is CR 17 or N, and each A 2 or A 3 is independently selected from CR 17 , O, S, N, or NR 14 , or wherein A is CR 17 or N, and each A 2 or A 3 is independently selected from CR 17 , O, S, N, or NR 14 , and, each 9-membered fused-ring moiety having 0-1 substituent selected from R 15
  • Each R 8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R 15 ;
  • R 9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from ⁇ N— and having 0-1 substituent selected from R 15 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R 9 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from ⁇ N—, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R 15 , and 0-3 substituent(s) independently selected from F, Cl, Br, or I and having a bond directly or indirectly attached to the core molecule where valency allows;
  • Each R 10 is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R 13 , cycloalkyl substituted with 1 substituent selected from R 13 , heterocycloalkyl substituted with 1 substituent selected from R 13 , halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;
  • Each R 11 is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;
  • R 12 is —NO 2 , —CN, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —C(O)N(R 11 ) 2 , —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , or —NR 11 S(O) 2 R 11 ;
  • R 13 is —OR 11 , —SR 11 , —N(R 11 ) 2 , —C(O)R 11 , —SOR 11 , —SO 2 R 11 , —C(O)N(R 11 ) 2 , —CN, —CF 3 , —NR 11 C(O)R 11 , —S(O) 2 N(R 11 ) 2 , —NR 11 S(O) 2 R 11 , or —NO 2 ;
  • R 14 is independently H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;
  • R 15 is alkyl, substituted alkyl, halogenated alkyl, —OR 11 , —CN, —NO 2 , —N(R 10 ) 2 ;
  • R 17 is H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R 18 , —OR 11 , —SR 11 , —N(R 11 ) 2 , —NR 11 S(O) 2 R 1 , F, Cl, Br, or I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R 18 , —OR 11 , —SR 11 , —NR 11 R 11 , —C(O)R 11 , —NO 2 , —C(O
  • R 18 is alkyl, cycloalkyl, heterocycloalkyl, any of which is substituted with 0-3 substituents independently selected from F, Cl, Br, or I and further substituted with 1 substituent selected from —NO 2 , —CN, —OR 10 , —SR 10 , —NR 10 R 10 , —C(O)R 10 , —C(O)NR 10 R 10 , —NR 10 C(O)R 10 , —S(O) 2 NR 10 R 10 , —NR 10 S(O) 2 R 10 , phenyl, or phenyl having 1 substituent selected from R 15 and further having 0-3 substituents independently selected from F, Cl, Br, or I;
  • R 19 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 0-4 substituents independently selected from F, Cl, Br, I, and R 15 ;
  • Alzheimer's disease pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or
  • the invention includes methods of treating a mammal suffering from schizophrenia or psychosis by administering compounds of Formula I in conjunction with antipsychotic drugs.
  • the compounds of Formula I and the antipsychotic drugs can be administered simultaneously or at separate intervals.
  • the compounds of Formula I and the antipsychotic drugs can be incorporated into a single pharmaceutical composition.
  • two separate compositions i.e., one containing compounds of Formula I and the other containing antipsychotic drugs, can be administered simultaneously.
  • the present invention also includes the intermediates, the processes to make them and the active compounds of Formula I, pharmaceutical compositions including the active compounds, and methods to treat the identified diseases.
  • Room temperature is within the range of 15-25 degrees Celsius.
  • AChR refers to acetylcholine receptor.
  • nAChR refers to nicotinic acetylcholine receptor.
  • Pre-senile dementia is also known as mild cognitive impairment.
  • 5HT 3 R refers to the serotonin-type 3 receptor.
  • ⁇ -btx refers to ⁇ -bungarotoxin.
  • FLIPR refers to a device marketed by Molecular Devices, Inc. designed to precisely measure cellular fluorescence in a high throughput whole-cell assay. (Schroeder et. al., J. Biomolecular Screening, 1(2), p 75-80, 1996).
  • TLC refers to thin-layer chromatography
  • HPLC refers to high pressure liquid chromatography.
  • MeOH refers to methanol
  • EtOH refers to ethanol
  • IPA refers to isopropyl alcohol.
  • THF refers to tetrahydrofuran
  • DMSO dimethylsulfoxide
  • DMF refers to N,N-dimethylformamide.
  • EtOAc refers to ethyl acetate.
  • TMS refers to tetramethylsilane.
  • TEA refers to triethylamine
  • DIEA refers to N,N-diisopropylethylamine.
  • MLA refers to methyllycaconitine
  • Ether refers to diethyl ether.
  • HATU refers to O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate.
  • DBU refers to 1,8-diazobicyclo[5.4.0]undec-7-one.
  • CDI refers to carbonyl diimidazole.
  • NMO refers to N-methylmorpholine-N-oxide.
  • TPAP refers to tetrapropylammonium perruthenate.
  • Halogen is F, Cl, Br, or I.
  • C i-j indicates a moiety of the integer “i” to the integer “j” carbon atoms, inclusive.
  • C 1-6 alkyl refers to alkyl of one to six carbon atoms.
  • alkyl, halogenated alkyl, or substituted alkyl is allowed, lower alkyl, halogenated lower alkyl and substituted lower alkyl would also be allowed, respectively.
  • Non-inclusive examples of heteroaryl compounds that fall within the definitions of R 7 and R 9 include, but are not limited to, thienyl, benzothienyl, pyridyl, thiazolyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, pyrrolyl, isoquinolinyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pydridazinyl, triazinyl, isoindolyl, purinyl, oxadiazoly
  • benzofuranyl includes 1-benzofuran-2-yl, 1-benzofuran-3-yl, 1-benzofuran-4-yl, 1-benzofuran-5-yl, 1-benzofuran-6-yl, 1-benzofuran-7-yl, 2-benzofuran-1-yl, 2-benzofuran-2-yl, 2-benzofuran-3-yl, 2-benzofuran-4-yl, or 2-benzofuran-5-yl.
  • the non-inclusive examples of R 7 and R 9 may be substituted as allowed within the respective definition of R 7 and R 9 as valency allows.
  • One of ordinary skill in the art can identify the allowed substitution by comparing the non-inclusive examples with the respective definitions of R 7 and R 9 .
  • heterocycloalkyl examples include, but are not limited to, tetrahydrofurano, tetrahydropyrano, morpholino, pyrrolidino, piperidino, piperazine, azetidino, azetidinono, oxindolo, dihydroimidazolo, pyrrolidino, or isoxazolinyl.
  • Mammal denotes human and other mammals.
  • Brine refers to an aqueous saturated sodium chloride solution.
  • Equ means molar equivalents.
  • IR refers to infrared spectroscopy.
  • Lv refers to leaving groups within a molecule, including Cl, OH, or mixed anhydride.
  • NMR nuclear (proton) magnetic resonance spectroscopy
  • MS refers to mass spectrometry expressed as m/e or mass/charge unit.
  • HRMS refers to high resolution mass spectrometry expressed as m/e or mass/charge unit.
  • [M+H] + refers to an ion composed of the parent plus a proton.
  • [M ⁇ H] ⁇ refers to an ion composed of the parent minus a proton.
  • [M+Na] + refers to an ion composed of the parent plus a sodium ion.
  • [M+K] + refers to an ion composed of the parent plus a potassium ion.
  • EI refers to electron impact.
  • ESI refers to electrospray ionization.
  • CI refers to chemical ionization.
  • FAB refers to fast atom bombardment.
  • Amino protecting group includes, but is not limited to, carbobenzyloxy (CBz), tert butoxy carbonyl (BOC) and the like. Examples of other suitable amino protecting groups are known to person skilled in the art and can be found in “Protective Groups in Organic synthesis,” 3rd Edition, authored by Theodora Greene and Peter Wuts.
  • compositions of the present invention may be in the form of pharmaceutically acceptable salts.
  • pharmaceutically acceptable salts refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases, and salts prepared from inorganic acids, and organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, ferric, ferrous, lithium, magnesium, potassium, sodium, zinc, and the like.
  • Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and the like.
  • cyclic amines such as arginine, betaine, caffeine, choline, N,N-
  • Salts derived from inorganic acids include salts of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, phosphorous acid and the like.
  • Salts derived from pharmaceutically acceptable organic non-toxic acids include salts of C 1-6 alkyl carboxylic acids, di-carboxylic acids, and tri-carboxylic acids such as acetic acid, propionic acid, fumaric acid, succinic acid, tartaric acid, maleic acid, adipic acid, and citric acid, and aryl and alkyl sulfonic acids such as toluene sulfonic acids and the like.
  • an effective amount of a compound as provided herein is meant a nontoxic but sufficient amount of the compound(s) to provide the desired effect.
  • the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease that is being treated, the particular compound(s) used, the mode of administration, and the like. Thus, it is not possible to specify an exact “effective amount.” However, an appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation.
  • the amount of therapeutically effective compound(s) that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound(s) employed, and thus may vary widely.
  • the compositions contain well know carriers and excipients in addition to a therapeutically effective amount of compounds of Formula I.
  • the pharmaceutical compositions may contain active ingredient in the range of about 0.001 to 100 mg/kg/day for an adult, preferably in the range of about 0.1 to 50 mg/kg/day for an adult. A total daily dose of about 1 to 1000 mg of active ingredient may be appropriate for an adult.
  • the daily dose can be administered in one to four doses per day.
  • the composition for therapeutic use may also comprise one or more non-toxic, pharmaceutically acceptable carrier materials or excipients.
  • carrier material or excipient herein means any substance, not itself a therapeutic agent, used as a carrier and/or diluent and/or adjuvant, or vehicle for delivery of a therapeutic agent to a subject or added to a pharmaceutical composition to improve its handling or storage properties or to permit or facilitate formation of a dose unit of the composition into a discrete article such as a capsule or tablet suitable for oral administration.
  • Excipients can include, by way of illustration and not limitation, diluents, disintegrants, binding agents, adhesives, wetting agents, polymers, lubricants, glidants, substances added to mask or counteract a disagreeable taste or odor, flavors, dyes, fragrances, and substances added to improve appearance of the composition.
  • Acceptable excipients include lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinyl-pyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration.
  • Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropyl-methyl cellulose, or other methods known to those skilled in the art.
  • the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. If desired, other active ingredients may be included in the composition.
  • compositions of the present invention may be administered by any suitable route, in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended.
  • the compositions may, for example, be administered parenterally, e.g., intravascularly, intraperitoneally, subcutaneously, or intramuscularly.
  • parenteral administration e.g., saline solution, dextrose solution, or water may be used as a suitable carrier.
  • Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions.
  • solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration.
  • the compounds may be dissolved in water, polyethylene glycol, propylene glycol, EtOH, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers.
  • Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
  • the serotonin type 3 receptor is a member of a superfamily of ligand-gated ion channels, which includes the muscle and neuronal nAChR, the glycine receptor, and the ⁇ -aminobutyric acid type A receptor. Like the other members of this receptor superfamily, the 5HT 3 R exhibits a large degree of sequence homology with ⁇ 7 nAChR but functionally the two ligand-gated ion channels are very different. For example, ⁇ 7 nAChR is rapidly inactivated, is highly permeable to calcium and is activated by acetylcholine and nicotine.
  • 5HT 3 R is inactivated slowly, is relatively impermeable to calcium and is activated by serotonin.
  • ⁇ 7 nAChR is a ligand-gated Ca ++ channel formed by a homopentamer of ⁇ 7 subunits.
  • ⁇ -bungarotoxin ⁇ -btx
  • MVA methyllycaconitine
  • ⁇ 7 nAChR is expressed at high levels in the hippocampus, ventral tegmental area and ascending cholinergic projections from nucleus basilis to thalamocortical areas.
  • ⁇ 7 nAChR agonists increase neurotransmitter release, and increase cognition, arousal, attention, learning and memory.
  • ABT-418 a compound that activates ⁇ 4 ⁇ 2 and ⁇ 7 nAChR, improves cognition and attention in clinical trials of Alzheimer's disease and attention-deficit disorders (Potter, A. et.
  • Schizophrenia is a complex multifactorial illness caused by genetic and non-genetic risk factors that produce a constellation of positive and negative symptoms.
  • the positive symptoms include delusions and hallucinations and the negative symptoms include deficits in affect, attention, cognition and information processing. No single biological element has emerged as a dominant pathogenic factor in this disease. Indeed, it is likely that schizophrenia is a syndrome that is produced by the combination of many low penetrance risk factors.
  • Pharmacological studies established that dopamine receptor antagonists are efficacious in treating the overt psychotic features (positive symptoms) of schizophrenia such as hallucinations and delusions.
  • Clozapine an “atypical” antipsychotic drug, is novel because it is effective in treating both the positive and some of the negative symptoms of this disease.
  • Clozapine's utility as a drug is greatly limited because continued use leads to an increased risk of agranulocytosis and seizure.
  • No other antipsychotic drug is effective in treating the negative symptoms of schizophrenia. This is significant because the restoration of cognitive functioning is the best predictor of a successful clinical and functional outcome of schizophrenic patients (Green, M. F., Am J Psychiatry, 153:321-30, 1996).
  • it is clear that better drugs are needed to treat the cognitive disorders of schizophrenia in order to restore a better state of mental health to patients with this disorder.
  • One aspect of the cognitive deficit of schizophrenia can be measured by using the auditory event-related potential (P50) test of sensory gating.
  • P50 auditory event-related potential
  • EEG electroencepholographic
  • Normal individuals respond to the first click with greater degree than to the second click.
  • schizophrenics and schizotypal patients respond to both clicks nearly the same (Cullum, C. M. et. al., Schizophr. Res., 10:13141, 1993).
  • biochemical data indicate that schizophrenics have 50% fewer of ⁇ 7 nAChR receptors in the hippocampus, thus giving a rationale to partial loss of ⁇ 7 nAChR functionality (Freedman, R. et. al., Biol. Psychiatry, 38:22-33, 1995).
  • genetic data indicate that a polymorphism in the promoter region of the ⁇ 7 nAChR gene is strongly associated with the sensory gating deficit in schizophrenia (Freedman, R. et. al., Proc. Nat'l Acad. Sci. USA, 94(2):587-92, 1997; Myles-Worsley, M. et. al., Am. J. Med.
  • schizophrenics express the same ⁇ 7 nAChR as non-schizophrenics.
  • Selective ⁇ 7 nAChR agonists may be found using a functional assay on FLIPR (see WO 00/73431 A2).
  • FLIPR is designed to read the fluorescent signal from each well of a 96 or 384 well plate as fast as twice a second for up to 30 minutes.
  • This assay may be used to accurately measure the functional pharmacology of ⁇ 7 nAChR and 5HT 3 R.
  • To conduct such an assay one uses cell lines that expressed functional forms of the ⁇ 7 nAChR using the ⁇ 7/5-HT 3 channel as the drug target and cell lines that expressed functional 5HT 3 R. In both cases, the ligand-gated ion channel was expressed in SH-EP1 cells. Both ion channels can produce robust signal in the FLIPR assay.
  • the compounds of the present invention are ⁇ 7 nAChR agonists and may be used to treat a wide variety of diseases. For example, they may be used in treating schizophrenia, or psychosis.
  • Schizophrenia is a disease having multiple aspects.
  • drugs are generally aimed at controlling the positive aspects of schizophrenia, such as delusions.
  • One drug, Clozapine is aimed at a broader spectrum of symptoms associated with schizophrenia. This drug has many side effects and is thus not suitable for many patients.
  • a drug to treat the cognitive and attention deficits associated with schizophrenia.
  • schizoaffective disorders or similar symptoms found in the relatives of schizophrenic patients.
  • Psychosis is a mental disorder characterized by gross impairment in the patient's perception of reality.
  • the patient may suffer from delusions, and hallucinations, and may be incoherent in speech. His behavior may be agitated and is often incomprehensible to those around him.
  • psychosis has been applied to many conditions that do not meet the stricter definition given above. For example, mood disorders were named as psychoses.
  • the conventional antipsychotic drugs include Chlorpromazine, Fluphenazine, Haloperidol, Loxapine, Mesoridazine, Molindone, Perphenazine, Pimozide, Thioridazine, Thiothixene, and Trifluoperazine. These drugs all have an affinity for the dopamine 2 receptor.
  • Atypical antipsychotic drugs generally are able to alleviate positive symptoms of psychosis while also improving negative symptoms of the psychosis to a greater degree than conventional antipsychotics. These drugs may improve neurocognitive deficits. Extrapyramidal (motor) side effects are not as likely to occur with the atypical antipsychotic drugs, and thus, these atypical antipsychotic drugs have a lower risk of producing tardive dyskinesia. Finally these atypical antipsychotic drugs cause little or no elevation of prolactin. Unfortunately, these drugs are not free of side effects.
  • the side effects include: agranulocytosis; increased risk of seizures, weight gain, somnolence, dizziness, tachycardia, decreased ejaculatory volume, and mild prolongation of QTc interval.
  • the compounds of Formula I and the anti-psychotic drugs can be administered simultaneously or at separate intervals.
  • the compounds of Formula I and the anti-psychotic drugs can be incorporated into a single pharmaceutical composition, e.g., a pharmaceutical combination therapy composition.
  • two separate compositions i.e., one containing compounds of Formula I and the other containing anti-psychotic drugs, can be administered simultaneously.
  • anti-psychotic drugs include, but are not limited to, Thorazine, Mellaril, Trilafon, Navane, Stelazine, Permitil, Prolixin, Risperdal, Zyprexa, Seroquel, ZELDOX, Acetophenazine, Carphenazine, Chlorprothixene, Droperidol, Loxapine, Mesoridazine, Molindone, Ondansetron, Pimozide, Prochlorperazine, and Promazine.
  • a pharmaceutical combination therapy composition can include therapeutically effective amounts of the compounds of Formula I, noted above, and a therapeutically effective amount of anti-psychotic drugs. These compositions may be formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated elixirs or solutions for convenient oral administration or administered by intramuscular intravenous routes. The compounds can be administered rectally, topically, orally, sublingually, or parenterally and may be formulated as sustained relief dosage forms and the like.
  • compositions containing compounds of Formula I and anti-psychotic drugs are administered on a different schedule.
  • One may be administered before the other as long as the time between the two administrations falls within a therapeutically effective interval.
  • a therapeutically effective interval is a period of time beginning when one of either (a) the compounds of Formula I, or (b) the anti-psychotic drugs is administered to a human and ending at the limit of the beneficial effect in the treatment of schizophrenia or psychosis of the combination of (a) and (b).
  • the methods of administration of the compounds of Formula I and the anti-psychotic drugs may vary. Thus, either agent or both agents may be administered rectally, topically, orally, sublingually, or parenterally.
  • the compounds of the present invention are ⁇ 7 nAChR agonists. Therefore, as another aspect of the present invention, the compounds of the present invention may be used to treat a variety of diseases including cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (also known as mild cognitive impairment), and senile dementia.
  • diseases including cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (also known as mild cognitive impairment), and senile dementia.
  • Alzheimer's disease has many aspects, including cognitive and attention deficits.
  • these deficits are treated with cholinesterase inhibitors. These inhibitors slow the break down of acetylcholine, and thereby provide a general nonspecific increase in the activity of the cholinergic nervous system. Since the drugs are nonspecific, they have a wide variety of side effects.
  • Neurodegeneration is a common problem associated with diseases such as Alzheimer's disease. While the current drugs treat some of the symptoms of this disease, they do not control the underlying pathology of the disease. Accordingly, it would be desirable to provide a drug that can slow the progress of Alzheimer's disease.
  • Pre-senile dementia (mild cognitive impairment) concerns memory impairment rather than attention deficit problems and otherwise unimpaired cognitive functioning. Mild cognitive impairment is distinguished from senile dementia in that mild cognitive impairment involves a more persistent and troublesome problem of memory loss for the age of the patient. There currently is no medication specifically identified for treatment of mild cognitive impairment, due somewhat to the newness of identifying the disease. Therefore, there is a need for a drug to treat the memory problems associated with mild cognitive impairment.
  • Senile dementia is not a single disease state. However, the conditions classified under this name frequently include cognitive and attention deficits. Generally, these deficits are not treated. Accordingly, there is a need for a drug that provides improvement in the cognitive and attention deficits associated with senile dementia.
  • the compounds of the present invention are ⁇ 7 nAChR agonists. Therefore, yet other diseases to be treated with compounds of the present invention include treating the cognitive and attention deficits as well as the neurodegeneration associated with any one or more or combination of the following: attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.
  • attention deficit disorder attention deficit hyperactivity disorder
  • Attention deficit disorder is generally treated with methylphenidate, an amphetamine-like molecule that has some potential for abuse. Accordingly, it would be desirable to provide a drug that treats attention deficit disorder while having fewer side effects than the currently used drug.
  • ADHD Attention deficit hyperactivity disorder
  • Treatment may include medications such as methylphenidate, dextroamphetamine, or pemoline, which act to decrease impulsivity and hyperactivity and to increase attention. No “cure” for ADHD currently exists. Children with the disorder seldom outgrow it; therefore, there is a need for appropriate medicaments.
  • HCA heterocyclic antidepressants
  • MAOI's monoamine oxidase inhibitors
  • Common side effects from HCA's are sedation and weight gain. In elderly patients with organic brain disease, the side effects from HCA's can also include seizures and behavioral symptoms. The main side effects from using MAOI's occur from dietary and drug interactions. Therefore, agents with fewer side effects would be useful.
  • Anxiety disorders (disorders with prominent anxiety or phobic avoidance), represent an area of umet medical needs in the treatment of psychiatric illness. See Diagnostic & Statistical Manual of Mental Disorders, IV (1994), pp 393-394, for various disease forms of anxiety.
  • GAD General anxiety disorder
  • Anxiety also includes post-traumatic stress disorder (PTSD), which is a form of anxiety triggered by memories of a traumatic event that directly affected the patient or that the patient may have witnessed.
  • PTSD post-traumatic stress disorder
  • the disorder commonly affects survivors of traumatic events including sexual assault, physical assault, war, torture, natural disasters, an automobile accident, an airplane crash, a hostage situation, or a death camp.
  • the affliction also can affect rescue workers at an airplane crash or a mass shooting, someone who witnessed a tragic accident or someone who has unexpectedly lost a loved one.
  • Treatment for PTSD includes cognitive-behavioral therapy, group psychotherapy, and medications such as Clonazepam, Lorazepam and selective serotonin-reuptake inhibitors such as Fluoxetine, Sertraline, Paroxetine, Citalopram and Fluvoxamine. These medications help control anxiety as well as depression.
  • Various forms of exposure therapy (such as systemic desensitization and imaginal flooding) have all been used with PTSD patients. Exposure treatment for PTSD involves repeated reliving of the trauma, under controlled conditions, with the aim of facilitating the processing of the trauma. Therefore, there is a need for better pharmaceutical agents to treat post traumatic stress disorder.
  • HCA's heterocyclic antidepressant
  • MAOI's monoamine oxidase inhibitors
  • Benign side effects from the use of lithium include, but are not limited to, weight gain, nausea, diarrhea, polyuria, polydipsia, and tremor.
  • Toxic side effects from lithium can include persistent headache, mental confusion, and may reach seizures and cardiac arrhythmias. Therefore, agents with less side effects or interactions with food or other medications would be useful.
  • Borderline personality disorder although not as well known as bipolar disorder, is more common. People having borderline personality disorder suffer from a disorder of emotion regulation. Pharmaceutical agents are used to treat specific symptoms, such as depression or thinking distortions.
  • AIDS Acquired immune deficiency syndrome
  • HAV human immunodeficiency virus
  • This virus attacks selected cells and impairs the proper function of the immune, nervous, and other systems.
  • HIv infection can cause other problems such as, but not limited to, difficulties in thinking, otherwise known as AIDS dementia complex. Therefore, there is a need to drugs to relieve the confusion and mental decline of persons with AIDS.
  • Amyotrophic lateral sclerosis also known as Lou Gehrig's disease, belongs to a class of disorders known as motor neuron diseases wherein specific nerve cells in the brain and spinal cord gradually degenerate to negatively affect the control of voluntary movement.
  • motor neuron diseases wherein specific nerve cells in the brain and spinal cord gradually degenerate to negatively affect the control of voluntary movement.
  • amyotrophic lateral sclerosis although patients may receive treatment from some of their symptoms and although Riluzole has been shown to prolong the survival of patients. Therefore, there is a need for a pharmaceutical agent to treat this disease.
  • Brain tumors are abnormal growths of tissue found inside of the skull. Symptoms of brain tumors include behavioral and cognitive problems. Surgery, radiation, and chemotherapy are used to treat the tumor, but other agents are necessary to address associated symptoms. Therefore, there is a need to address the symptoms of behavioral and cognitive problems.
  • Huntington's disease Genetically programmed degeneration of neurons in certain areas of the brain cause Huntington's disease. Early symptoms of Huntington's disease include mood swings, or trouble learning new things or remembering a fact. Most drugs used to treat the symptoms of Huntington's disease have side effects such as fatigue, restlessness, or hyperexcitability. Currently, there is no treatment to stop or reverse the progression of Huntington's disease. Therefore, there is a need of a pharmaceutical agent to address the symptoms with fewer side effects.
  • Dementia with Lewy Bodies is a neurodegenerative disorder involving abnormal structures known as Lewy bodies found in certain areas of the brain. Symptoms of dementia with Lewy bodies include, but are not limited to, fluctuating cognitive impairment with episodic delirium. Currently, treatment concerns addressing the parkinsonian and psychiatric symptoms. However, medicine to control tremors or loss of muscle movement may actually accentuate the underlying disease of dementia with Lewy bodies. Therefore, there is a need of a pharmaceutical agent to treat dementia with Lewy bodies.
  • Parkinson's disease is a neurological disorder characterized by tremor, hypokinesia, and muscular rigidity. Currently, there is no treatment to stop the progression of the disease. Therefore, there is a need of a pharmaceutical agent to address Parkinson's.
  • Tardive dyskinesia is associated with the use of conventional antipsychotic drugs. This disease is characterized by involuntary movements most often manifested by puckering of the lips and tongue and/or writhing of the arms or legs. The incidence of tardive dyskinesia is about 5% per year of drug exposure among patients taking conventional antipsychotic drugs. In about 2% of persons with the disease, tardive dyskinesia is severely disfiguring. Currently, there is no generalized treatment for tardive dyskinesia. Furthermore, the removal of the effect-causing drugs is not always an option due to underlying problems. Therefore, there is a need for a pharmaceutical agent to address the symptoms of tardive dyskinesia.
  • Pick's disease results from a slowly progressive deterioration of social skills and changes in personality with the resulting symptoms being impairment of intellect, memory, and language. Common symptoms include memory loss, lack of spontaneity, difficulty in thinking or concentrating, and speech disturbances.
  • Common symptoms include memory loss, lack of spontaneity, difficulty in thinking or concentrating, and speech disturbances.
  • antipsychotic medications may alleviate symptoms in FTD patients who are experiencing delusions or hallucinations. Therefore, there is a need for a pharmaceutical agent to treat the progressive deterioration of social skills and changes in personality and to address the symptoms with fewer side effects.
  • Dysregulation of food intake associated with eating disease involve neurophysiological pathways.
  • Anorexia nervosa is hard to treat due to patients not entering or remaining in after entering programs.
  • Cognitive behavioral therapy has helped patients suffering from bulemia nervosa; however, the response rate is only about 50% and current treatment does not adequately address emotional regulation. Therefore, there is a need for pharmaceutical agents to address neurophysiological problems underlying diseases of dysregulation of food intake.
  • Cigarette smoking has been recognized as a major public health problem for a long time. However, in spite of the public awareness of health hazard, the smoking habit remains extraordinarily persistent and difficult to break. There are many treatment methods available, and yet people continue to smoke. Administration of nicotine transdermally, or in a chewing gum base is common treatments. However, nicotine has a large number of actions in the body, and thus can have many side effects. It is clear that there is both a need and a demand of long standing for a convenient and relatively easy method for aiding smokers in reducing or eliminating cigarette consumption. A drug that could selectively stimulate only certain of the nicotinic receptors would be useful in smoke cessation programs.
  • Smoke cessation programs may involve oral dosing of the drug of choice.
  • the drug may be in the form of tablets. However, it is preferred to administer the daily dose over the waking hours, by administration of a series of incremental doses during the day.
  • the preferred method of such administration is a slowly dissolving lozenge, troche, or chewing gum, in which the drug is dispersed.
  • Another drug in treating nicotine addiction is Zyban. This is not a nicotine replacement, as are the gum and patch. Rather, this works on other areas of the brain, and its effectiveness is to help control nicotine craving or thoughts about cigarette use in people trying to quit.
  • Zyban is not very effective and effective drugs are needed to assist smokers in their desire to stop smoking.
  • These drugs may be administered transdermally through the use of skin patches. In certain cases, the drugs may be administered by subcutaneous injection, especially if sustained release formulations are used.
  • Drug use and dependence is a complex phenomenon, which cannot be encapsulated within a single definition. Different drugs have different effects, and therefore different types of dependence. Drug dependence has two basic causes, that is, tolerance and physical dependence. Tolerance exists when the user must take progressively larger doses to produce the effect originally achieved with smaller doses. Physical dependence exists when the user has developed a state of physiologic adaptation to a drug, and there is a withdrawal (abstinence) syndrome when the drug is no longer taken. A withdrawal syndrome can occur either when the drug is discontinued or when an antagonist displaces the drug from its binding site on cell receptors, thereby counteracting its effect. Drug dependence does not always require physical dependence.
  • Drug dependence often involves psychological dependence, that is, a feeling of pleasure or satisfaction when taking the drug. These feelings lead the user to repeat the drug experience or to avoid the displeasure of being deprived of the drug.
  • Drugs that produce strong physical dependence such as nicotine, heroin and alcohol are often abused, and the pattern of dependence is difficult to break. Drugs that produce dependence act on the CNS and generally reduce anxiety and tension; produce elation, euphoria, or other pleasurable mood changes; provide the user feelings of increased mental and physical ability; or alter sensory perception in some pleasurable manner.
  • narcotic addiction is to switch the patient to a comparable drug that produces milder withdrawal symptoms, and then gradually taper off the substitute medication.
  • the medication used most often is methadone, taken orally once a day. Patients are started on the lowest dose that prevents the more severe signs of withdrawal and then the dose is gradually reduced. Substitutes can be used also for withdrawal from sedatives. Patients can be switched to long-acting sedatives, such as diazepam or phenobarbital, which are then gradually reduced.
  • Gilles de la Tourette's Syndrome is an inherited neurological disorder.
  • the disorder is characterized by uncontrollable vocal sounds called tics and involuntary movements.
  • the symptoms generally manifest in an individual before the person is 18 years of age.
  • the movement disorder may begin with simple tics that progress to multiple complex tics, including respiratory and vocal ones.
  • Vocal tics may begin as grunting or barking noises and evolve into compulsive utterances.
  • Coprolalia involuntary scatologic utterances
  • Tics tend to be more complex than myoclonus, but less flowing than choreic movements, from which they must be differentiated. The patient may voluntarily suppress them for seconds or minutes.
  • Clonidine may be used for simple and complex tics. Long-term use of Clonidine does not cause tardive dyskinesia; its limiting adverse effect is hypotension. In more severe cases, antipsychotics, such as Haloperidol may be required, but side effects of dysphoria, parkinsonism, akathisia, and tardive dyskinesia may limit use of such antipsychotics. There is a need for safe and effective methods for treating this syndrome.
  • Age-related macular degeneration is a common eye disease of the macula which is a tiny area in the retina that helps produce sharp, central vision required for “straight ahead” activities that include reading and driving. Persons with AMD lose their clear, central vision. AMD takes two forms: wet and dry. In dry AMD, there is a slow breakdown of light-sensing cells in the macula. There currently is no cure for dry AMD. In wet AMD, new, fragile blood vessels growing beneath the macula as dry AMD worsens and these vessels often leak blood and fluid to cause rapid damage to the macula quickly leading to the loss of central vision. Laser surgery can treat some cases of wet AMD. Therefore, there is a need of a pharmaceutical agent to address AMD.
  • Glaucoma is within a group of diseases occurs from an increase in intraocular pressure causing pathological changes in the optical disk and negatively affects the field of vision.
  • Medicaments to treat glaucoma either decrease the amount of fluid entering the eye or increase drainage of fluids from the eye in order to decrease intraocular pressure.
  • current drugs have drawbacks such as not working over time or causing side effects so the eye-care professional has to either prescribe other drugs or modify the prescription of the drug being used. There is a need for safe and effective methods for treating problems manifesting into glaucoma.
  • Alpha 7 nicotinic agonists may stimulate the release of inhibitory amino acids such as GABA which will dampen hyperexcitablity.
  • Alpha 7 nicotinic agonists are also directly neuroprotective on neuronal cell bodies. Thus alpha 7 nicotinic agonists have the potential to be neuroprotective in glaucoma.
  • Pain can manifest itself in various forms, including, but not limited to, headaches of all severity, back pain, neurogenic, and pain from other ailments such as arthritis and cancer from its existence or from therapy to irradicate it. Pain can be either chronic (persistent pain for months or years) or acute (short-lived, immediate pain to inform the person of possible injury and need of treatment). Persons suffering from pain respond differently to individual therapies with varying degrees of success. There is a need for safe and effective methods for treating pain.
  • the compounds of the present invention may be used in combination therapy with typical and atypical anti-psychotic drugs. All compounds within the present invention are useful for and may also be used in combination with each other to prepare pharmaceutical compositions. Such combination therapy lowers the effective dose of the anti-psychotic drug and thereby reduces the side effects of the anti-psychotic drugs.
  • Some typical anti-psychotic drugs that may be used in the practice of the invention include Haldol.
  • Some atypical anti-psychotic drugs include Ziprasidone, Olanzapine, Resperidone, and Quetiapine.
  • “Peptides” pp. 39-91, San Diego, Calif., Academic Press, (1995), and include, but are not limited to, agents such as a carbodiimides, phosphonium and uronium salts (such as uronium salt HATU).
  • agents such as a carbodiimides, phosphonium and uronium salts (such as uronium salt HATU).
  • heterocycles W—H can be reacted with azabicyclo isocyanates using procedures described in Synlett 1995, 605. Methods to prepare azabicyclo isocyanates are know to one of ordinary skill in the art (see EP 550007).
  • the amine precursor for Azabicyclo I where R 2 is other than H can be obtained.
  • the scheme depicted below is for compounds where R 2 is at the C-6 position of the quinuclidine, one of ordinary skill in the art would be able to obtain the quinuclidine with substitution at C-2 also.
  • the substituted-[2.2.2]-3-amine can be prepared by reduction of an oxime or an imine of the corresponding substituted-3-quinuclidinone by methods known to one of ordinary skill in the art (see J. Labelled Compds. Radiopharm. 1995, 53; J. Med. Chem. 1998, 988; Synth. Commun. 1992, 1895; Synth. Commun. 1996, 2009).
  • the substituted-[2.2.2]-3-amine can be prepared from a substituted-3-hydroxyquinuclidine by Mitsunobu reaction followed by deprotection as described in Synth. Commun. 1995, 1895.
  • the substituted-[2.2.2]-3-amine can be prepared by conversion of a substituted-3-hydroxyquinuclidine into the corresponding mesylate or tosylate, followed by displacement with sodium azide and reduction as described in J. Med. Chem. 1975, 587.
  • the 2-substituted-3-quinuclidinones where R 2 is substituted alkyl, cycloalkyl, or can be prepared by known procedures (see Tett. Lett. 1972, 1015; J. Am. Chem. Soc. 1994, 1278; J. Am. Chem. Soc. 1989, 4548; Tetrahedron, 2000, 1139).
  • the 2-substituted-3-quinuclidinones, where R 2 is aryl can be prepared by palladium catalyzed arylation as described in J. Am. Chem. Soc. 1999, 1473 and J. Am. Chem. Soc. 2000, 1360.
  • the 6-substituted-3-quinuclidinones can be prepared by known procedures (see J. Gen. Chem. Russia 1963, 3791, J. Chem. Soc. Perkin Trans. I 1991, 409, J. Org. Chem. 2000, 3982).
  • compounds can also be prepared by modification of intermediates described in the synthesis of exo-3-amino-1-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt, described in detail herein.
  • Int 6 can be oxidized to the aldehyde and treated with an organometallic reagent to provide Int 20 using procedures described in Tetrahedron (1999), 55, p 13899.
  • Int 20 can be converted into the amine using methods described for the synthesis of exo-3-amino-1-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt. Once the amine is obtained, the desired salt can be made using standard procedures.
  • the R 2 substituent may be introduced as known to one skilled in the art through standard alkylation chemistry. Exposure of 1-azabicyclo[3.2.1]octan-3-one or 1-azabicyclo[3.2.2]nonan-3-one to a hindered base such as LDA (lithium diisopropylamide) in a solvent such as THF or ether between 0° C. to ⁇ 78° C.
  • LDA lithium diisopropylamide
  • Chromatographic resolution flash, HPLC, or chiral HPLC
  • From there, formation of the oxime and subsequent reduction will provide the desired stereoisomers.
  • Lv can be —CH 2 Ph, —CH(Me)Ph, —OH, —OMe, or —OCH 2 Ph.
  • the respective amine precursors for Azabicyclo V and Azabicyclo VI can be prepared by reduction of an oxime or an imine of the corresponding N-2-azabicyclo[2.2.1]-heptanone by methods known to one skilled in the art (see J. Labelled Compds. Radiopharm., 53-60 (1995), J. Med. Chem. 988-995, (1998), Synth. Commun. 1895-1911 (1992), Synth. Commun. 2009-2015 (1996)).
  • the oximes can be prepared by treatment of the N-2-azabicyclo[2.2.1]heptanones with hydroxylamine hydrochloride in the presence of a base.
  • the imines can be prepared by treatment of the N-2-azabicyclo[2.2.1]-heptanones with a primary amine under dehydrating conditions.
  • the N-2-azabicyclo[2.2.1]heptanones can be prepared by known procedures (see Tet. Lett. 1419-1422 (1999), J. Med. Chem. 2184-2191 (1992), J. Med. Chem. 706-720 (2000), J. Org. Chem., 46024616 (1995)).
  • hydrogenolysis of adduct 1a,b or 2a,b followed by isomerization of the endo products as described by Singh (Singh, S., Basmadjian, G. P., Tetrahedron Lett., 38, 6829-6830, 1997) could provide access to the required exo acid 3a-d.
  • R 6 tert-butyloxycarbonyl
  • deprotection of the 7-aza group can be conveniently accomplished under acidic conditions in a suitable solvent such as methanol.
  • the secondary amine may be functionalized with alkyl and substituted alkyl via reductive amination or alkylative procedures.
  • carboxylic acids or carboxylic acid equivalents can be obtained through synthesis via literature procedures or through the slight modification thereof.
  • methods to prepare carboxylic acids or carboxylic acid equivalents starting from pyrroles or pyrazoles are known to one of ordinary skill in the art (see J. Org. Chem. 1987, 52, 2319, Tetrahedron Lett. 1999, 40, 2733 and Greene, T. W. and Wuts, P. G. M. “Protective Groups in Organic Synthesis”, 3rd Edition, p. 549, New York:Wiley, (1999)).
  • 2-Methylenequinuclidin-3-one (17.8 g, 0.13 mol, 1 eq) is dissolved in 40 mL MeOH in a Parr hydrogenation bottle. A THF slurry of 10% Pd/C (0.57 g) is added. The mixture is hydrogenated for 45 min at 45 psi, recharging as needed. The mixture is filtered through a pad of Celite. The Celite is washed with excess MeOH. The solution is concentrated to give a solid and a yellow oil. The mixture is taken up in ether, filtered and concentrated to provide 16.2 g (90%) of 2-methylquinuclidin-3-one. MS (ESI) for C 8 H 13 NO m/z 140.2 (M + ).
  • a solution of sodium n-propoxide (prepared from 5.5 g sodium (0.24 mol) and 100 mL n-propanol) is added dropwise to a suspension of (3E/Z)-2-methyl-1-azabicyclo[2.2.2]octan-3-one oxime hydrochloride (45.8 g, 0.24 mol, 1 eq) in 150 mL n-propanol.
  • 250 mL of n-propanol is added, and the mixture is heated under reflux.
  • Sodium (55.2 g, 2.40 mol, 10 eq) is added in portions to the refluxing mixture. The mixture is heated under reflux overnight. After about 14 h, the mixture is cooled, water is added and the layers are separated.
  • Ethyl E-4-bromo-2-butenoate (10 mL, 56 mmol, tech grade) is added to a stirred solution of benzylamine (16 mL, 146 mmol) in CH 2 Cl 2 (200 mL) at rt.
  • the reaction mixture stirs for 15 min, and is diluted with ether (1 L).
  • the mixture is washed with saturated aqueous NaHCO 3 solution (3 ⁇ ) and water, dried over Na 2 SO 4 , filtered and concentrated in vacuo.
  • the residue is purified by flash chromatography on silica gel.
  • Step D Preparation of trans-4-amino-1-(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 4)
  • Step E Preparation of trans-4-(1,1-dimethylethoxycarbonylamido)-1-(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 5)
  • Di-tert-butyldicarbonate (3.67 g, 16.8 mmol) is added to a stirred solution of Int 4 (2.94 g, 11.2 mmol) in CH 2 Cl 2 (30 mL) cooled in an ice bath. The reaction is allowed to warm to rt and stirred overnight. The mixture is concentrated in vacuo. The crude product is purified by flash chromatography on silica gel.
  • Step F Preparation of trans (tert-butoxycarbonylamino)-4-(2-hydroxyethyl)-1-(N-phenylmethyl) pyrrolidine (Int 6)
  • LiAlH 4 powder (627 mg, 16.5 mmol) is added in small portions to a stirred solution of Int 5 (3.0 g, 8.3 mmol) in anhydrous THF (125 mL) in a ⁇ 5° C. bath. The mixture is stirred for 20 min in a ⁇ 5° C. bath, then quenched by the sequential addition of water (0.6 mL), 15% (w/v) aqueous NaOH (0.6 mL) and water (1.8 mL). Excess anhydrous K 2 CO 3 is added, and the mixture is stirred for 1 h, then filtered. The filtrate is concentrated in vacuo. The residue is purified by flash chromatography on silica gel.
  • Int 6 is a racemic mixture that can be resolved via chromatography using a Diacel chiral pack AD column. From the two enantiomers thus obtained, the (+)-enantiomer, [ ⁇ ] 25 D +35 (c 1.0, MeOH), gives rise to the corresponding optically pure exo-4-S final compounds, whereas the ( ⁇ )-enantiomer, [ ⁇ ] 25 D ⁇ 34 (c 0.98, MeOH), gives rise to optically pure exo-4-R final compounds.
  • the methods described herein use the (+)-enantiomer of Int 6 to obtain the optically pure exo-4-S final compounds. However, the methods used are equally applicable to the ( ⁇ )-enantiomer of Int 6, making non-critical changes to the methods provided herein to obtain the optically pure exo-4-R final compounds.
  • Step G Preparation of exo 3-(tert-butoxycarbonylamino)-1-azabicyclo[2.2.1]heptane (Int 7)
  • TEA 8.0 g, 78.9 mmol
  • CH 2 Cl 2 50 mL
  • CH 3 SO 2 Cl 5.5 g, 47.8 mmol
  • the resulting yellow mixture is diluted with saturated aqueous NaHCO 3 solution, extracted with CH 2 Cl 2 several times until no product remains in the aqueous layer by TLC.
  • the organic layers are combined, washed with brine, dried over Na 2 SO 4 and concentrated in vacuo.
  • the residue is dissolved in EtOH (85 mL) and is heated to reflux for 16 h.
  • the reaction mixture is allowed to cool to rt, transferred to a Parr bottle and treated with 10% Pd/C catalyst (1.25 g).
  • the bottle is placed under an atmosphere of hydrogen (53 psi) for 16 h.
  • the mixture is filtered through Celite, and fresh catalyst (10% Pd/C, 1.25 g) is added. Hydrogenolysis continues overnight. The process is repeated three more times until the hydrogenolysis is complete.
  • the final mixture is filtered through Celite and concentrated in vacuo.
  • the residue is purified by flash chromatography on silica gel.
  • Step I Preparation of ethyl 5-hydroxy-6-oxo-1,2,3,6-tetrahydropyridine-4-carboxylate (Int 10)
  • Absolute EtOH (92.0 mL, 1.58 mol) is added to a mechanically stirred suspension of potassium ethoxide (33.2 g, 395 mmol) in dry toluene (0.470 L).
  • 2-pyrrolidinone (33.6 g, 395 mmol) is added, and then a solution of diethyl oxalate (53.1 mL, 390 mmol) in toluene (98 mL) is added via an addition funnel.
  • toluene (118 mL) and EtOH (78 mL) are added sequentially.
  • the mixture is heated to reflux for 18 h.
  • Step K Preparation of cis-4-(hydroxymethyl)piperidin-3-ol (Int 12)
  • Int 11 (3.7 g, 19.9 mmol) as a solid is added in small portions to a stirred solution of LiAlH 4 in THF (80 mL of a 1.0 M solution) in an ice-water bath.
  • the mixture is warmed to rt, and then the reaction is heated to reflux for 48 h.
  • the mixture is cooled in an ice-water bath before water (3.0 mL, 170 mmol) is added dropwise, followed by the sequential addition of NaOH (3.0 mL of a 15% (w/v) solution) and water (9.0 mL, 500 mmol).
  • Excess K 2 CO 3 is added, and the mixture is stirred vigorously for 15 min.
  • N-(benzyloxy carbonyloxy)succinimide (3.04 g, 12.2 mmol) is added to a stirred solution of Int 12 (1.6 g, 12.2 mmol) in saturated aqueous NaHCO 3 (15 mL) at rt. The mixture is stirred at rt for 18 h. The organic and aqueous layers are separated. The aqueous layer is extracted with ether (3 ⁇ ).
  • Step M Preparation of benzyl cis-3-hydroxy-4-[(4-methylphenyl)sulfonyl oxymethyl]piperidine-1-carboxylate (Int 14)
  • Para-toluenesulfonyl chloride (1.0 g, 5.3 mmol) is added to a stirred solution of Int 13 (3.6 g, 5.3 mmol) in pyridine (10 mL) in a ⁇ 15° C. bath. The mixture is stirred for 4 h, followed by addition of HCl (4.5 mL of a 6.0 M solution). CH 2 Cl 2 (5 mL) is added. The organic and aqueous layers are separated. The aqueous layer is extracted with CH 2 Cl 2 .
  • the pH of the aqueous layer is adjusted to 9 with 50% aqueous NaOH solution.
  • the aqueous layer is extracted with CH 2 Cl 2 (3 ⁇ ), and the combined organic layers are washed with brine, dried over Na 2 SO 4 , filtered and concentrated in vacuo.
  • the crude product is purified by flash chromatography on silica gel. Elution with CHCl 3 -MeOH—NH 4 OH (92:7:1) affords Int 16 as a colorless oil (41% yield): 1 H NMR (CDCl 3 ) ⁇ 4.1, 3.2, 2.8, 2.7-2.5, 2.2, 1.9, 1.5.
  • Methyl propiolate (52 ml, 0.583 mol) is combined with recrystallized N-bromo-succinimide (120 g, 0.674 mol) in 1,700 ml acetone under nitrogen.
  • the solution is treated with silver nitrate (9.9 g, 0.0583 mol) neat in a single lot and the reaction is stirred 6 h at RT.
  • the acetone is removed under reduced pressure (25° C., bath temperature) to provide a gray slurry.
  • the slurry is washed with 2 ⁇ 200 ml hexane, the gray solid is removed by filtration, and the filtrate is concentrated in vacuo to provide 95 g of a pale yellow oily residue.
  • Methyl-3-bromo-propiolate (83.7 g, 0.513 mol) is added to N-t-butyloxy-pyrrole (430 ml, 2.57 mol) under nitrogen.
  • the dark mixture is warmed in a 90° C. bath for 30 h, is cooled, and the bulk of the excess N-t-butyloxy-pyrrole is removed in vacuo using a dry ice/acetone condenser.
  • the dark oily residue is chromatographed over 1 kg silica gel (230-400 mesh) eluting with 0-15% EtOAc/hexane.
  • (+/ ⁇ )Endo-7-tert-butyl 2-methyl 7-azabicyclo[2.2.1]heptane-2,7-dicarboxylate (72.8 g, 0.285 mol) is dissolved in 1000 ml dry MeOH in a dried flask under nitrogen. The solution is treated with solid NaOMe (38.5 g, 0.713 mol) neat, in a single lot and the reaction is warmed to reflux for 4 h. The mixture is cooled to 0° C., is treated with 400 ml water, and the reaction is stirred 1 h as it warms to RT. The mixture is concentrated in vacuo to about 400 ml and the pH of the aqueous residue is adjusted to 4.5 with 12N HCl.
  • (+/ ⁇ )Exo-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]heptane-2-carboxylic acid (103.9 g, 0.430 mol) is combined with TEA (60 ml, 0.430 mol) in 1200 ml dry toluene in a dry flask under nitrogen. The solution is treated drop-wise with diphenylphosphoryl azide (92.8 ml, 0.430 mol), and is allowed to stir for 20 min at RT. The mixture is treated with benzyl alcohol (47.9 ml, 0.463 mol), and the reaction is stirred overnight at 55° C.
  • the 2R enantiomer is triturated with 40 ml ether followed by 40 ml hexane (to remove lingering diastereo and enantiomeric impurities) and is dried to afford 30 g (56%) of purified tert-butyl (1S, 2R, 4R)-(+)-2 ⁇ [(benzyloxy)carbonyl]amino ⁇ -7-azabicyclo[2.2.1]heptane-7-carboxylate with 99% enantiomeric excess.
  • MS (EI) for C 19 H 26 N 2 O 4 , m/z: 346 (M) + . [ ⁇ ] 25 D 22, (c 0.42, chloroform).
  • Acetyl chloride (270 mL, 3.8 mol) was carefully added to a flask containing chilled (0° C.) methanol (1100 mL). After the addition was complete, the acidic solution stirred for 45 min (0° C.) and then (3R)-1-[(S)-1-phenethyl]-3-(cyanomethyl)pyrrolidine (40.50 g, 189.0 mmol) in methanol (200 mL) was added. The ice bath was removed and the mixture stirred for 100 h at rt. The resulting suspension was concentrated. Water (600 mL) was added, the mixture stirred for 45 min and then the pH was adjusted (made basic) through the addition of 700 mL sat. aq.
  • Sodium hydride (60% oil dispersion, 2.01 g, 50.2 mmol) is washed with pentane (3 ⁇ ) and suspended in dry THF (40 mL). The solution is cooled to 0° C. before diethyl (2-oxopropyl)phosphonate (9.75 g, 50.2 mmol) is added dropwise. After complete addition, the solution is warmed to rt and stirred for 30 min.
  • tert-Butyl 4-oxo-1-piperidinecarboxylate (5.0 g, 25.1 mmol) is added in portions over 10 min, followed by stirring at rt for 2 h. A saturated aqueous solution of ammonium chloride is added, followed by dilution with ether.
  • the amine can be coupled to form the appropriate amides or thioamides as a racemic mixture.
  • the racemic mixture can then be resolved by chromatography using chiral columns or chiral HPLC, techniques widely known in the art, to provide the requisite resolved enantiomers 3(R) and 3(S) of said amides.
  • Phenyl chloroformate (0.75 mL, 6.0 mmol) is added dropwise to a solution of 4-iodopyrazole (1.05 g, 5.4 mmol) and triethylamine (0.9 mL, 6.5 mmol) in 15 mL CH 2 Cl 2 .
  • the reaction is stirred at RT. After 60 h, water is added. The mixture is extracted with CH 2 Cl 2 , dried (MgSO 4 ), filtered and concentrated. Hexane is added and the solvent is removed in vacuo. A white solid forms on standing to provide 1.6 g (95%) of phenyl 4-iodo-1H-pyrazole-1-carboxylate.
  • MS (EI) m/z 315.1 (M + ).
  • Phenyl 4-iodo-1H-pyrazole-1-carboxylate (1.6 g, 5.2 mmol) and (R)-(+)-3-aminoquinuclidine dihydrochloride (1.0 g, 5.2 mmol) are suspended in 10 mL DMF.
  • DIEA 2.7 mL, 15.5 mmol
  • the solvent is removed and the residue is taken up in 1N NaOH and CHCl 3 .
  • the aqueous layer is extracted with CHCl 3 , dried (MgSO 4 ), filtered and concentrated.
  • Example 4 (0.142 g, 20%) as a white solid: HRMS (ESI) calcd for C 11 H 15 N 4 OI (MH+) 347.0370, found 347.0370. Anal. Calcd for C 11 H 15 IN 4 O: C, 38.17; H, 4.37; N, 16.18. Found: C, 38.43; H, 4.42; N, 16.11.
  • the acids are coupled with the other amines identified herein using the coupling methods described herein to make examples with the acids and corresponding amines.
  • the cDNA encoding the N-terminal 201 amino acids from the human ⁇ 7 nAChR that contain the ligand binding domain of the ion channel was fused to the cDNA encoding the pore forming region of the mouse 5HT 3 receptor as described by Eisele J L, et al., Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities, Nature (1993), Dec. 2;366(6454):479-83, and modified by Groppi, et al., WO 00/73431.
  • the chimeric ⁇ 7-5HT 3 ion channel was inserted into pGS175 and pGS179 which contain the resistance genes for G-418 and hygromycin B, respectively. Both plasmids were simultaneously transfected into SH-EP1 cells and cell lines were selected that were resistant to both G-418 and hyrgromycin B. Cell lines expressing the chimeric ion channel were identified by their ability to bind fluorescent ⁇ -bungarotoxin on their cell surface. The cells with the highest amount of fluorescent ⁇ -bungarotoxin binding were isolated using a Fluorescent Activated Cell Sorter (FACS).
  • FACS Fluorescent Activated Cell Sorter
  • Cell lines that stably expressed the chimeric ⁇ 7-5HT 3 were identified by measuring fluorescent ⁇ -bungarotoxin binding after growing the cells in minimal essential medium containing nonessential amino acids supplemented with 10% fetal bovine serum, L-glutamine, 100 units/ml penicillin/streptomycin, 250 ng/mg fungizone, 400 ⁇ g/ml hygromycin B, and 400 ⁇ g/ml G-418 at 37° C. with 6% CO 2 in a standard mammalian cell incubator for at least 4 weeks in continuous culture.
  • the ion conditions of the MMEBSS was adjusted to maximize the flux of calcium ion through the chimeric ⁇ 7-5HT 3 ion channel as described in WO 00/73431.
  • the activity of compounds on the chimeric ⁇ 7-5HT 3 ion channel was analyzed on FLIPR.
  • the instrument was set up with an excitation wavelength of 488 nanometers using 500 milliwatts of power. Fluorescent emission was measured above 525 nanometers with an appropriate F-stop to maintain a maximal signal to noise ratio.
  • Agonist activity of each compound was measured by directly adding the compound to cells expressing the chimeric ⁇ 7-5HT 3 ion channel and measuring the resulting increase in intracellular calcium that is caused by the agonist-induced activation of the chimeric ion channel.
  • the assay is quantitative such that concentration-dependent increase in intracelluar calcium is measured as concentration-dependent change in Calcium Green fluorescence.
  • the effective concentration needed for a compound to cause a 50% maximal increase in intracellular calcium is termed the EC 50 .
  • the examples of the present invention have EC 50 values between 171 nM and 366 nM.
  • Another way for measuring ⁇ 7 nAChR agonist activity is to determine binding constants of a potential agonist in a competition binding assay.
  • ⁇ 7 nAChR agonists there is good correlation between functional EC 50 values using the chimeric ⁇ 7-5HT 3 ion channel as a drug target and binding affinity of compounds to the endogenous ⁇ 7 nAChR.
  • mice Male Sprague-Dawley rats (300-350 g) are sacrificed by decapitation and the brains (whole brain minus cerebellum) are dissected quickly, weighed and homogenized in 9 volumes/g wet weight of ice-cold 0.32 M sucrose using a rotating pestle on setting 50 (10 up and down strokes). The homogenate is centrifuged at 1,000 ⁇ g for 10 minutes at 4° C. The supernatant is collected and centrifuged at 20,000 ⁇ g for 20 minutes at 4° C. The resulting pellet is resuspended to a protein concentration of 1-8 mg/mL. Aliquots of 5 mL homogenate are frozen at ⁇ 80° C. until needed for the assay.
  • 0.4 mL homogenate are added to test tubes containing buffer and various concentrations of radioligand, and are incubated in a final volume of 0.5 mL for 1 hour at 25° C. Nonspecific binding was determined in tissues incubated in parallel in the presence of 0.05 mls MLA for a final concentration of 1 ⁇ M, added before the radioligand.
  • drugs are added in increasing concentrations to the test tubes before addition of 0.05 mls [ 3 H]-MLA for a final concentration 3.0 to 4.0 nM.
  • the incubations are terminated by rapid vacuum filtration through Whatman GF/B glass filter paper mounted on a 48 well Brandel cell harvester.
  • Filters are pre-soaked in 50 mM Tris HCl pH 7.0-0.05% polyethylenimine. The filters are rapidly washed two times with 5 mL aliquots of cold 0.9% saline and then counted for radioactivity by liquid scintillation spectrometry.

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

The invention provides compounds of Formula I:
Figure US20060116395A1-20060601-C00001
wherein Azabicyclo is
Figure US20060116395A1-20060601-C00002
W is
Figure US20060116395A1-20060601-C00003
 where the variables have the definitions discussed herein. These compounds may be in the form of pharmaceutical salts or compositions, may be in pure enantiomeric form or racemic mixtures, and are useful in pharmaceuticals to treat a disease or condition in which α7 is known to be involved.

Description

    CROSS REFERENCE TO RELATED APPLICATIONS
  • This application claims the benefit of U.S. provisional application Ser. No. 60/400,339 filed on Aug. 1, 2002, under 35 USC 119(e)(i), which is incorporated herein by reference in its entirety.
    • FIELD OF INVENTION
  • Nicotinic acetylcholine receptors (nAChRs) play a large role in central nervous system (CNS) activity. Particularly, they are known to be involved in cognition, learning, mood, emotion, and neuroprotection. There are several types of nicotinic acetylcholine receptors, and each one appears to have a different role in regulating CNS function. Nicotine affects all such receptors, and has a variety of activities. Unfortunately, not all of the activities are desirable. In fact, one of the least desirable properties of nicotine is its addictive nature and the low ratio between efficacy and safety. The present invention relates to molecules that have a greater effect upon the α7 nAChRs as compared to other closely related members of this large ligand-gated receptor family. Thus, the invention provides compounds that are active drug molecules with fewer side effects.
  • The invention also concerns the synthesis of and isolation of intermediates and final compounds. Specifically, the present invention concerns the preparation of 1H-pyrazole and 1H-pyrrole-azabicyclic compounds and pharmaceutically acceptable salts thereof.
    • BACKGROUND OF THE INVENTION
  • U.S. Pat. No. 6,255,490 discloses 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands.
  • U.S. Pat. No. 6,117,889 discloses discloses 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as analgesics and anti-inflammatory agents.
  • U.S. Pat. No. 6,060,473 discloses 7-azabicyclo[2.2.1]-heptane and -heptene derivatives as cholinergic receptor ligands.
  • U.S. Pat. No. 6,054,464 discloses azabicyclic esters of carbamic acids useful in therapy, especially in the treatment or prophylaxis of psychotic disorders and intellectual impairment disorders, as well as intermediates and use of intermediates in synthesis.
  • U.S. Pat. No. 5,977,144 discloses compositions for benzylidene- and cinnamylidene-anabaseines and methods for using these compositions for treating conditions associated with defects or malfunctioning of nicotinic subtypes brain receptors. These compositions target the α7 receptor subtype with little or no activation of the α4β2 or other receptor subtypes.
  • U.S. Pat. No. 5,712,270 discloses a group of 2-aroylaminothiazole derivatives which bind to and stimulate central muscarinic acetylcholine receptors and are useful agents for treating symptoms of cognitive disorders, specifically the impaired memory associated with a decrease in the neurotransmitter, acetylcholine. Some of the compounds of this invention also bind to 5HT1A receptors and dopamine D2 receptors, making them useful as antipsychotic agents.
  • U.S. Pat. No. 5,624,941 discloses pyrazole derivatives useful in pharmaceuticals in which cannabis is known to be involved.
  • U.S. Pat. No. 5,561,149 discloses the use of a mono or bicyclic carbocyclic, or heterocyclic carboxylic, acid ester or amide or an imidazolyl carbazol in the manufacture of a medicament suitable for the treatment of stress-related psychiatric disorders, for increasing vigilance, for the treatment of rhinitis or serotonin-induced disorders and/or coadministration with another active agent to increase the bioavailability thereof, or for nasal administration.
  • U.S. Pat. No. 5,510,478 discloses a group of 2-aroylaminothiazole derivatives which bind to and stimulate central muscarinic acetylcholine receptors and are useful agents for treating symptoms of cognitive disorders, specifically the impaired memory associated with a decrease in the neurotransmitter, acetylcholine. Some of the compounds of this invention also bind to 5HT1A receptors and dopamine D2 receptors, making them useful as antipsychotic agents.
  • U.S. Pat. No. 5,342,845 discloses indole derivatives and drugs effective as gastrointestinal motor activity regulator, antimigraine, antipsychotic or antianxiety drugs.
  • U.S. Pat. No. 5,237,066 discloses enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their use as medicinal products having activity in respect of gastric movements and antiemetic activity. U.S. Pat. No. 5,217,975 discloses azabicyclic compounds for treating dementia.
  • U.S. Pat. No. 5,206,246 discloses anxiolytic-R-N-(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof. A preferred compound is R-(+)-4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.
  • U.S. Pat. No. 5,106,843 discloses heterocyclic compounds useful as 5-HT3 antagonists.
  • U.S. Pat. No. 5,057,519 discloses 5-HT3 antagonists as being useful in reducing opiate tolerance.
  • U.S. Pat. No. 5,039,680 discloses 5-HT3 antagonists in preventing or reducing dependency on dependency-inducing agents.
  • U.S. Pat. No. 5,025,022 discloses a method of treating or preventing schizophrenia and/or psychosis using S-N-(1-azabicyclo[2.2.2]oct-3-yl)benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof. A preferred compound is S(−)-4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.
  • U.S. Pat. No. 5,017,580 discloses memory enhancing R-N-(1-azabicyclo[2.2.2.]oct-3-yl)benzamides and thiobenzamides, their N-oxides and pharmaceutically acceptable salts thereof. A preferred compound is R-(+)-4-amino-N-(1-azabicyclo[2.2.2]oct-3-yl)-5-chloro-2-methoxybenzamide.
  • U.S. Pat. No. 4,988,691 discloses isoxazole-containing compounds exhibiting anti-serotonin activity.
  • U.S. Pat. No. 4,835,162 discloses agonists and antagonists to nicotine as smoking deterrents.
  • U.S. Pat. No. 4,822,795 discloses pharmaceutically useful esters and amides having 5-HT3 antagonist activity.
  • U.S. Pat. No. 4,803,199 discloses pharmaceutically useful heterocyclic acid esters and amides or alkylene bridged peperidines as serotonin M antagonists.
  • U.S. Pat. No. 4,798,829 discloses 1-azabicyclo[3.2.2]nonane derivatives having gastric motility enhancing activity and/or anti-emetic activity and/or 5-HT receptor antagonist activity.
  • U.S. Pat. No. 4,789,673 discloses dicarboxylic, heterocyclic and substituted benzoic acid alkylene-bridged piperidyl amides and esters as being serotonin M antagonists.
  • U.S. Pat. No. 4,721,720 discloses a method of treating emesis, anxiety and/or irritable bowel syndrome.
  • U.S. Pat. No. 4,657,911 discloses 3-amino quinuclidine derivatives and the application thereof as accelerators of gastro-intestinal motor function and as medicament potentiators.
  • U.S. Pat. No. 4,605,652 discloses a method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes, and the pharmaceutically acceptable acid addition salts, hydrates and alcoholates thereof.
  • WO 01/76576 discloses a pharmaceutical composition for treatment of acute, chronic pain and/or neuropathic pain and migraines.
  • WO 01/60821 discloses biarylcarboxamides.
  • WO 01/36417 A1 discloses N-azabicyclo-amide derivatives and use in therapy, especially in the treatment of prophylaxis of psychotic disorders and intellectual impairment disorders.
  • WO 01/29304 discloses quinuclidine acrylamides.
  • WO 00/73431 A2 discloses two binding assays to directly measure the affinity and selectivity of compounds at the α7 nAChR and the 5-HT3R. The combined use of these functional and binding assays may be used to identify compounds that are selective agonists of the α7 nAChR.
  • WO 92/15579 discloses multicyclic tertiary amine polyaromatic squalene synthase inhibitors and method of treatment for lowering serum cholesterol levels using the compounds.
  • WO 90/14347 A as abstracted in chemical abstract 1991:143,158 discloses N-quinuclidinyl-indolecarboxamide derivatives as being antiemetics.
  • FR 2 625 678 discloses N-(quinuclidin-3-yl)-benzamides and thiobenzamides useful as diet-control agents.
  • In Bioorg. & Med. Chem. Lett. 11 (2001) 319-321, the 5-HT3 antagonist tropisetron (ICS 205-930) is discussed as a potent and selective α7 Nicotinic receptor partial agonist.
  • In Behavioral Brain Res., 113 (2000) 169-181, it is discussed that the brain α7 nicotinic receptor may be an important therapeutic target for the treatment of Alzheimer's disease using DMXBA which is known as GTS-21.
  • Cell surface receptors are, in general, excellent and validated drug targets. nAChRs comprise a large family of ligand-gated ion channels that control neuronal activity and brain function. These receptors have a pentameric structure. In mammals, this gene family is composed of nine alpha and four beta subunits that co-assemble to form multiple subtypes of receptors that have a distinctive pharmacology. Acetylcholine is the endogenous regulator of all of the subtypes, while nicotine non-selectively activates all nAChRs.
  • The α7 nAChR is one receptor system that has proved to be a difficult target for testing. Native α7 nAChR is not routinely able to be stably expressed in most mammalian cell lines (Cooper and Millar, J. Neurochem., 1997, 68(5):2140-51). Another feature that makes functional assays of α7 nAChR challenging is that the receptor is rapidly (100 milliseconds) inactivated. This rapid inactivation greatly limits the functional assays that can be used to measure channel activity.
  • Recently, Eisele et al. has indicated that a chimeric receptor formed between the N-terminal ligand binding domain of the α7 nAChR (Eisele et al., Nature, 366(6454), p 479-83, 1993), and the pore forming C-terminal domain of the 5-HT3 receptor expressed well in Xenopus oocytes while retaining nicotinic agonist sensitivity. Eisele et al. used the N-terminus of the avian (chick) form of the α7 nAChR receptor and the C-terminus of the mouse form of the 5-HT3 gene. However, under physiological conditions the α7 nAChR is a calcium channel while the 5-HT3R is a sodium and potassium channel. Indeed, Eisele et al. teaches that the chicken α7 nAChR/mouse 5-HT3R behaves quite differently than the native α7 nAChR with the pore element not conducting calcium but actually being blocked by calcium ions. WO 00/73431 A2 reports on assay conditions under which the 5-HT3R can be made to conduct calcium. This assay may be used to screen for agonist activity at this receptor.
    • SUMMARY OF THE INVENTION
  • The present invention discloses compounds of the Formula I:
    Figure US20060116395A1-20060601-C00004
    wherein Azabicyclo is
    Figure US20060116395A1-20060601-C00005
    W is
    Figure US20060116395A1-20060601-C00006
    wherein W1 is N or CH;
  • X is O or S;
  • R0 is H, lower alkyl, substituted lower alkyl, or halogenated lower alkyl;
  • R1 is H, alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl;
  • R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
  • k1, k2, k5, k6, and k7 are independently 0, or 1;
  • k3, and k4 are independently 0, 1, or 2;
  • Each R3 is independently F, Cl, Br, I, —CN, —NO2, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocyloalkyl, substituted heterocycloalkyl, lactam heterocyclcoalkyl, aryl, R7, R9, —OR10, —SR10, —SOR10, —SO2R10, —SCN, —S(O)N(R10)2, —S(O)2N(R10)2, —C(O)R10, —C(O)2R10, —C(O)N(R10)2, C(R10)═N—OR10, —NC(O)R7, —NC(O)R8, —NC(O)R9, —N(R10)2, —NR10C(O)R10, —NR10S(O)2R10, or two R3 on adjacent carbon atoms may fuse to form a 6-membered ring to give a 5-6 fused, bicyclic moiety where the 6-membered ring is optionally substituted with 1-3 substitutents selected from R4;
  • m is 0, 1, or 2;
  • R4 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR8, —SR8, —S(O)2R8, —S(O)R8, —OS(O)2R8, —N(R8)2, —C(O)R8, —C(S)R8, —C(O)OR8, —CN, —C(O)N(R8)2, —NR8C(O)R8, —S(O)2N(R8)2, —NR8S(O)2R8, —NO2, —N(R8)C(O)N(R8)2, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, phenyl having 0-4 substituents independently selected from F, Cl, Br, I and R15, naphthyl, naphthyl having 0-4 substituents independently selected from F, Cl, Br, I, or R15, or two R4 on adjacent carbon atoms may combine to form a three-ring-fused-5-6-6 system optionally substituted with up to 3 substituents independently selected from Br, Cl, F, I, —CN, —NO2, —CF3, —N(R8)2, —N(R8)C(O)R8, alkyl, alkenyl, and alkynyl;
  • Each R5 is independently H, alkyl, or substituted alkyl;
  • R6 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, 1, —OH, —CN, —NH2, —NH(alkyl), or —N(alkyl)2;
  • R7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of —O—, ═N—, —N(R14)—, and —S—, and having 0-1 substituent selected from R15, and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R7 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula
    Figure US20060116395A1-20060601-C00007
    wherein A1 is O, S, or NR14,
    Figure US20060116395A1-20060601-C00008
    wherein A is CR17 or N, and each A2 or A3 is independently selected from CR17, O, S, N, or NR14, or
    Figure US20060116395A1-20060601-C00009
    wherein A is CR17 or N, and each A2 or A3 is independently selected from CR17, O, S, N, or NR14, and, each 9-membered fused-ring moiety having 0-1 substituent selected from R15, and further having 0-3 substituent(s) independently selected from F, Cl, Br, or I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;
  • Each R8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R15;
  • R9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from ═N— and having 0-1 substituent selected from R15 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R9 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from ═N—, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R15, and 0-3 substituent(s) independently selected from F, Cl, Br, or I and having a bond directly or indirectly attached to the core molecule where valency allows;
  • Each R10 is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R13, cycloalkyl substituted with 1 substituent selected from R13, heterocycloalkyl substituted with 1 substituent selected from R13, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;
  • Each R11 is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;
  • R12 is —NO2, —CN, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —OR11, —SR11, —N(R11)2, —C(O)R11, —C(O)N(R11)2, —NR11C(O)R11, —S(O)2N(R11)2, or —NR11S(O)2R11;
  • R13 is —OR11, —SR11, —N(R11)2, —C(O)R11, —SOR11, —SO2R11, —C(O)N(R11)2, —CN, —CF3, —NR11C(O)R11, —S(O)2N(R11)2, —NR11S(O)2R11, or —NO2;
  • R14 is independently H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;
  • R15 is alkyl, substituted alkyl, halogenated alkyl, —OR11, —CN, —NO2, —N(R10)2;
  • R17 is H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R18, —OR11, —SR11, —N(R11)2, —NR11S(O)2R11, F, Cl, Br, or I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R18, —OR11, —SR11, —NR11R11, —C(O)R11, —NO2, —C(O)NR11R11, —CN, —NR11C(O)R11, —S(O)2NR11R11, or —NR11S(O)2R11, and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I;
  • R18 is alkyl, cycloalkyl, heterocycloalkyl, any of which is substituted with 0-3 substituents independently selected from F, Cl, Br, or I and further substituted with I substituent selected from —NO2, —CN, —OR10, —SR10, —NR10R10, —C(O)R10, —C(O)NR10R10, —NR10C(O)R10, —S(O)2NR10R10, —NR10S(O)2R10, phenyl, or phenyl having 1 substituent selected from R15 and further having 0-3 substituents independently selected from F, Cl, Br, or I;
  • or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.
  • The compounds of Formula I are used to treat any one of or combination of cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.
  • Embodiments and aspects of the invention may include the following.
  • An embodiment of the present invention provides a method comprising administering a therapeutically effective amount of a compound of Formula I, or a pharmaceutically acceptable salt thereof or pharmaceutical composition containing said compound or salt thereof, to the mammal.
  • The compound of Formula I, where X is O or S.
  • The compound of Formula I, where any one of k1, k2, k3, k4, k5, k6, or k7 is 1. The compound of Formula I, where any one of k1, k2, k3, k4, k5, k6, or k7 is 0, this means R2 is absent. The compound of Formula I, where each k3 or k4 is 2.
  • The compound of Formula I, where R0 is H, lower alkyl, substituted lower alkyl, or halogenated lower alkyl, where R1 is H, alkyl, or cycloalkyl, and where each R2 is independently absent, alkyl, substituted alkyl, cycloalkyl, halogenated alkyl, or aryl.
  • The compound of Formula I, where Azabicyclo is any one or more or combination of the following: I, II, III, IV, V, VI, or VII.
  • The compound of Formula I, where each R5 is independently H, lower alkyl, or substituted lower alkyl.
  • The compound of Formula I, where R6 is an amino protecting group.
  • The compound of Formula I, where R6 is H, or lower alkyl optionally substituted with up to 3 substituents independently selected from F, Cl, Br, I, —OH, —CN, —NH2, —NH(alkyl), or —N(alkyl)2.
  • The compound of Formula I, where at least one R5 is H and one R5 is H or lower alkyl optionally substituted with 1 substituent selected from —CN, —NO2, —OR10, —SR10, —S(O)R10, —S(O)2R10, —OS(O)2R10, —NR10R10, —C(O)R10, —C(O)OR10, —C(S)R10, —C(O)NR10R10, —NR10C(O)R10, —NR10C(O)NR10R10, —S(O)2NR10R10, —NR10S(O)2R10, or optionally substituted phenyl, provided that R10 is H, lower alkyl, or halogenated lower alkyl, and further provided that when said lower alkyl is optionally substituted, said lower alkyl can be further optionally substituted with up to 3 substituents independently selected from F, Cl, Br, and I. This allows the lower alkyl of R5 to be substituted with one substituent selected from —CN, —NO2, —OR10, —SR10, —S(O)R10, —S(O)2R10, —OS(O)2R10, —NR10R10, —C(O)R10, —C(O)OR10, —C(S)R10, —C(O)NR10R10, —NR10C(O)R10, —NR10C(O)NR10R10, —S(O)2NR10R10, —NR10S(O)2R10, or optionally substituted phenyl, and further optionally substituted with up to 3 substituents independently selected from F, Cl, Br, and I on any carbon with sufficient valency for said substitution. This further provides that for the following optional substituents on R5, the R10 of said substituents is H, lower alkyl or halogenated lower alkyl: —OR10, —SR10, —S(O)R10, —S(O)2R10, —OS(O)2R10, —NR10R10, —C(O)R10, —C(O)OR10, —C(S)R10, —C(O)NR10R10, —NR10C(O)R10, —NR10C(O)NR10R10, —S(O)2NR10R10, —NR10S(O)2R10.
  • Optionally substituted phenyl is phenyl optionally substituted with up to 3 substituents independently selected from F, Cl, Br, I, and R13 and further optionally substituted with up to 1 substituent selected from R15.
  • The compound of Formula I, where R0 is H or lower alkyl, wherein R1 is H or lower alkyl, and wherein each R2 is absent or lower alkyl.
  • The compound of Formula I, where m is 2, m is 1 or m is 0.
  • The compound of Formula I, where W1 is CH. The compound of Formula I, where W1 is N.
  • The compound of Formula I, where R0, R1, and each R5 are H and R2 is absent.
  • Another group of compounds of Formula I includes compounds where each R3 is absent. Another group of compounds of Formula I includes compounds where each R3 independently includes being absent and being any one of F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, substituted phenyl, —OR10, —SR10, —SOR10, —SO2R10, —NR10R10, —NO2, —C(O)R10, —CN, —C(O)2R10, —C(O)NR10R10, —SCN, —NR10C(O)R10, —S(O)NR10R10, —S(O)2NR10R10, —NR10S(O)2R10, R7, or R9.
  • Another group of compounds of Formula I includes compounds where each R3 independently includes being absent and being any one of H, F, Cl, Br, I, alkyl, halogenated alkyl, —OR10, —SR10, —C(O)R10, —NO2, —CN, or —C(O)NR10R10.
  • Another group of compounds of Formula I includes compounds where R4 includes any one of the following: H, F, Cl, Br, I, alkyl, halogenated alkyl, —OR10, —C(O)R10, —NO2, —CN, or —C(O)NR10R10.
  • Another group of compounds of Formula I includes compounds where W is 1H-pyrazol-1-yl, substituted at the four position with any one of the following: halogen, methyl, cyano, methylthio, aryl, R7 or R9. Another group of compounds of Formula I includes compounds where W is 1H-pyrazol-1-yl, substituted at the four position with phenyl optionally substituted whever valency allows with any one of the following: halogen, lower alkyl, or —O-(lower alkyl). Another group of compounds of Formula I includes compounds where W is 1H-pyrazol-1-yl, substituted at the four position with thienyl or pyridinyl.
  • Another group of compounds of Formula I includes compounds where W is 1H-pyrrol-1-yl, substituted at the three position with any one of the following: halogen, methyl, cyano, methylthio, aryl, R7 or R9. Another group of compounds of Formula I includes compounds where W is 1H-pyrrol-1-yl, substituted at the three position with phenyl optionally substituted whever valency allows with any one of the following: halogen, lower alkyl, or —O-(lower alkyl). Another group of compounds of Formula I includes compounds where W is 1H-pyrrol-1-yl, substituted at the three position with thienyl or pyridinyl.
  • Another group of compounds of Formula I includes any one or more or combination of the following as a free base or pharmaceutically acceptable salt thereof:
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-chloro-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-bromo-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-iodo-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-methyl-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-cyano-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(methylthio)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-thien-2-yl-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-thien-3-yl-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-pyridin-2-yl-1-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-phenyl-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(3-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-chloro-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-iodo-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(methylthio)-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-thien-2-yl-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-thien-3-yl-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-phenyl-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide;
      any of which is optionally substituted at either the two or six position on the quinuclidine with methyl, provided that if the quinuclidine is substituted at the two position, the quinuclidine has the 2S,3R configuration, e.g., N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide, or N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide.
  • Another group of compounds of Formula I includes any one or more or combination of the following as a free base or pharmaceutically acceptable salt thereof:
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-chloro-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-bromo-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-iodo-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-methyl-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-cyano-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(methylthio)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)4-thien-2-yl-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-thien-3-yl-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-pyridin-2-yl-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-phenyl-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(3-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-chloro-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-bromo-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-iodo-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-methyl-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-cyano-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(methylthio)-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-thien-2-yl-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-thien-3-yl-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-phenyl-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2. I]hept-3-yl)-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-chloro-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-bromo-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-iodo-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-methyl-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-cyano-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(methylthio)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-thien-2-yl-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-thien-3-yl-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-pyridin-2-yl-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-phenyl-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-chloro-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-bromo-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-iodo-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-methyl-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-cyano-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(methylthio)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-thien-2-yl-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-thien-3-yl-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-phenyl-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-chloro-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-bromo-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-iodo-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-methyl-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-cyano-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(methylthio)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-thien-2-yl-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-thien-3-yl-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-pyridin-2-yl-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-phenyl-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(3-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-chloro-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-bromo-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-iodo-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-methyl-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-cyano-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-(methylthio)-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-thien-2-yl-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-thien-3-yl-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-phenyl-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N−1-azabicyclo[3.2.2]non-3-yl-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-1-azabicyclo[3.2.2]non-3-yl-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-chloro-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-bromo-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-iodo-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-methyl-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-cyano-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(methylthio)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-thien-2-yl-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-thien-3-yl-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-pyridin-2-yl-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-phenyl-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(3-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-chloro-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-bromo-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-iodo-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-methyl-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-cyano-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(methylthio)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-thien-2-yl-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-thien-3-yl-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-phenyl-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-5-yl-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-chloro-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-bromo-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-iodo-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-methyl-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-cyano-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(methylthio)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-thien-2-yl-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-thien-3-yl-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-pyridin-2-yl-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-phenyl-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(3-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-chloro-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-bromo-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-iodo-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-methyl-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-cyano-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(methylthio)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-thien-2-yl-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-thien-3-yl-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-phenyl-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-2-azabicyclo[2.2.1]hept-6-yl-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-chloro-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-bromo-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-iodo-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-methyl-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-cyano-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-(methylthio)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.]hept-2-yl-4-thien-2-yl-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-thien-3-yl-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-pyridin-2-yl-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-phenyl-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2. I]hept-2-yl-4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2. I]hept-2-yl-4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-(3-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-chloro-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-bromo-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-iodo-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-methyl-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-cyano-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-(methylthio)-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-thien-2-yl-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-thien-3-yl-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-phenyl-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2. I]hept-2-yl-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide; or
    • N-(1S, 2R, 4R)-7-azabicyclo[2.2.1]hept-2-yl-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide.
  • The present invention also includes a pharmaceutical composition comprising a compound of Formula I or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable excipient and optionally an anti-psychotic agent. The pharmaceutical composition is administered rectally, topically, orally, sublingually, or parenterally for a therapeutically effective interval. The pharmaceutical composition is administered to deliver a compound of Formula I in an amount of from about 0.001 to about 100 mg/kg of body weight of said mammal per day. The pharmaceutical composition is also administered to deliver a compound of Formula I in an amount of from about 0.1 to about 50 mg/kg of body weight of said mammal per day.
  • The present invention also includes a method to use a compound according to Formula I or pharmaceutically acceptable salt thereof by itself or optionally in combination with an anti-psychotic agent for treating, or preparing a medicament to treat, a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of α7 nicotinic acetylcholine receptor agonist.
  • The present invention also includes a method to use a compound according to Formula I or pharmaceutically acceptable salt thereof by itself or optionally in combination with an anti-psychotic agent for treating, or preparing a medicament to treat, a disease or condition, wherein the mammal would receive symptomatic relief from the administration of a therapeutically effective amount of α7 nicotinic acetylcholine receptor agonist, and wherein the disease, or condition is any one or more or combination of the following: cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems in general and associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.
  • The invention also concerns the synthesis of and isolation of stereospecific intermediates and final compounds. Specifically, the present invention concerns the stereoselective synthesis of (3R,5R)-1-azabicyclo[3.2.1]octan-3-amine, or salts thereof. Although there are known procedures for making 1-azabicyclo[3.2.1]octan-3-amine, separation of the different stereoismers as described herein occurs without using a chiral HPLC separation procedure. The procedure within this invention results in an efficient selective synthesis of (3R,5R)-1-azabicyclo[3.2.1]octan-3-amine.
  • The present invention also includes the compounds of the present invention, pharmaceutical compositions containing the active compounds, and methods to treat the identified diseases.
  • The compounds of Formula I where Azabicyclo is I have optically active centers on the quinuclidine ring. The compounds of the present invention include quinuclidines with the 2S, 3R configuration and also includes racemic mixtures and compositions of varying degrees of streochemical purities. For example, and not by limitation, compounds of Formula I include compounds with stereospecificity including:
    Figure US20060116395A1-20060601-C00010
  • The compounds of Formula I where Azabicyclo is VII have optically active centers on the 7-azabicyclo[2.2.1]heptane ring which can exhibit a number of stereochemical configurations.
    Figure US20060116395A1-20060601-C00011
  • The terms exo and endo are stereochemical prefixes that describe the relative configuration of a substituent on a bridge (not a bridgehead) of a bicyclic system. If a substituent is oriented toward the larger of the other bridges, it is endo. If a substituent is oriented toward the smaller bridge it is exo. Depending on the substitution on the carbon atoms, the endo and exo orientations can give rise to different stereoisomers. For instance, when carbons 1 and 4 are substituted with hydrogen and carbon 2 is bonded to a nitrogen-containing species, the endo orientation gives rise to the possibility of a pair of enantiomers: either the 1S, 2S, 4R isomer or its enantiomer, the 1R, 2R, 4S isomer. Likewise, the exo orientation gives rise to the possibility of another pair of stereoisomers which are diastereomeric and C-2 epimeric with respect to the endo isomers: either the 1R, 2S, 4S isomer or its enantiomer, the 1S, 2R, 4R isomer. The compounds of this invention exist in the exo orientation. For example, when R2 is absent and each R5 is H, the absolute stereochemistry is exo-(1S, 2R, 4R).
  • Stereoselective syntheses and/or subjecting the reaction product to appropriate purification steps produces substantially optically pure materials. Suitable stereoselective synthetic procedures for producing optically pure materials are well known in the art, as are procedures for purifying racemic mixtures into optically pure fractions.
  • The compounds of the present invention have the exo orientation at the C-2 carbon and S configuration at the C-1 carbon and the R configuration at the C-2 and the C-4 carbons of the 7-azabicyclo[2.2.1]heptane ring. Unexpectedly, the inventive compounds exhibit much higher activity relative to compounds lacking the exo, 1S, 2R, and 4R stereochemistry. For example, the ratio of activities for compounds having the exo, 1S, 2R, and 4R configuration to other stereochemical configurations may be greater than about 100. Although it is desirable that the stereochemical purity be as high as possible, absolute purity is not required. For example, pharmaceutical compositions can include one or more compounds, each having an exo, 1S, 2R, and 4R configuration, or mixtures of compounds having exo, 1S, 2R, and 4R and other configurations. In mixtures of compounds, those species possessing stereochemical configurations other than exo, 1S, 2R, and 4R act as diluents and tend to lower the activity of the pharmaceutical composition. Typically, pharmaceutical compositions including mixtures of compounds possess a larger percentage of species having the exo, 1S, 2R, and 4R configuration relative to other configurations.
  • The compounds of Formula I (Azabicyclo is II) have optically active center(s) on the [2.2.1] azabicyclic ring at C3 and C4. The scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being endo-4S, endo-4R, exo-4S, exo-4R:
    Figure US20060116395A1-20060601-C00012
    The endo isomer is the isomer where the non-hydrogen substituent at C3 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges. The exo isomer is the isomer where the non-hydrogen substituent at C3 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges. Thus, there can be four separate isomers: exo-4(R), exo-4(S), endo-4(R), and endo-4(S).
  • The compounds of Formula I (Azabicyclo is III) have optically active center(s) on the [3.2.1] azabicyclic ring at C3 and C5. The scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being endo-3S, 5R, endo-3R, 5S, exo-3R, 5R, exo-3S, 5S:
    Figure US20060116395A1-20060601-C00013
  • The compounds of Formula I (Azabicyclo is TV) have optically active centers on the [3.2.2] azabicyclic ring with one center being at C3 when R2 is absent. The scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being 3(S) and 3(R):
    Figure US20060116395A1-20060601-C00014
  • The compounds of Formula I (Azabicyclo V) have optically active center(s) on the [2.2.1] azabicyclic ring at C1, C4 and C5. The scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being (1R,4R,5S), (1R,4R,5R), (1S,4S,5R), (1S,4S,5S):
    Figure US20060116395A1-20060601-C00015
  • The endo isomer is the isomer where the non-hydrogen substituent at C5 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges. The exo isomer is the isomer where the non-hydrogen substituent at C5 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges. Thus, there can be four separate isomers: exo-(1R,4R,5S), exo-(1S,4S,5R), endo-(1S,4S,5S), endo-(1R,4R,5R).
  • The compounds of Formula I (Azabicyclo VI) have optically active center(s) on the [2.2.1] azabicyclic ring at C1, C4 and C6. The scope of this invention includes racemic mixtures and the separate stereoisomers of Formula I being exo-(1S,4R,6S), exo-(1R,4S,6R), endo-(1S,4R,6R), and endo-(1R,4S,6S):
    Figure US20060116395A1-20060601-C00016
  • The endo isomer is the isomer where the non-hydrogen substituent at C6 of the [2.2.1] azabicyclic compound is projected toward the larger of the two remaining bridges. The exo isomer is the isomer where the non-hydrogen substituent at C6 of the [2.2.1] azabicyclic compound is projected toward the smaller of the two remaining bridges. Thus, there can be four separate isomers: exo-(1S,4R,6S), exo-(1R,4S,6R), endo-(1S,4R,6R), and endo-(1R,4S,6S).
  • The compounds of the present invention having the specified stereochemistry have different levels of activity and that for a given set of values for the variable substitutuents one isomer may be preferred over the other isomers. Although it is desirable that the stereochemical purity be as high as possible, absolute purity is not required. This invention involves racemic mixtures and compositions of varying degrees of streochemical purities when R2 is absent and when R2 is present (a substituent rather than H). This invention involves racemic mixtures and compositions of varying degrees of streochemical purities. It is preferred to carry out stereoselective syntheses and/or to subject the reaction product to appropriate purification steps so as to produce substantially optically pure materials. Suitable stereoselective synthetic procedures for producing optically pure materials are well known in the art, as are procedures for purifying racemic mixtures into optically pure fractions.
  • Another embodiment of the compounds of Formula I of the present invention includes any one or more or combination of the following configurations for compounds where Azabicyclo is:
    Figure US20060116395A1-20060601-C00017
  • where (i) R2 is absent (k1 is 0) and where the compound is a racemic mixture, or (ii) R2 is absent and where the compound is has the R stereochemistry at C-3 as discussed herein.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds where Azabicyclo is:
    Figure US20060116395A1-20060601-C00018
    where (i) R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl and where the compound is a racemic mixture;
  • (ii) R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl and where the compound is a racemic mixture; or
  • (iii) R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl and where the compound has the 3R, 2S stereochemistry as discussed herein, respectively.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds where Azabicyclo is:
    Figure US20060116395A1-20060601-C00019
    where (i) R2 is absent (k2 is 0);
  • (ii) R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • (iii) R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, respectively.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds wherein Azabicyclo is
    Figure US20060116395A1-20060601-C00020
    where (i) R2 is absent (k3 is 0);
  • (ii) R2 is absent and where the Azabicyclo has the stereochemistry of 3R, 5R;
  • (iii) k3 is 2, R2 is R2-a and R2-b, where R2-a is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, and where R2-b is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
  • (iv) R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • (v) R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, respectively.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds wherein Azabicyclo is
    Figure US20060116395A1-20060601-C00021
    where (i) R2 is absent (k4 is 0);
  • (ii) k4 is 2, R2 is R2-a and R2-b, R2-a is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl and where each R2-b is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
  • (iii) R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • (iv) R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, respectively.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds where Azabicyclo is:
    Figure US20060116395A1-20060601-C00022
    where (i) R2 is absent (k5 is 0);
  • (ii) R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • (iii) R2 is alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, respectively.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds where Azabicyclo is:
    Figure US20060116395A1-20060601-C00023
    where (i) R2 is absent (k6 is 0);
  • (ii) R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl; or
  • (iii) R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl, respectively.
  • Another group of compounds of Formula I includes any one or more or combination of the following configurations for compounds where Azabicyclo is:
    Figure US20060116395A1-20060601-C00024
  • where (i) the 7-azabicyclo[2.2.1]heptane ring moiety is the 2R stereoisomer;
  • (ii) R2 is absent (k7 is 0), and each R5 may independently be H, alkyl, or substituted alkyl, and where R6 is any one of H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents independently selected from F, Cl, Br, I, —OH, —CN, —NH2, —NH(alkyl), or —N(alkyl)2, and where the 7-azabicyclo[2.2.1]heptane ring moiety has the 1S, 2R, 4R stereochemistry; or
  • (iii) R2 is alkyl, or substituted alkyl, and where each R5 may independently be H, alkyl, or substituted alkyl, and where R6 is any one of H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, —OH, —CN, —NH2, —NH(alkyl), or —N(alkyl)2, and where the 7-azabicyclo[2.2.1]heptane ring moiety has the 1S, 2R, 4R stereochemistry, respectively.
  • The azabicyclic moiety of Formula I is connected to W by a urea or thiourea linkage. This type of linkage imparts different physical properties to the compounds compared to the corresponding amide or thioamide. The different physical properties offer advantages in ease of formulation, reduced toxicity or a different metabolism profile.
  • Another group of compounds of Formula I includes compounds where W is any one or more or combination of the following:
    Figure US20060116395A1-20060601-C00025
    where R3 has any definition as described herein.
  • Another group of compounds of Formula I includes compounds where W is any one or more or combination of the following:
    Figure US20060116395A1-20060601-C00026
    where R4 has any definition as described herein, and where n is 0, 1, 2, or 3.
  • Another group of compounds of Formula I includes compounds where W is a three-fused ring moiety and includes any one of the following:
    Figure US20060116395A1-20060601-C00027
    The three-fused ring moiety is composed of a five-membered ring fused to a middle 6-membered ring fused to a terminal 6-membered ring. The middle 6-membered ring and the terminal 6-membered ring are each optionally substituted with one substituent selected from Br, Cl, F, I, —CN, —NO2, —CF3, —N(R8)2, —N(R8)C(O)R8, alkyl, alkenyl, and alkynyl.
  • Further aspects and embodiments of the invention may become apparent to those skilled in the art from a review of the following detailed description, taken in conjunction with the examples and the appended claims. While the invention is susceptible of embodiments in various forms, described hereafter are specific embodiments of the invention with the understanding that the present disclosure is intended as illustrative, and is not intended to limit the invention to the specific embodiments described herein.
    • DETAILED DESCRIPTION OF THE INVENTION
  • Surprisingly, we have found that compounds of Formula I:
    Figure US20060116395A1-20060601-C00028
    wherein Azabicyclo is
    Figure US20060116395A1-20060601-C00029
    W is
    Figure US20060116395A1-20060601-C00030
    wherein W1 is N or CH;
  • X is O or S;
  • R0 is H, lower alkyl, substituted lower alkyl, or halogenated lower alkyl;
  • Lower alkyl is both straight- and branched-chain moieties having 1-4 carbon atoms;
  • Substituted lower alkyl is lower alkyl having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R7, R9, —NO2, —CN, —OR10, —SR10, —NR10R10, —C(O)R10, —C(O)NR10R10, —NR10C(O)R10, —S(O)2NR10R10, —NR10S(O)2R10, phenyl, or phenyl having 1 substituent selected from R15 and further having 0-3 substituents independently selected from F, Cl, Br, or I;
  • Halogenated lower alkyl is lower alkyl having 1 to (2n+1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • R1 is H, alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl;
  • Alkyl is both straight- and branched-chain moieties having from 1-6 carbon atoms;
  • Halogenated alkyl is an alkyl moiety having from 1-6 carbon atoms and having 1 to (2n+1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • Cycloalkyl is a cyclic alkyl moiety having from 3-6 carbon atoms;
  • Substituted phenyl is a phenyl either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from R12 and 0-3 substituents independently selected from F, Cl, Br, or I;
  • Substituted naphthyl is a naphthalene moiety either having 1-4 substituents independently selected from F, Cl, Br, or I, or having 1 substituent selected from R12 and 0-3 substituents independently selected from F, Cl, Br, or I, where the substitution can be independently on either only one ring or both rings of said naphthalene moiety;
  • R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
  • k1, k2, k5, k6, and k7 are independently 0, or 1;
  • k3, and k4 are independently 0, 1, or 2;
  • Substituted alkyl is an alkyl moiety from 1-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R7, R9, —NO2, —CN, —OR10, —SR10, —NR10R10, —C(O)R10, —C(S)R10, —C(O)OR10, —C(O)N(R10)2, —NR10C(O)R10, —NR10C(O)R10N(R10)2, —NR10S(O)2R10, —S(O)R10, —S(O)OR10, —OS(O)2R10, —S(O)2NR10R10, —NR10S(O)2R10, phenyl, or phenyl having 0-3 substituents independently selected from F, Cl, Br, I, or R13, and further having 1 substituent selected from R15;
  • Aryl is phenyl, substituted phenyl, naphthyl, or substituted naphthyl;
  • Each R3 is independently F, Cl, Br, I, —CN, —NO2, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocyloalkyl, substituted heterocycloalkyl, lactam heterocyclcoalkyl, aryl, R7, R9, —OR10, —SR10, —SOR10, —SO2R10, —SCN, —S(O)N(R10)2, —S(O)2N(R10)2, —C(O)R10, —C(O)2R10, —C(O)N(R10)2, C(R10)═N—OR10, —NC(O)R7, —NC(O)R8, —NC(O)R9, —N(R10)2, —NR10C(O)R10, —NR10S(O)2R10, or two R3 on adjacent carbon atoms may fuse to form a 6-membered ring to give a 5-6 fused, bicyclic moiety where the 6-membered ring is optionally substituted with 1-3 substitutents selected from R4;
  • m is 0, 1, or 2;
  • Alkenyl is straight- and branched-chain moieties having from 2-6 carbon atoms and having at least one carbon-carbon double bond;
  • Halogenated alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 1 to (2n−1) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • Substituted alkenyl is an unsaturated alkenyl moiety having from 2-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R7, R9, —NO2, —CN, —OR10, —SR10, —NR10R10, —C(O)R10, —C(S)R10, —C(O)OR10, —C(O)N(R10)2, —NR10C(O)R10, —NR10C(O)R10N(R10)2, —NR10S(O)2R10, —S(O)R10, —S(O)OR10, —OS(O)2R10, —S(O)2NR10R10, —NR10S(O)2R10, phenyl, or phenyl having 0-3 substituents independently selected from F, Cl, Br, I, or R13, and further having 1 substituent selected from R15;
  • Alkynyl is straight- and branched-chained moieties having from 2-6 carbon atoms and having at least one carbon-carbon triple bond;
  • Halogenated alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 1 to (2n−3) substituent(s) independently selected from F, Cl, Br, or I where n is the maximum number of carbon atoms in the moiety;
  • Substituted alkynyl is an unsaturated alkynyl moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R7, R9, —NO2, —CN, —OR10, —SR10, —NR10R10, —C(O)R10, —C(S)R10, —C(O)OR10, —C(O)N(R10)2, —NR10C(O)R10, —NR10C(O)R10N(R10)2, —NR10S(O)2R10, —S(O)R10, —S(O)OR10, —OS(O)2R10, —S(O)2NR10R10, —NR10S(O)2R10, phenyl, or phenyl having 0-3 substituents independently selected from F, Cl, Br, I, or R13, and further having 1 substituent selected from R15;
  • Halogenated cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 1-4 substituents independently selected from F, or Cl;
  • Substituted cycloalkyl is a cyclic moiety having from 3-6 carbon atoms and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R7, R9, —NO2, —CN, —OR10, —SR10, —NR10R10, —C(O)R10, —C(S)R10, —C(O)OR10, —C(O)N(R10)2, —NR10C(O)R10, —NR10C(O)R10N(R10)2, —NR10S(O)2R10, —S(O)R10, —S(O)OR10, —OS(O)2R10, —S(O)2NR10R10, —NR10S(O)2R10, phenyl, or phenyl having 0-3 substituents independently selected from F, Cl, Br, I, or R13, and further having 1 substituent selected from R15;
  • Heterocycloalkyl is a cyclic moiety having 4-7 atoms with 1-2 atoms within the ring being —S—, —N(R19)—, or —O—;
  • Halogenated heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being —S—, —N(R19)—, or —O—, and having 1-4 substituents independently selected from F, or Cl;
  • Substituted heterocycloalkyl is a cyclic moiety having from 4-7 atoms with 1-2 atoms within the ring being —S—, —N(R19)—, or —O— and having 0-3 substituents independently selected from F, Cl, Br, or I and further having 1 substituent selected from R7, R9, —NO2, —CN, —OR10, —SR10, —NR10R10, —C(O)R10, —C(S)R10, —C(O)OR10, —C(O)N(R10)2, —NR10C(O)R10, —NR10C(O)R10N(R10)2, —NR10S(O)2R10, —S(O)R10, —S(O)OR10, —OS(O)2R10, —S(O)2NR10R10, —NR10S(O)2R10, phenyl, or phenyl having 0-3 substituents independently selected from F, Cl, Br, I, or R13, and further having 1 substituent selected from R15;
  • Lactam heterocycloalkyl is a cyclic moiety having from 4-7 atoms with one atom being only nitrogen with the bond to the lactam heterocycloalkyl thru said atom being only nitrogen and having a ═O on a carbon adjacent to said nitrogen, and having up to 1 additional ring atom being oxygen, sulfur, or nitrogen and further having 0-2 substituents selected from F, Cl, Br, I, or R15 where valency allows;
  • R4 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR8, —SR8, —S(O)2R8, —S(O)R8, —OS(O)2R8, —N(R8)2, —C(O)R8, —C(S)R8, —C(O)OR8, —CN, —C(O)N(R8)2, —NR8C(O)R8, —S(O)2N(R8)2, —NR8S(O)2R8, —NO2, —N(R8)C(O)N(R8)2, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, phenyl having 0-4 substituents independently selected from F, Cl, Br, I and R15, naphthyl, naphthyl having 0-4 substituents independently selected from F, Cl, Br, I, or R15, or two R4 on adjacent carbon atoms may combine to form a three-ring-fused-5-6-6 system optionally substituted with up to 3 substituents independently selected from Br, Cl, F, I, —CN, —NO2, —CF3, —N(R8)2, —N(R8)C(O)R8, alkyl, alkenyl, and alkynyl;
  • Each R5 is independently H, alkyl, or substituted alkyl;
  • R6 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, —OH, —CN, —NH2, —NH(alkyl), or —N(alkyl)2;
  • R7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of —O—, ═N—, —N(R14)—, and —S—, and having 0-1 substituent selected from R15, and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R7 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula
    Figure US20060116395A1-20060601-C00031
    wherein A1 is O, S, or NR14,
    Figure US20060116395A1-20060601-C00032
    wherein A is CR17 or N, and each A2 or A3 is independently selected from CR17, O, S, N, or NR14, or
    Figure US20060116395A1-20060601-C00033
    wherein A is CR17 or N, and each A2 or A3 is independently selected from CR17, O, S, N, or NR14, and, each 9-membered fused-ring moiety having 0-1 substituent selected from R15, and further having 0-3 substituent(s) independently selected from F, Cl, Br, or I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;
  • Each R8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R15;
  • R9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from ═N— and having 0-1 substituent selected from R15 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R9 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from ═N—, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R15, and 0-3 substituent(s) independently selected from F, Cl, Br, or I and having a bond directly or indirectly attached to the core molecule where valency allows;
  • Each R10 is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R13, cycloalkyl substituted with 1 substituent selected from R13, heterocycloalkyl substituted with 1 substituent selected from R13, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;
  • Each R11 is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;
  • R12 is —NO2, —CN, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —OR11, —SR11, —N(R11)2, —C(O)R11, —C(O)N(R11)2, —NR11C(O)R11, —S(O)2N(R11)2, or —NR11S(O)2R11;
  • R13 is —OR11, —SR11, —N(R11)2, —C(O)R11, —SOR11, —SO2R11, —C(O)N(R11)2, —CN, —CF3, —NR11C(O)R11, —S(O)2N(R11)2, —NR11S(O)2R11, or —NO2;
  • R14 is independently H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;
  • R15 is alkyl, substituted alkyl, halogenated alkyl, —OR11, —CN, —NO2, —N(R10)2;
  • R17 is H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R18, —OR11, —SR11, —N(R11)2, —NR11S(O)2R1, F, Cl, Br, or I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R18, —OR11, —SR11, —NR11R11, —C(O)R11, —NO2, —C(O)NR11R11, —CN, —NR11C(O)R1, —S(O)2NR11R11, or —NR11S(O)2R11, and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I;
  • R18 is alkyl, cycloalkyl, heterocycloalkyl, any of which is substituted with 0-3 substituents independently selected from F, Cl, Br, or I and further substituted with 1 substituent selected from —NO2, —CN, —OR10, —SR10, —NR10R10, —C(O)R10, —C(O)NR10R10, —NR10C(O)R10, —S(O)2NR10R10, —NR10S(O)2R10, phenyl, or phenyl having 1 substituent selected from R15 and further having 0-3 substituents independently selected from F, Cl, Br, or I;
  • R19 is H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, phenyl, or phenyl having 0-4 substituents independently selected from F, Cl, Br, I, and R15;
  • or pharmaceutical composition, pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof useful to treat any one of or combination of cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (mild cognitive impairment), senile dementia, schizophrenia, psychosis, attention deficit disorder, attention deficit hyperactivity disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, depression, general anxiety disorder, age-related macular degeneration, Parkinson's disease, tardive dyskinesia, Pick's disease, post traumatic stress disorder, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.
  • In another aspect, the invention includes methods of treating a mammal suffering from schizophrenia or psychosis by administering compounds of Formula I in conjunction with antipsychotic drugs. The compounds of Formula I and the antipsychotic drugs can be administered simultaneously or at separate intervals. When administered simultaneously the compounds of Formula I and the antipsychotic drugs can be incorporated into a single pharmaceutical composition. Alternatively, two separate compositions, i.e., one containing compounds of Formula I and the other containing antipsychotic drugs, can be administered simultaneously.
  • The present invention also includes the intermediates, the processes to make them and the active compounds of Formula I, pharmaceutical compositions including the active compounds, and methods to treat the identified diseases.
  • Abbreviations which are well known to one of ordinary skill in the art may be used (e.g., “Ph” for phenyl, “Me” for methyl, “Et” for ethyl, “h” or “hr” for hour or hours, min for minute or minutes, and “rt” or “RT” for room temperature).
  • All temperatures are in degrees Centigrade.
  • Room temperature is within the range of 15-25 degrees Celsius.
  • AChR refers to acetylcholine receptor.
  • nAChR refers to nicotinic acetylcholine receptor.
  • Pre-senile dementia is also known as mild cognitive impairment.
  • 5HT3R refers to the serotonin-type 3 receptor.
  • α-btx refers to α-bungarotoxin.
  • FLIPR refers to a device marketed by Molecular Devices, Inc. designed to precisely measure cellular fluorescence in a high throughput whole-cell assay. (Schroeder et. al., J. Biomolecular Screening, 1(2), p 75-80, 1996).
  • TLC refers to thin-layer chromatography.
  • HPLC refers to high pressure liquid chromatography.
  • MeOH refers to methanol.
  • EtOH refers to ethanol.
  • IPA refers to isopropyl alcohol.
  • THF refers to tetrahydrofuran.
  • DMSO refers to dimethylsulfoxide.
  • DMF refers to N,N-dimethylformamide.
  • EtOAc refers to ethyl acetate.
  • TMS refers to tetramethylsilane.
  • TEA refers to triethylamine.
  • DIEA refers to N,N-diisopropylethylamine.
  • MLA refers to methyllycaconitine.
  • Ether refers to diethyl ether.
  • HATU refers to O-(7-azabenzotriazol-1-yl)-N,N,N′,N′-tetramethyluronium hexafluorophosphate.
  • DBU refers to 1,8-diazobicyclo[5.4.0]undec-7-one.
  • CDI refers to carbonyl diimidazole.
  • NMO refers to N-methylmorpholine-N-oxide.
  • TPAP refers to tetrapropylammonium perruthenate.
  • Halogen is F, Cl, Br, or I.
  • The carbon atom content of various hydrocarbon-containing moieties is indicated by a prefix designating the minimum and maximum number of carbon atoms in the moiety, i.e., the prefix Ci-j indicates a moiety of the integer “i” to the integer “j” carbon atoms, inclusive. Thus, for example, C1-6 alkyl refers to alkyl of one to six carbon atoms.
  • One will recognize that where alkyl, halogenated alkyl, or substituted alkyl is allowed, lower alkyl, halogenated lower alkyl and substituted lower alkyl would also be allowed, respectively.
  • Non-inclusive examples of heteroaryl compounds that fall within the definitions of R7 and R9 include, but are not limited to, thienyl, benzothienyl, pyridyl, thiazolyl, quinolyl, pyrazinyl, pyrimidyl, imidazolyl, furanyl, benzofuranyl, benzothiazolyl, isothiazolyl, benzisothiazolyl, benzisoxazolyl, benzimidazolyl, indolyl, benzoxazolyl, pyrazolyl, triazolyl, tetrazolyl, isoxazolyl, oxazolyl, pyrrolyl, isoquinolinyl, cinnolinyl, indazolyl, indolizinyl, phthalazinyl, pydridazinyl, triazinyl, isoindolyl, purinyl, oxadiazolyl, furazanyl, benzofurazanyl, benzothiophenyl, benzothiazolyl, quinazolinyl, quinoxalinyl, naphthridinyl, furopyridinyl, pyrrolopyridinyl, or thienopyridinyl. All isomeric forms of the non-inclusive named moieties are included, e.g., benzofuranyl includes 1-benzofuran-2-yl, 1-benzofuran-3-yl, 1-benzofuran-4-yl, 1-benzofuran-5-yl, 1-benzofuran-6-yl, 1-benzofuran-7-yl, 2-benzofuran-1-yl, 2-benzofuran-2-yl, 2-benzofuran-3-yl, 2-benzofuran-4-yl, or 2-benzofuran-5-yl. The non-inclusive examples of R7 and R9 may be substituted as allowed within the respective definition of R7 and R9 as valency allows. One of ordinary skill in the art can identify the allowed substitution by comparing the non-inclusive examples with the respective definitions of R7 and R9.
  • Non-inclusive examples of heterocycloalkyl include, but are not limited to, tetrahydrofurano, tetrahydropyrano, morpholino, pyrrolidino, piperidino, piperazine, azetidino, azetidinono, oxindolo, dihydroimidazolo, pyrrolidino, or isoxazolinyl.
  • Mammal denotes human and other mammals.
  • Brine refers to an aqueous saturated sodium chloride solution.
  • Equ means molar equivalents.
  • IR refers to infrared spectroscopy.
  • Lv refers to leaving groups within a molecule, including Cl, OH, or mixed anhydride.
  • NMR refers to nuclear (proton) magnetic resonance spectroscopy, chemical shifts are reported in ppm (δ) downfield from TMS.
  • MS refers to mass spectrometry expressed as m/e or mass/charge unit. HRMS refers to high resolution mass spectrometry expressed as m/e or mass/charge unit. [M+H]+ refers to an ion composed of the parent plus a proton. [M−H]− refers to an ion composed of the parent minus a proton. [M+Na]+ refers to an ion composed of the parent plus a sodium ion. [M+K]+ refers to an ion composed of the parent plus a potassium ion. EI refers to electron impact. ESI refers to electrospray ionization. CI refers to chemical ionization. FAB refers to fast atom bombardment.
  • Amino protecting group includes, but is not limited to, carbobenzyloxy (CBz), tert butoxy carbonyl (BOC) and the like. Examples of other suitable amino protecting groups are known to person skilled in the art and can be found in “Protective Groups in Organic synthesis,” 3rd Edition, authored by Theodora Greene and Peter Wuts.
  • Compounds of the present invention may be in the form of pharmaceutically acceptable salts. The term “pharmaceutically acceptable salts” refers to salts prepared from pharmaceutically acceptable non-toxic bases including inorganic bases and organic bases, and salts prepared from inorganic acids, and organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, ferric, ferrous, lithium, magnesium, potassium, sodium, zinc, and the like. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, such as arginine, betaine, caffeine, choline, N,N-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, and the like. Salts derived from inorganic acids include salts of hydrochloric acid, hydrobromic acid, hydroiodic acid, sulfuric acid, phosphoric acid, phosphorous acid and the like. Salts derived from pharmaceutically acceptable organic non-toxic acids include salts of C1-6 alkyl carboxylic acids, di-carboxylic acids, and tri-carboxylic acids such as acetic acid, propionic acid, fumaric acid, succinic acid, tartaric acid, maleic acid, adipic acid, and citric acid, and aryl and alkyl sulfonic acids such as toluene sulfonic acids and the like.
  • By the term “effective amount” of a compound as provided herein is meant a nontoxic but sufficient amount of the compound(s) to provide the desired effect. As pointed out below, the exact amount required will vary from subject to subject, depending on the species, age, and general condition of the subject, the severity of the disease that is being treated, the particular compound(s) used, the mode of administration, and the like. Thus, it is not possible to specify an exact “effective amount.” However, an appropriate effective amount may be determined by one of ordinary skill in the art using only routine experimentation.
  • The amount of therapeutically effective compound(s) that is administered and the dosage regimen for treating a disease condition with the compounds and/or compositions of this invention depends on a variety of factors, including the age, weight, sex and medical condition of the subject, the severity of the disease, the route and frequency of administration, and the particular compound(s) employed, and thus may vary widely. The compositions contain well know carriers and excipients in addition to a therapeutically effective amount of compounds of Formula I. The pharmaceutical compositions may contain active ingredient in the range of about 0.001 to 100 mg/kg/day for an adult, preferably in the range of about 0.1 to 50 mg/kg/day for an adult. A total daily dose of about 1 to 1000 mg of active ingredient may be appropriate for an adult. The daily dose can be administered in one to four doses per day.
  • In addition to the compound(s) of Formula I, the composition for therapeutic use may also comprise one or more non-toxic, pharmaceutically acceptable carrier materials or excipients. The term “carrier” material or “excipient” herein means any substance, not itself a therapeutic agent, used as a carrier and/or diluent and/or adjuvant, or vehicle for delivery of a therapeutic agent to a subject or added to a pharmaceutical composition to improve its handling or storage properties or to permit or facilitate formation of a dose unit of the composition into a discrete article such as a capsule or tablet suitable for oral administration. Excipients can include, by way of illustration and not limitation, diluents, disintegrants, binding agents, adhesives, wetting agents, polymers, lubricants, glidants, substances added to mask or counteract a disagreeable taste or odor, flavors, dyes, fragrances, and substances added to improve appearance of the composition. Acceptable excipients include lactose, sucrose, starch powder, cellulose esters of alkanoic acids, cellulose alkyl esters, talc, stearic acid, magnesium stearate, magnesium oxide, sodium and calcium salts of phosphoric and sulfuric acids, gelatin, acacia gum, sodium alginate, polyvinyl-pyrrolidone, and/or polyvinyl alcohol, and then tableted or encapsulated for convenient administration. Such capsules or tablets may contain a controlled-release formulation as may be provided in a dispersion of active compound in hydroxypropyl-methyl cellulose, or other methods known to those skilled in the art. For oral administration, the pharmaceutical composition may be in the form of, for example, a tablet, capsule, suspension or liquid. If desired, other active ingredients may be included in the composition.
  • In addition to the oral dosing, noted above, the compositions of the present invention may be administered by any suitable route, in the form of a pharmaceutical composition adapted to such a route, and in a dose effective for the treatment intended. The compositions may, for example, be administered parenterally, e.g., intravascularly, intraperitoneally, subcutaneously, or intramuscularly. For parenteral administration, saline solution, dextrose solution, or water may be used as a suitable carrier. Formulations for parenteral administration may be in the form of aqueous or non-aqueous isotonic sterile injection solutions or suspensions. These solutions and suspensions may be prepared from sterile powders or granules having one or more of the carriers or diluents mentioned for use in the formulations for oral administration. The compounds may be dissolved in water, polyethylene glycol, propylene glycol, EtOH, corn oil, cottonseed oil, peanut oil, sesame oil, benzyl alcohol, sodium chloride, and/or various buffers. Other adjuvants and modes of administration are well and widely known in the pharmaceutical art.
  • The serotonin type 3 receptor (5HT3R) is a member of a superfamily of ligand-gated ion channels, which includes the muscle and neuronal nAChR, the glycine receptor, and the γ-aminobutyric acid type A receptor. Like the other members of this receptor superfamily, the 5HT3R exhibits a large degree of sequence homology with α7 nAChR but functionally the two ligand-gated ion channels are very different. For example, α7 nAChR is rapidly inactivated, is highly permeable to calcium and is activated by acetylcholine and nicotine. On the other hand, 5HT3R is inactivated slowly, is relatively impermeable to calcium and is activated by serotonin. These experiments suggest that the α7 nAChR and 5HT3R proteins have some degree of homology, but function very differently. Indeed the pharmacology of the channels is very different. For example, Ondansetron, a highly selective 5HT3R antagonist, has little activity at the α7 nAChR. The converse is also true. For example, GTS-21, a highly selective α7 nAChR agonist, has little activity at the 5HT3R.
  • α7 nAChR is a ligand-gated Ca++ channel formed by a homopentamer of α7 subunits. Previous studies have established that α-bungarotoxin (α-btx) binds selectively to this homopetameric, α7 nAChR subtype, and that α7 nAChR has a high affinity binding site for both α-btx and methyllycaconitine (MLA). α7 nAChR is expressed at high levels in the hippocampus, ventral tegmental area and ascending cholinergic projections from nucleus basilis to thalamocortical areas. α7 nAChR agonists increase neurotransmitter release, and increase cognition, arousal, attention, learning and memory.
  • Data from human and animal pharmacological studies establish that nicotinic cholinergic neuronal pathways control many important aspects of cognitive function including attention, learning and memory (Levin, E. D., Psychopharmacology, 108:417-31, 1992; Levin, E. D. and Simon B. B., Psychopharmacology, 138:217-30, 1998). For example, it is well known that nicotine increases cognition and attention in humans. ABT-418, a compound that activates α4β2 and α7 nAChR, improves cognition and attention in clinical trials of Alzheimer's disease and attention-deficit disorders (Potter, A. et. al., Psychopharmacology (Berl), 142(4):33442, March 1999; Wilens, T. E. et. al., Am. J. Psychiatry, 156(12):1931-7, December 1999). It is also clear that nicotine and selective but weak α7 nAChR agonists increase cognition and attention in rodents and non-human primates.
  • Schizophrenia is a complex multifactorial illness caused by genetic and non-genetic risk factors that produce a constellation of positive and negative symptoms. The positive symptoms include delusions and hallucinations and the negative symptoms include deficits in affect, attention, cognition and information processing. No single biological element has emerged as a dominant pathogenic factor in this disease. Indeed, it is likely that schizophrenia is a syndrome that is produced by the combination of many low penetrance risk factors. Pharmacological studies established that dopamine receptor antagonists are efficacious in treating the overt psychotic features (positive symptoms) of schizophrenia such as hallucinations and delusions. Clozapine, an “atypical” antipsychotic drug, is novel because it is effective in treating both the positive and some of the negative symptoms of this disease. Clozapine's utility as a drug is greatly limited because continued use leads to an increased risk of agranulocytosis and seizure. No other antipsychotic drug is effective in treating the negative symptoms of schizophrenia. This is significant because the restoration of cognitive functioning is the best predictor of a successful clinical and functional outcome of schizophrenic patients (Green, M. F., Am J Psychiatry, 153:321-30, 1996). By extension, it is clear that better drugs are needed to treat the cognitive disorders of schizophrenia in order to restore a better state of mental health to patients with this disorder.
  • One aspect of the cognitive deficit of schizophrenia can be measured by using the auditory event-related potential (P50) test of sensory gating. In this test, electroencepholographic (EEG) recordings of neuronal activity of the hippocampus are used to measure the subject's response to a series of auditory “clicks” (Adler, L. E. et. al., Biol. Psychiatry, 46:8-18, 1999). Normal individuals respond to the first click with greater degree than to the second click. In general, schizophrenics and schizotypal patients respond to both clicks nearly the same (Cullum, C. M. et. al., Schizophr. Res., 10:13141, 1993). These data reflect a schizophrenic's inability to “filter” or ignore unimportant information. The sensory gating deficit appears to be one of the key pathological features of this disease (Cadenhead, K. S. et. al., Am. J. Psychiatry, 157:55-9, 2000). Multiple studies show that nicotine normalizes the sensory deficit of schizophrenia (Adler, L. E. et. al., Am. J. Psychiatry, 150:1856-61, 1993). Pharmacological studies indicate that nicotine's effect on sensory gating is via the α7 nAChR (Adler, L. E. et. al., Schizophr. Bull., 24:189-202, 1998). Indeed, the biochemical data indicate that schizophrenics have 50% fewer of α7 nAChR receptors in the hippocampus, thus giving a rationale to partial loss of α7 nAChR functionality (Freedman, R. et. al., Biol. Psychiatry, 38:22-33, 1995). Interestingly, genetic data indicate that a polymorphism in the promoter region of the α7 nAChR gene is strongly associated with the sensory gating deficit in schizophrenia (Freedman, R. et. al., Proc. Nat'l Acad. Sci. USA, 94(2):587-92, 1997; Myles-Worsley, M. et. al., Am. J. Med. Genet, 88(5):544-50, 1999). To date, no mutation in the coding region of the α7 nAChR has been identified. Thus, schizophrenics express the same α7 nAChR as non-schizophrenics.
  • Selective α7 nAChR agonists may be found using a functional assay on FLIPR (see WO 00/73431 A2). FLIPR is designed to read the fluorescent signal from each well of a 96 or 384 well plate as fast as twice a second for up to 30 minutes. This assay may be used to accurately measure the functional pharmacology of α7 nAChR and 5HT3R. To conduct such an assay, one uses cell lines that expressed functional forms of the α7 nAChR using the α7/5-HT3 channel as the drug target and cell lines that expressed functional 5HT3R. In both cases, the ligand-gated ion channel was expressed in SH-EP1 cells. Both ion channels can produce robust signal in the FLIPR assay.
  • The compounds of the present invention are α7 nAChR agonists and may be used to treat a wide variety of diseases. For example, they may be used in treating schizophrenia, or psychosis.
  • Schizophrenia is a disease having multiple aspects. Currently available drugs are generally aimed at controlling the positive aspects of schizophrenia, such as delusions. One drug, Clozapine, is aimed at a broader spectrum of symptoms associated with schizophrenia. This drug has many side effects and is thus not suitable for many patients. Thus, there is a need for a drug to treat the cognitive and attention deficits associated with schizophrenia. Similarly, there is a need for a drug to treat the cognitive and attention deficits associated with schizoaffective disorders, or similar symptoms found in the relatives of schizophrenic patients.
  • Psychosis is a mental disorder characterized by gross impairment in the patient's perception of reality. The patient may suffer from delusions, and hallucinations, and may be incoherent in speech. His behavior may be agitated and is often incomprehensible to those around him. In the past, the term psychosis has been applied to many conditions that do not meet the stricter definition given above. For example, mood disorders were named as psychoses.
  • There are a variety of antipsychotic drugs. The conventional antipsychotic drugs include Chlorpromazine, Fluphenazine, Haloperidol, Loxapine, Mesoridazine, Molindone, Perphenazine, Pimozide, Thioridazine, Thiothixene, and Trifluoperazine. These drugs all have an affinity for the dopamine 2 receptor.
  • These conventional antipsychotic drugs have several side effects, including sedation, weight gain, tremors, elevated prolactin levels, akathisia (motor restlessness), dystonia and muscle stiffness. These drugs may also cause tardive dyskinesia. Unfortunately, only about 70% of patients with schizophrenia respond to conventional antipsychotic drugs. For these patients, atypical antipsychotic drugs are available.
  • Atypical antipsychotic drugs generally are able to alleviate positive symptoms of psychosis while also improving negative symptoms of the psychosis to a greater degree than conventional antipsychotics. These drugs may improve neurocognitive deficits. Extrapyramidal (motor) side effects are not as likely to occur with the atypical antipsychotic drugs, and thus, these atypical antipsychotic drugs have a lower risk of producing tardive dyskinesia. Finally these atypical antipsychotic drugs cause little or no elevation of prolactin. Unfortunately, these drugs are not free of side effects. Although these drugs each produce different side effects, as a group the side effects include: agranulocytosis; increased risk of seizures, weight gain, somnolence, dizziness, tachycardia, decreased ejaculatory volume, and mild prolongation of QTc interval.
  • In a combination therapy to treat multiple symptoms of diseases including schizophrenia, the compounds of Formula I and the anti-psychotic drugs can be administered simultaneously or at separate intervals. When administered simultaneously the compounds of Formula I and the anti-psychotic drugs can be incorporated into a single pharmaceutical composition, e.g., a pharmaceutical combination therapy composition. Alternatively, two separate compositions, i.e., one containing compounds of Formula I and the other containing anti-psychotic drugs, can be administered simultaneously. Examples of anti-psychotic drugs, in addition to those listed above, include, but are not limited to, Thorazine, Mellaril, Trilafon, Navane, Stelazine, Permitil, Prolixin, Risperdal, Zyprexa, Seroquel, ZELDOX, Acetophenazine, Carphenazine, Chlorprothixene, Droperidol, Loxapine, Mesoridazine, Molindone, Ondansetron, Pimozide, Prochlorperazine, and Promazine.
  • A pharmaceutical combination therapy composition can include therapeutically effective amounts of the compounds of Formula I, noted above, and a therapeutically effective amount of anti-psychotic drugs. These compositions may be formulated with common excipients, diluents or carriers, and compressed into tablets, or formulated elixirs or solutions for convenient oral administration or administered by intramuscular intravenous routes. The compounds can be administered rectally, topically, orally, sublingually, or parenterally and may be formulated as sustained relief dosage forms and the like.
  • When separately administered, therapeutically effective amounts of compositions containing compounds of Formula I and anti-psychotic drugs are administered on a different schedule. One may be administered before the other as long as the time between the two administrations falls within a therapeutically effective interval. A therapeutically effective interval is a period of time beginning when one of either (a) the compounds of Formula I, or (b) the anti-psychotic drugs is administered to a human and ending at the limit of the beneficial effect in the treatment of schizophrenia or psychosis of the combination of (a) and (b). The methods of administration of the compounds of Formula I and the anti-psychotic drugs may vary. Thus, either agent or both agents may be administered rectally, topically, orally, sublingually, or parenterally.
  • As discussed, the compounds of the present invention are α7 nAChR agonists. Therefore, as another aspect of the present invention, the compounds of the present invention may be used to treat a variety of diseases including cognitive and attention deficit symptoms of Alzheimer's, neurodegeneration associated with diseases such as Alzheimer's disease, pre-senile dementia (also known as mild cognitive impairment), and senile dementia.
  • Alzheimer's disease has many aspects, including cognitive and attention deficits. Currently, these deficits are treated with cholinesterase inhibitors. These inhibitors slow the break down of acetylcholine, and thereby provide a general nonspecific increase in the activity of the cholinergic nervous system. Since the drugs are nonspecific, they have a wide variety of side effects. Thus, there is a need for a drug that stimulates a portion of the cholinergic pathways and thereby provides improvement in the cognitive and attention deficits associated with Alzheimer's disease without the side effects created by nonspecific stimulation of the cholinergic pathways.
  • Neurodegeneration is a common problem associated with diseases such as Alzheimer's disease. While the current drugs treat some of the symptoms of this disease, they do not control the underlying pathology of the disease. Accordingly, it would be desirable to provide a drug that can slow the progress of Alzheimer's disease.
  • Pre-senile dementia (mild cognitive impairment) concerns memory impairment rather than attention deficit problems and otherwise unimpaired cognitive functioning. Mild cognitive impairment is distinguished from senile dementia in that mild cognitive impairment involves a more persistent and troublesome problem of memory loss for the age of the patient. There currently is no medication specifically identified for treatment of mild cognitive impairment, due somewhat to the newness of identifying the disease. Therefore, there is a need for a drug to treat the memory problems associated with mild cognitive impairment.
  • Senile dementia is not a single disease state. However, the conditions classified under this name frequently include cognitive and attention deficits. Generally, these deficits are not treated. Accordingly, there is a need for a drug that provides improvement in the cognitive and attention deficits associated with senile dementia.
  • As discussed, the compounds of the present invention are α7 nAChR agonists. Therefore, yet other diseases to be treated with compounds of the present invention include treating the cognitive and attention deficits as well as the neurodegeneration associated with any one or more or combination of the following: attention deficit disorder, attention deficit hyperactivity disorder, depression, anxiety, general anxiety disorder, post traumatic stress disorder, mood and affective disorders, amyotrophic lateral sclerosis, borderline personality disorder, traumatic brain injury, behavioral and cognitive problems associated with brain tumors, AIDS dementia complex, dementia associated with Down's syndrome, dementia associated with Lewy Bodies, Huntington's disease, Parkinson's disease, tardive dyskinesia, Pick's disease, dysregulation of food intake including bulemia and anorexia nervosa, withdrawal symptoms associated with smoking cessation and dependant drug cessation, Gilles de la Tourette's Syndrome, age-related macular degeneration, glaucoma, neurodegeneration associated with glaucoma, or symptoms associated with pain.
  • Attention deficit disorder is generally treated with methylphenidate, an amphetamine-like molecule that has some potential for abuse. Accordingly, it would be desirable to provide a drug that treats attention deficit disorder while having fewer side effects than the currently used drug.
  • Attention deficit hyperactivity disorder, otherwise known as ADHD, is a neurobehavioral disorder affecting 3-5% of all American children. ADHD concerns cognitive alone or both cognitive and behavioral actions by interfering with a person's ability to stay on a task and to exercise age-appropriate inhibition. Several types of ADHD exist: a predominantly inattentive subtype, a predominantly hyperactive-impulsive subtype, and a combined subtype. Treatment may include medications such as methylphenidate, dextroamphetamine, or pemoline, which act to decrease impulsivity and hyperactivity and to increase attention. No “cure” for ADHD currently exists. Children with the disorder seldom outgrow it; therefore, there is a need for appropriate medicaments.
  • Depression is a mood disorder of varying lengths of normally several months to more than two years and of varying degrees of feelings involving sadness, despair, and discouragement. The heterocyclic antidepressants (HCA's) are currently the largest class of antidepressants, but monoamine oxidase inhibitors (MAOI's) are used in particular types of depression. Common side effects from HCA's are sedation and weight gain. In elderly patients with organic brain disease, the side effects from HCA's can also include seizures and behavioral symptoms. The main side effects from using MAOI's occur from dietary and drug interactions. Therefore, agents with fewer side effects would be useful.
  • Anxiety disorders (disorders with prominent anxiety or phobic avoidance), represent an area of umet medical needs in the treatment of psychiatric illness. See Diagnostic & Statistical Manual of Mental Disorders, IV (1994), pp 393-394, for various disease forms of anxiety.
  • General anxiety disorder (GAD) occurs when a person worries about things such as family, health, or work when there is no reason to worry and is unable not to worry. About 3 to 4% of the U.S. population has GAD during the course of a year. GAD most often strikes people in childhood or adolescence, but can begin in adulthood, too. It affects women more often than men. Currently, treatment involves cognitive-behavioral therapy, relaxation techniques, and biofeedback to control muscle tension and medications such as benzodiazepines, imipramine, and buspirone. These drugs are effective but all have side-effect liabilities. Therefore, there is a need of a pharmaceutical agent to address the symptoms with fewer side effects.
  • Anxiety also includes post-traumatic stress disorder (PTSD), which is a form of anxiety triggered by memories of a traumatic event that directly affected the patient or that the patient may have witnessed. The disorder commonly affects survivors of traumatic events including sexual assault, physical assault, war, torture, natural disasters, an automobile accident, an airplane crash, a hostage situation, or a death camp. The affliction also can affect rescue workers at an airplane crash or a mass shooting, someone who witnessed a tragic accident or someone who has unexpectedly lost a loved one. Treatment for PTSD includes cognitive-behavioral therapy, group psychotherapy, and medications such as Clonazepam, Lorazepam and selective serotonin-reuptake inhibitors such as Fluoxetine, Sertraline, Paroxetine, Citalopram and Fluvoxamine. These medications help control anxiety as well as depression. Various forms of exposure therapy (such as systemic desensitization and imaginal flooding) have all been used with PTSD patients. Exposure treatment for PTSD involves repeated reliving of the trauma, under controlled conditions, with the aim of facilitating the processing of the trauma. Therefore, there is a need for better pharmaceutical agents to treat post traumatic stress disorder.
  • Mood and affective disorders fall within a large group of diseases, including monopolar depression and bi-polar mood disorder. These diseases are treated with three major classes of compounds. The first group is the heterocyclic antidepressant (HCA's). This group includes the well-known tricyclic antidepressants. The second group of compounds used to treat mood disorders is the monoamine oxidase inhibitors (MAOI's) that are used in particular types of diseases. The third drug is lithium. Common side effects from HCA's are sedation and weight gain. In elderly patients with organic brain disease, the side effects of HCA's can also include seizures and behavioral symptoms. The main side effects from using MAOI's occur from dietary and drug interactions. Benign side effects from the use of lithium include, but are not limited to, weight gain, nausea, diarrhea, polyuria, polydipsia, and tremor. Toxic side effects from lithium can include persistent headache, mental confusion, and may reach seizures and cardiac arrhythmias. Therefore, agents with less side effects or interactions with food or other medications would be useful.
  • Borderline personality disorder, although not as well known as bipolar disorder, is more common. People having borderline personality disorder suffer from a disorder of emotion regulation. Pharmaceutical agents are used to treat specific symptoms, such as depression or thinking distortions.
  • Acquired immune deficiency syndrome (AIDS) results from an infection with the human immunodeficiency virus (HIV). This virus attacks selected cells and impairs the proper function of the immune, nervous, and other systems. HIv infection can cause other problems such as, but not limited to, difficulties in thinking, otherwise known as AIDS dementia complex. Therefore, there is a need to drugs to relieve the confusion and mental decline of persons with AIDS.
  • Amyotrophic lateral sclerosis, also known as Lou Gehrig's disease, belongs to a class of disorders known as motor neuron diseases wherein specific nerve cells in the brain and spinal cord gradually degenerate to negatively affect the control of voluntary movement. Currently, there is no cure for amyotrophic lateral sclerosis although patients may receive treatment from some of their symptoms and although Riluzole has been shown to prolong the survival of patients. Therefore, there is a need for a pharmaceutical agent to treat this disease.
  • Traumatic brain injury occurs when the brain is damaged from a sudden physical assault on the head. Symptoms of the traumatic brain injury include confusion and other cognitive problems. Therefore, there is a need to address the symptoms of confusion and other cognitive problems.
  • Brain tumors are abnormal growths of tissue found inside of the skull. Symptoms of brain tumors include behavioral and cognitive problems. Surgery, radiation, and chemotherapy are used to treat the tumor, but other agents are necessary to address associated symptoms. Therefore, there is a need to address the symptoms of behavioral and cognitive problems.
  • Persons with Down's syndrome have in all or at least some of their cells an extra, critical portion of the number 21 chromosome. Adults who have Down's syndrome are known to be at risk for Alzheimer-type dementia. Currently, there is no proven treatment for Down's syndrome. Therefore, there is a need to address the dementia associated with Down's syndrome.
  • Genetically programmed degeneration of neurons in certain areas of the brain cause Huntington's disease. Early symptoms of Huntington's disease include mood swings, or trouble learning new things or remembering a fact. Most drugs used to treat the symptoms of Huntington's disease have side effects such as fatigue, restlessness, or hyperexcitability. Currently, there is no treatment to stop or reverse the progression of Huntington's disease. Therefore, there is a need of a pharmaceutical agent to address the symptoms with fewer side effects.
  • Dementia with Lewy Bodies is a neurodegenerative disorder involving abnormal structures known as Lewy bodies found in certain areas of the brain. Symptoms of dementia with Lewy bodies include, but are not limited to, fluctuating cognitive impairment with episodic delirium. Currently, treatment concerns addressing the parkinsonian and psychiatric symptoms. However, medicine to control tremors or loss of muscle movement may actually accentuate the underlying disease of dementia with Lewy bodies. Therefore, there is a need of a pharmaceutical agent to treat dementia with Lewy bodies.
  • Parkinson's disease is a neurological disorder characterized by tremor, hypokinesia, and muscular rigidity. Currently, there is no treatment to stop the progression of the disease. Therefore, there is a need of a pharmaceutical agent to address Parkinson's.
  • Tardive dyskinesia is associated with the use of conventional antipsychotic drugs. This disease is characterized by involuntary movements most often manifested by puckering of the lips and tongue and/or writhing of the arms or legs. The incidence of tardive dyskinesia is about 5% per year of drug exposure among patients taking conventional antipsychotic drugs. In about 2% of persons with the disease, tardive dyskinesia is severely disfiguring. Currently, there is no generalized treatment for tardive dyskinesia. Furthermore, the removal of the effect-causing drugs is not always an option due to underlying problems. Therefore, there is a need for a pharmaceutical agent to address the symptoms of tardive dyskinesia.
  • Pick's disease results from a slowly progressive deterioration of social skills and changes in personality with the resulting symptoms being impairment of intellect, memory, and language. Common symptoms include memory loss, lack of spontaneity, difficulty in thinking or concentrating, and speech disturbances. Currently, there is no specific treatment or cure for Pick's disease but some symptoms can be treated with cholinergic and serotonin-boosting antidepressants. In addition, antipsychotic medications may alleviate symptoms in FTD patients who are experiencing delusions or hallucinations. Therefore, there is a need for a pharmaceutical agent to treat the progressive deterioration of social skills and changes in personality and to address the symptoms with fewer side effects.
  • Dysregulation of food intake associated with eating disease, including bulemia nervosa and anorexia nervosa, involve neurophysiological pathways. Anorexia nervosa is hard to treat due to patients not entering or remaining in after entering programs. Currently, there is no effective treatment for persons suffering from severe anorexia nervosa. Cognitive behavioral therapy has helped patients suffering from bulemia nervosa; however, the response rate is only about 50% and current treatment does not adequately address emotional regulation. Therefore, there is a need for pharmaceutical agents to address neurophysiological problems underlying diseases of dysregulation of food intake.
  • Cigarette smoking has been recognized as a major public health problem for a long time. However, in spite of the public awareness of health hazard, the smoking habit remains extraordinarily persistent and difficult to break. There are many treatment methods available, and yet people continue to smoke. Administration of nicotine transdermally, or in a chewing gum base is common treatments. However, nicotine has a large number of actions in the body, and thus can have many side effects. It is clear that there is both a need and a demand of long standing for a convenient and relatively easy method for aiding smokers in reducing or eliminating cigarette consumption. A drug that could selectively stimulate only certain of the nicotinic receptors would be useful in smoke cessation programs.
  • Smoke cessation programs may involve oral dosing of the drug of choice. The drug may be in the form of tablets. However, it is preferred to administer the daily dose over the waking hours, by administration of a series of incremental doses during the day. The preferred method of such administration is a slowly dissolving lozenge, troche, or chewing gum, in which the drug is dispersed. Another drug in treating nicotine addiction is Zyban. This is not a nicotine replacement, as are the gum and patch. Rather, this works on other areas of the brain, and its effectiveness is to help control nicotine craving or thoughts about cigarette use in people trying to quit. Zyban is not very effective and effective drugs are needed to assist smokers in their desire to stop smoking. These drugs may be administered transdermally through the use of skin patches. In certain cases, the drugs may be administered by subcutaneous injection, especially if sustained release formulations are used.
  • Drug use and dependence is a complex phenomenon, which cannot be encapsulated within a single definition. Different drugs have different effects, and therefore different types of dependence. Drug dependence has two basic causes, that is, tolerance and physical dependence. Tolerance exists when the user must take progressively larger doses to produce the effect originally achieved with smaller doses. Physical dependence exists when the user has developed a state of physiologic adaptation to a drug, and there is a withdrawal (abstinence) syndrome when the drug is no longer taken. A withdrawal syndrome can occur either when the drug is discontinued or when an antagonist displaces the drug from its binding site on cell receptors, thereby counteracting its effect. Drug dependence does not always require physical dependence.
  • In addition drug dependence often involves psychological dependence, that is, a feeling of pleasure or satisfaction when taking the drug. These feelings lead the user to repeat the drug experience or to avoid the displeasure of being deprived of the drug. Drugs that produce strong physical dependence, such as nicotine, heroin and alcohol are often abused, and the pattern of dependence is difficult to break. Drugs that produce dependence act on the CNS and generally reduce anxiety and tension; produce elation, euphoria, or other pleasurable mood changes; provide the user feelings of increased mental and physical ability; or alter sensory perception in some pleasurable manner. Among the drugs that are commonly abused are ethyl alcohol, opioids, anxiolytics, hypnotics, cannabis (marijuana), cocaine, amphetamines, and hallucinogens. The current treatment for drug-addicted people often involves a combination of behavioral therapies and medications. Medications, such as methadone or LAAM (levo-alpha-acetyl-methadol), are effective in suppressing the withdrawal symptoms and drug craving associated with narcotic addiction, thus reducing illicit drug use and improving the chances of the individual remaining in treatment. The primary medically assisted withdrawal method for narcotic addiction is to switch the patient to a comparable drug that produces milder withdrawal symptoms, and then gradually taper off the substitute medication. The medication used most often is methadone, taken orally once a day. Patients are started on the lowest dose that prevents the more severe signs of withdrawal and then the dose is gradually reduced. Substitutes can be used also for withdrawal from sedatives. Patients can be switched to long-acting sedatives, such as diazepam or phenobarbital, which are then gradually reduced.
  • Gilles de la Tourette's Syndrome is an inherited neurological disorder. The disorder is characterized by uncontrollable vocal sounds called tics and involuntary movements. The symptoms generally manifest in an individual before the person is 18 years of age. The movement disorder may begin with simple tics that progress to multiple complex tics, including respiratory and vocal ones. Vocal tics may begin as grunting or barking noises and evolve into compulsive utterances. Coprolalia (involuntary scatologic utterances) occurs in 50% of patients. Severe tics and coprolalia may be physically and socially disabling. Tics tend to be more complex than myoclonus, but less flowing than choreic movements, from which they must be differentiated. The patient may voluntarily suppress them for seconds or minutes.
  • Currently simple tics are often treated with benzodiazepines. For simple and complex tics, Clonidine may be used. Long-term use of Clonidine does not cause tardive dyskinesia; its limiting adverse effect is hypotension. In more severe cases, antipsychotics, such as Haloperidol may be required, but side effects of dysphoria, parkinsonism, akathisia, and tardive dyskinesia may limit use of such antipsychotics. There is a need for safe and effective methods for treating this syndrome.
  • Age-related macular degeneration (AMD) is a common eye disease of the macula which is a tiny area in the retina that helps produce sharp, central vision required for “straight ahead” activities that include reading and driving. Persons with AMD lose their clear, central vision. AMD takes two forms: wet and dry. In dry AMD, there is a slow breakdown of light-sensing cells in the macula. There currently is no cure for dry AMD. In wet AMD, new, fragile blood vessels growing beneath the macula as dry AMD worsens and these vessels often leak blood and fluid to cause rapid damage to the macula quickly leading to the loss of central vision. Laser surgery can treat some cases of wet AMD. Therefore, there is a need of a pharmaceutical agent to address AMD.
  • Glaucoma is within a group of diseases occurs from an increase in intraocular pressure causing pathological changes in the optical disk and negatively affects the field of vision. Medicaments to treat glaucoma either decrease the amount of fluid entering the eye or increase drainage of fluids from the eye in order to decrease intraocular pressure. However, current drugs have drawbacks such as not working over time or causing side effects so the eye-care professional has to either prescribe other drugs or modify the prescription of the drug being used. There is a need for safe and effective methods for treating problems manifesting into glaucoma.
  • Ischemic periods in glaucoma cause release of excitotoxic amino acids and stimulate inducible form of nitric oxide synthase (iNOS) leading to neurodegeneration. Alpha 7 nicotinic agonists may stimulate the release of inhibitory amino acids such as GABA which will dampen hyperexcitablity. Alpha 7 nicotinic agonists are also directly neuroprotective on neuronal cell bodies. Thus alpha 7 nicotinic agonists have the potential to be neuroprotective in glaucoma.
  • Persons afflicted with pain often have what is referred to as the “terrible triad” of suffering from the pain, resulting in sleeplessness and sadness, all of which are hard on the afflicted individual and that individual's family. Pain can manifest itself in various forms, including, but not limited to, headaches of all severity, back pain, neurogenic, and pain from other ailments such as arthritis and cancer from its existence or from therapy to irradicate it. Pain can be either chronic (persistent pain for months or years) or acute (short-lived, immediate pain to inform the person of possible injury and need of treatment). Persons suffering from pain respond differently to individual therapies with varying degrees of success. There is a need for safe and effective methods for treating pain.
  • Finally, the compounds of the present invention may be used in combination therapy with typical and atypical anti-psychotic drugs. All compounds within the present invention are useful for and may also be used in combination with each other to prepare pharmaceutical compositions. Such combination therapy lowers the effective dose of the anti-psychotic drug and thereby reduces the side effects of the anti-psychotic drugs. Some typical anti-psychotic drugs that may be used in the practice of the invention include Haldol. Some atypical anti-psychotic drugs include Ziprasidone, Olanzapine, Resperidone, and Quetiapine.
  • Compounds of Formula I can be prepared as shown in Scheme 1. The key step in the preparation of this class of compounds is the coupling of an amino-azabicyclic moiety with the requisite acid chloride (Lv=Cl), aryl carbamate (e.g., Lv=phenyl, p-NO2-phenyl), carbonyl imidazole or carboxylic acid (Lv=OH) in the presence of an activating reagent using procedures described in J. Org. Chem. 1987, 52, 2319, Tetrahedron Lett. 1999, 40, 2733 and J. Med. Chem. 1985, 28, 1346. Suitable activating reagents are well known in the art, for examples see Kiso, Y.; Yajima, H. “Peptides” pp. 39-91, San Diego, Calif., Academic Press, (1995), and include, but are not limited to, agents such as a carbodiimides, phosphonium and uronium salts (such as uronium salt HATU). Alternatively, heterocycles W—H can be reacted with azabicyclo isocyanates using procedures described in Synlett 1995, 605. Methods to prepare azabicyclo isocyanates are know to one of ordinary skill in the art (see EP 550007).
    Figure US20060116395A1-20060601-C00034
  • One of ordinary skill in the art will recognize that the methods described for the reaction of the unsubstituted 3-aminoquinuclidine (R2 is absent) are equally applicable to substituted compounds (R2 is present). Certain 6-substituted-[2.2.2]-3-amines (Azabicyclo 1) are known in the art. The preparation of compounds where R2 is at C-6 of the quinuclidine and is other than H is described in Acta Pol. Pharm. 1981, 179. Certain 2-substituted-[2.2.2]-3-amines (Azabicyclo I) are known in the art. The preparation of compounds where R2 is at C-2 of the quinuclidine and is other than H is described in J. Med. Chem. 1975, 18, 587.
  • Alternatively, there are several methods by which the amine precursor for Azabicyclo I where R2 is other than H can be obtained. Although the scheme depicted below is for compounds where R2 is at the C-6 position of the quinuclidine, one of ordinary skill in the art would be able to obtain the quinuclidine with substitution at C-2 also. The substituted-[2.2.2]-3-amine can be prepared by reduction of an oxime or an imine of the corresponding substituted-3-quinuclidinone by methods known to one of ordinary skill in the art (see J. Labelled Compds. Radiopharm. 1995, 53; J. Med. Chem. 1998, 988; Synth. Commun. 1992, 1895; Synth. Commun. 1996, 2009). Alternatively, the substituted-[2.2.2]-3-amine can be prepared from a substituted-3-hydroxyquinuclidine by Mitsunobu reaction followed by deprotection as described in Synth. Commun. 1995, 1895. Alternatively, the substituted-[2.2.2]-3-amine can be prepared by conversion of a substituted-3-hydroxyquinuclidine into the corresponding mesylate or tosylate, followed by displacement with sodium azide and reduction as described in J. Med. Chem. 1975, 587.
    Figure US20060116395A1-20060601-C00035
  • The 2-substituted-3-quinuclidinones, where R2 is substituted alkyl, cycloalkyl, or can be prepared by known procedures (see Tett. Lett. 1972, 1015; J. Am. Chem. Soc. 1994, 1278; J. Am. Chem. Soc. 1989, 4548; Tetrahedron, 2000, 1139). The 2-substituted-3-quinuclidinones, where R2 is aryl, can be prepared by palladium catalyzed arylation as described in J. Am. Chem. Soc. 1999, 1473 and J. Am. Chem. Soc. 2000, 1360. The 6-substituted-3-quinuclidinones can be prepared by known procedures (see J. Gen. Chem. Russia 1963, 3791, J. Chem. Soc. Perkin Trans. I 1991, 409, J. Org. Chem. 2000, 3982).
  • One of ordinary skill in the art will recognize that the methods described for the reaction of the unsubstituted 3-amino-1-azabicyclo[2.2.1]heptane (R2=H) are equally applicable to substituted compounds (R2≠H). For where Azabicyclo II has substitution at C-2, compounds can be prepared from appropriately substituted nitro alcohols using procedures described in Tetrahedron (1997), 53, p. 11121 as shown below. Methods to synthesize nitro alcohols are well known in the art (see J. Am. Chem. Soc. (1947), 69, p 2608). The scheme below is a modification of the synthesis of exo-3-amino-1-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt, described in detail herein, to show how to obtain these amine precursors. The desired salt can be made using standard procedures.
    Figure US20060116395A1-20060601-C00036
  • For Azabicyclo II where R2 is other than H at the C-6 position, compounds can also be prepared by modification of intermediates described in the synthesis of exo-3-amino-1-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt, described in detail herein. For example, Int 6 can be oxidized to the aldehyde and treated with an organometallic reagent to provide Int 20 using procedures described in Tetrahedron (1999), 55, p 13899. Int 20 can be converted into the amine using methods described for the synthesis of exo-3-amino-1-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt. Once the amine is obtained, the desired salt can be made using standard procedures.
    Figure US20060116395A1-20060601-C00037
  • The schemes used are for making exo-3-amino-1-azabicyclo[2.2.1]heptane. However, the modifications discussed are applicable to make the endo isomer also.
  • One of ordinary skill in the art will also recognize that the methods described for the reaction of the unsubstituted 1-azabicyclo[3.2.1]octan-3-amine or 1-azabicyclo[3.2.2]nonan-3-amine (R2=H) are equally applicable to substituted compounds (R2≠H). The R2 substituent may be introduced as known to one skilled in the art through standard alkylation chemistry. Exposure of 1-azabicyclo[3.2.1]octan-3-one or 1-azabicyclo[3.2.2]nonan-3-one to a hindered base such as LDA (lithium diisopropylamide) in a solvent such as THF or ether between 0° C. to −78° C. followed by the addition of an alkylating agent (R2Lv, where Lv=Cl, Br, I, OTs, etc.) will, after being allowed to warm to about 0° C. to rt followed by an aqueous workup, provide the desired compound as a mixture of isomers. Chromatographic resolution (flash, HPLC, or chiral HPLC) will provided the desired purified alkylated ketones. From there, formation of the oxime and subsequent reduction will provide the desired stereoisomers.
    • N-(2-azabicyclo[2.2.1]hept)-5-amine and 6-amine:
  • Figure US20060116395A1-20060601-C00038
    where Lv can be —CH2Ph, —CH(Me)Ph, —OH, —OMe, or —OCH2Ph.
  • The respective amine precursors for Azabicyclo V and Azabicyclo VI can be prepared by reduction of an oxime or an imine of the corresponding N-2-azabicyclo[2.2.1]-heptanone by methods known to one skilled in the art (see J. Labelled Compds. Radiopharm., 53-60 (1995), J. Med. Chem. 988-995, (1998), Synth. Commun. 1895-1911 (1992), Synth. Commun. 2009-2015 (1996)). The oximes can be prepared by treatment of the N-2-azabicyclo[2.2.1]heptanones with hydroxylamine hydrochloride in the presence of a base. The imines can be prepared by treatment of the N-2-azabicyclo[2.2.1]-heptanones with a primary amine under dehydrating conditions. The N-2-azabicyclo[2.2.1]heptanones can be prepared by known procedures (see Tet. Lett. 1419-1422 (1999), J. Med. Chem. 2184-2191 (1992), J. Med. Chem. 706-720 (2000), J. Org. Chem., 46024616 (1995)).
  • There are various methods for the construction of the optionally substituted 7-azabicyclo[2.2.1]heptane ring system. For example, the independent work of Trudell (R5=H, Zhang, C., Trudell, M. L., J. Org. Chem., 61, 7189-7191, 1996), and Schultz (R5=Me, Schultz, A. G., Shen, M. S., Tetrahedron Lett., 22, 3347-3350, 1981) describes the utility of a Diels-Alder approach toward preparing this ring system with functionality suitable for further elaboration to the desired 2-amino-7-azabicyclo[2.2.1]heptane (Scheme 2). For instance, Trudell reports (Zhang, C., Trudell, M. L., Tetrahedron, 54, 8349-8354, 1998) that Diels-Alder adduct 1a (where R6=methylcarbamate, R5=H, and Lv=Br) could readily be functionalized at C-3 via reaction with organocopper species to introduce the substituent R2 in 2a,b. Likewise, hydrogenolysis of adduct 1a,b or 2a,b followed by isomerization of the endo products as described by Singh (Singh, S., Basmadjian, G. P., Tetrahedron Lett., 38, 6829-6830, 1997) could provide access to the required exo acid 3a-d. Treatment of 3 with diphenylphosphoryl azide in the presence of a tertiary amine base (e.g., Et3N) in a suitable solvent such as toluene, followed by warming of the intermediate acylazide in the presence of a suitable alcohol (e.g., benzyl alcohol) would effect the well-known Curtius rearrangement to provide a differentially protected bis carbamate which could be cleaved under typical hydrogenolysis conditions (e.g., 10% Pd/C, EtOH, H2, ambient to 50 psi) to give the desired amine 4. Alternatively, the differentially protected bis carbamate might provide an attractive point of intervention for the chromatographic resolution of the individual 2-exo isomers prior to cleavage to amine 4.
    Figure US20060116395A1-20060601-C00039
  • In the case where R6=tert-butyloxycarbonyl, deprotection of the 7-aza group can be conveniently accomplished under acidic conditions in a suitable solvent such as methanol. After deprotection, the secondary amine may be functionalized with alkyl and substituted alkyl via reductive amination or alkylative procedures.
  • It will be apparent to those skilled in the art that the requisite carboxylic acids or carboxylic acid equivalents can be obtained through synthesis via literature procedures or through the slight modification thereof. For example, methods to prepare carboxylic acids or carboxylic acid equivalents starting from pyrroles or pyrazoles are known to one of ordinary skill in the art (see J. Org. Chem. 1987, 52, 2319, Tetrahedron Lett. 1999, 40, 2733 and Greene, T. W. and Wuts, P. G. M. “Protective Groups in Organic Synthesis”, 3rd Edition, p. 549, New York:Wiley, (1999)). Several pyrroles and pyrazoles of the Formula W-H are commercially available or can be obtained by methods described in Synthesis 1997, 563, J. Org. Chem. 1997, 62, 2649, J. Heterocyclic Chem. 1993, 30, 865, Monatsh. Chem. 1993, 124, 199, J. Heterocyclic Chem. 1993, 30, 865, J. Org. Chem. 1992, 57, 1653, J. Org. Chem. 1990, 55, 6317, J. Org. Chem. 1984, 49, 3239, Tetrahedron Lett. 1983, 24, 3455, and Heterocycles 1982, 19, 1223.
  • Treatment of the carboxamide with a sulfurating agent such as Lawesson's Reagent (2,4-bis(4-methoxyphenyl)-1,3-dithia-2,4-diphosphetane-2,4-disulfide) in, for instance, dioxane at an appropriate temperature provides the corresponding thioamide, e.g., X in formula I is S. See Lawesson et. al. in Bull. Soc. Chim. Belg., 229 (1978)), or P4S10 (see Chem. Rev., 45 (1961). Alternatively, one can react a dithiocarboxylic ester with the corresponding azbicyclo moiety to form the same thioamide.
    • Amines Preparation of N-(2S,3R)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine dihydrochloride (2S-methyl-2.2.2-Amine) Preparation of 2-methylquinuclidin-3-one
  • A mixture of 2-methylene-3-quinuclidinone dihydrate hydrochloride (27.2 g, 0.13 mol, 1 eq) and K2CO3 (86.0 g, 0.62 mol, 4.8 eq) is dissolved in 130 mL water and 250 mL CH2Cl2 and stirred vigorously. After 3 days, the layers are separated and the aqueous layer is extracted with CH2Cl2. The combined organic layers are dried (MgSO4), filtered and concentrated to give 17.8 g (100%) of 2-methylenequinuclidin-3-one as a yellow oil. MS (ESI) for C8H11NO m/z 138.1 (M+).
    • Preparation of 2-methylquinuclidin-3-one
  • 2-Methylenequinuclidin-3-one (17.8 g, 0.13 mol, 1 eq) is dissolved in 40 mL MeOH in a Parr hydrogenation bottle. A THF slurry of 10% Pd/C (0.57 g) is added. The mixture is hydrogenated for 45 min at 45 psi, recharging as needed. The mixture is filtered through a pad of Celite. The Celite is washed with excess MeOH. The solution is concentrated to give a solid and a yellow oil. The mixture is taken up in ether, filtered and concentrated to provide 16.2 g (90%) of 2-methylquinuclidin-3-one. MS (ESI) for C8H13NO m/z 140.2 (M+).
    • Preparation of (3E/Z)-2-methyl-1-azabicyclo[2.2.2]octan-3-one oxime hydrochloride
  • 2-Methylquinuclidin-3-one (39.6 g, 0.28 mol, 1 eq) and hydroxylamine hydrochloride (20.0 g, 0.29 mol, 1.01 eq) are dissolved in 170 mL absolute EtOH. The mixture is heated under reflux until a clear solution develops (about 20 min), after which is immediately followed by formation of a white precipitate. The reaction is cooled and allowed to stand overnight. The mixture is cooled in an ice bath, the solids are filtered and dried (house vacuum) to provide 46.4 g of (3E/Z)-2-methyl-1-azabicyclo[2.2.2]octan-3-one oxime hydrochloride. A second crop of 2.4 g is also obtained. Overall yield is 48.8 g (90%). The 2-methyl-1-azabicyclo[2.2.2]octan-3-one oxime hydrochloride is a 4:1 mixture of oxime isomers. MS (ESI) for C8H14N2O m/z 154.8 (M+). Partial 1H NMR (400 MHz, DMSO) δ 4.39 (0.2H), 4.29 (0.8H), 1.57 (0.6H), 1.47 (2.4H).
  • A solution of sodium n-propoxide (prepared from 5.5 g sodium (0.24 mol) and 100 mL n-propanol) is added dropwise to a suspension of (3E/Z)-2-methyl-1-azabicyclo[2.2.2]octan-3-one oxime hydrochloride (45.8 g, 0.24 mol, 1 eq) in 150 mL n-propanol. After complete addition, 250 mL of n-propanol is added, and the mixture is heated under reflux. Sodium (55.2 g, 2.40 mol, 10 eq) is added in portions to the refluxing mixture. The mixture is heated under reflux overnight. After about 14 h, the mixture is cooled, water is added and the layers are separated. The n-propanol layer is washed with brine and dried (MgSO4). The combined aqueous layers are extracted with CHCl3 and dried (MgSO4). The combined, dried organic layers are treated with about 70 mL concentrated HCl. The solvent is removed in vacuo. Absolute EtOH is added, and the solvent is removed. The sequence is repeated 2-3 times with fresh EtOH until a white solid formed. Absolute EtOH is added, the solids are filtered and dried (vacuum oven, about 60° C.) to provide 36.5 g of trans 3-amino-2-methylquinuclidine dihydrochloride. MS (ESI) for C8H16N2 m/Z 141.3 (M+). Additional material is obtained from the mother liquor: 7.8 g (2nd crop) and 1.5 g (3rd crop); this material is a mixture of both trans and cis isomers.
  • 4-Chlorobenzoic acid (26.3 g, 0.17 mol, 1.1 eq) and TEA (106 mL, 0.76 mol, 5 eq) are dissolved in 300 mL THF. Diphenylphosphoryl chloride (32.0 mL, 0.1681 mol, 1.1 eq) is added dropwise. After 1 h, trans 2-methylquinuclidin-3-amine dihydrochloride (32.6 g, 0.15 mol, 1 eq) is added. The mixture is allowed to stir at RT overnight. 1N NaOH (about 100 mL) is added, and the pH is adjusted to pH 11 with 50% NaOH and about 50 g K2CO3. The layers are separated. The aqueous layer is extracted with CHCl3. The combined organic layers are dried (MgSO4), filtered and concentrated. The residue is taken up in heptane and concentrated to give 35.1 g (82%) of 4-chloro-N-(2-methyl-1-azabicyclo[2.2.2]oct-3-yl)phenyl-2-carboxamide as a light yellow solid. The enantiomers are separated on a 5×50 cm Chiralcel OD column at 30° C., eluting with 15% IPA/heptane+0.1% DEA at 90 mL/min to provide 17.4 g of 4-chloro-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]benzamide at about 97% ee. The p-TsOH salt is prepared and recrystallized from EtOH/EtOAc. [α]25 D=+3° (c 0.96, methanol). HRMS (FAB) calcd for C15H19ClN2O+H 279.1264, found 279.1272.
  • A solution of 4-chloro-N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]benzamide (17.2 g, 61.7 mmol) in absolute EtOH (70 mL) and concentrated HCl (70 mL) is heated under reflux for about 64 h. The reaction is monitored for disappearance of starting amide by reverse phase HPLC (ZORBAX Eclipse XDB-C8, 4.6 mm×15 cm, 80:12:8H2O/CH3CN/IPA). The solvent is removed in vacuo. The residue is dissolved/suspended in EtOH and the solvent is removed (twice). The solid is suspended in boiling EtOH, filtered and dried (vacuum oven, about 60° C.) to provide 8.8 g (67%) of N-(2S,3R)-2-methyl-1-azabicyclo[2.2.2]octan-3-amine dihydrochloride as a white solid. MS (EI) m/z 141.2 (M+).
    • Preparation of the 1-azabicyclo-2.2.1 Amines Synthesis of exo-3-amino-1-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt (exo-[2.2.1]-Amine):
  • Figure US20060116395A1-20060601-C00040
    • Step A. Preparation of 2-(benzoyloxy)-1-nitroethane (Int 1)
  • Benzoyl chloride (14.9 mL, 128 mmol) is added to a stirred solution of nitroethanol (9.2 mL, 128 mmol) in dry benzene (120 mL). The solution is refluxed for 24 hr and then concentrated in vacuo. The crude product is purified by flash chromatography on silica gel. Elution with hexanes-EtOAc (80:20) affords Int 1 as a white solid (68% yield): 1H NMR (CDCl3) δ 8.0, 7.6, 7.4, 4.9, 4.8.
    • Step B. Preparation of ethyl E4-(benzylamino)-2-butenoate (Int 2)
  • Ethyl E-4-bromo-2-butenoate (10 mL, 56 mmol, tech grade) is added to a stirred solution of benzylamine (16 mL, 146 mmol) in CH2Cl2 (200 mL) at rt. The reaction mixture stirs for 15 min, and is diluted with ether (1 L). The mixture is washed with saturated aqueous NaHCO3 solution (3×) and water, dried over Na2SO4, filtered and concentrated in vacuo. The residue is purified by flash chromatography on silica gel. Elution with hexanes-EtOAc (70:30) affords Int 2 as a clear oil (62% yield): 1H NMR (CDCl3) δ 7.4-7.2, 7.0, 6.0, 4.2, 3.8, 3.4, 2.1-1.8, 1.3.
    • Step C. Preparation of trans-4-nitro-1-(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 3)
  • A solution of Int 1 (6.81 g, 34.9 mmol) and Int 2 (7.65 g, 34.9 mmol) in EtOH (70 mL) stirs at rt for 15 h and is then concentrated in vacuo. The residue is diluted with ether (100 mL) and saturated aqueous NaHCO3 solution (100 mL). The organic layer is separated and dried over Na2SO4, filtered and concentrated in vacuo. The crude product is purified by flash chromatography on silica gel. Elution with hexanes-EtOAc (85:15) affords Int 3 as a clear oil (76% yield): 1H NMR (CDCl3) δ 7.4-7.3, 4.8-4.7, 4.1, 3.8-3.6, 3.3-3.0, 2.7-2.6, 2.4-2.3, 1.2.
    • Step D. Preparation of trans-4-amino-1-(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 4)
  • A mixture of Int 3 (3.28 g, 11.2 mmol) and RaNi (1.5 g) in EtOH (100 mL) is placed in a Parr bottle and hydrogenated for 4 h under an atmosphere of hydrogen (46 psi) at rt. The mixture is filtered through a pad of Celite, and the solvent is removed in vacuo to afford Int 4 as a clear oil (100% yield): 1H NMR (300 MHz, CDCl3) δ 7.3-7.2, 4.1, 3.6, 3.2, 3.0-2.9, 2.8, 2.8-2.6, 2.6-2.4, 2.30-2.2, 1.2.
    • Step E. Preparation of trans-4-(1,1-dimethylethoxycarbonylamido)-1-(phenylmethyl)-3-pyrrolidineacetic acid ethyl ester (Int 5)
  • Di-tert-butyldicarbonate (3.67 g, 16.8 mmol) is added to a stirred solution of Int 4 (2.94 g, 11.2 mmol) in CH2Cl2 (30 mL) cooled in an ice bath. The reaction is allowed to warm to rt and stirred overnight. The mixture is concentrated in vacuo. The crude product is purified by flash chromatography on silica gel. Elution with hexanes-EtOAc (80:20) affords Int 5 as a white solid (77% yield): 1H NMR (300 MHz, CDCl3) δ 7.4-7.2, 5.14.9, 4.1, 4.0-3.8, 3.6, 3.2-3.0, 2.8-2.6, 2.5-2.4, 2.3-2.1, 1.4, 1.3.
    • Step F. Preparation of trans (tert-butoxycarbonylamino)-4-(2-hydroxyethyl)-1-(N-phenylmethyl) pyrrolidine (Int 6)
  • LiAlH4 powder (627 mg, 16.5 mmol) is added in small portions to a stirred solution of Int 5 (3.0 g, 8.3 mmol) in anhydrous THF (125 mL) in a −5° C. bath. The mixture is stirred for 20 min in a −5° C. bath, then quenched by the sequential addition of water (0.6 mL), 15% (w/v) aqueous NaOH (0.6 mL) and water (1.8 mL). Excess anhydrous K2CO3 is added, and the mixture is stirred for 1 h, then filtered. The filtrate is concentrated in vacuo. The residue is purified by flash chromatography on silica gel. Elution with EtOAc affords Int 6 as a white solid (94% yield): 1H NMR (CDCl3) δ 7.4-7.3, 5.3-5.2, 4.1-4.0, 3.9-3.7, 3.3-3.2, 2.8-2.7, 2.3-2.1, 1.7, 1.5.
  • Int 6 is a racemic mixture that can be resolved via chromatography using a Diacel chiral pack AD column. From the two enantiomers thus obtained, the (+)-enantiomer, [α]25 D +35 (c 1.0, MeOH), gives rise to the corresponding optically pure exo-4-S final compounds, whereas the (−)-enantiomer, [α]25 D −34 (c 0.98, MeOH), gives rise to optically pure exo-4-R final compounds. The methods described herein use the (+)-enantiomer of Int 6 to obtain the optically pure exo-4-S final compounds. However, the methods used are equally applicable to the (−)-enantiomer of Int 6, making non-critical changes to the methods provided herein to obtain the optically pure exo-4-R final compounds.
    • Step G. Preparation of exo 3-(tert-butoxycarbonylamino)-1-azabicyclo[2.2.1]heptane (Int 7)
  • TEA (8.0 g, 78.9 mmol) is added to a stirred solution of Int 6 (2.5 g, 7.8 mmol) in CH2Cl2 (50 mL), and the reaction is cooled in an ice-water bath. CH3SO2Cl (5.5 g, 47.8 mmol) is then added dropwise, and the mixture is stirred for 10 min in an ice-water bath. The resulting yellow mixture is diluted with saturated aqueous NaHCO3 solution, extracted with CH2Cl2 several times until no product remains in the aqueous layer by TLC. The organic layers are combined, washed with brine, dried over Na2SO4 and concentrated in vacuo. The residue is dissolved in EtOH (85 mL) and is heated to reflux for 16 h. The reaction mixture is allowed to cool to rt, transferred to a Parr bottle and treated with 10% Pd/C catalyst (1.25 g). The bottle is placed under an atmosphere of hydrogen (53 psi) for 16 h. The mixture is filtered through Celite, and fresh catalyst (10% Pd/C, 1.25 g) is added. Hydrogenolysis continues overnight. The process is repeated three more times until the hydrogenolysis is complete. The final mixture is filtered through Celite and concentrated in vacuo. The residue is purified by flash chromatography on silica gel. Elution with CHCl3-MeOH—NH4OH (90:9.5:0.5) affords Int 7 as a white solid (46% yield): 1H NMR (CDCl3) δ 5.6-5.5, 3.8-3.7, 3.3-3.2, 2.8-2.7, 2.0-1.8, 1.7-1.5, 1.5.
    • Step H. Preparation of exo-3-amino-1-azabicyclo[2.2.1]heptane bis(hydro-para-toluenesulfonate)
  • Para-toluenesulfonic acid monohydrate (1.46 g, 7.68 mmol) is added to a stirred solution of Int 7 (770 mg, 3.63 mmol) in EtOH (50 mL). The reaction mixture is heated to reflux for 10 h, followed by cooling to rt. The precipitate is collected by vacuum filtration and washed with cold EtOH to give exo-[2.2. I]-Amine as a white solid (84% yield): 1H NMR (CD3OD) δ 7.7, 7.3, 3.9-3.7, 3.7-3.3, 3.2, 2.4, 2.3-2.2, 1.9-1.8.
    • Synthesis of endo-3-amino-1-azabicyclo[2.2.1]heptane as the bis(hydro para-toluenesulfonate) salt (endo-[2.2.1]-Amine)
  • Figure US20060116395A1-20060601-C00041
    • Step I. Preparation of ethyl 5-hydroxy-6-oxo-1,2,3,6-tetrahydropyridine-4-carboxylate (Int 10)
  • Absolute EtOH (92.0 mL, 1.58 mol) is added to a mechanically stirred suspension of potassium ethoxide (33.2 g, 395 mmol) in dry toluene (0.470 L). When the mixture is homogeneous, 2-pyrrolidinone (33.6 g, 395 mmol) is added, and then a solution of diethyl oxalate (53.1 mL, 390 mmol) in toluene (98 mL) is added via an addition funnel. After complete addition, toluene (118 mL) and EtOH (78 mL) are added sequentially. The mixture is heated to reflux for 18 h. The mixture is cooled to rt and aqueous HCl (150 mL of a 6.0 M solution) is added. The mixture is mechanically stirred for 15 min. The aqueous layer is extracted with CH2Cl2, and the combined organic layers are dried over MgSO4, filtered and concentrated in vacuo to a yellow residue. The residue is recrystallized from EtOAc to afford Int 10 as a yellow solid (38% yield): 1H NMR (CDCl3) δ 11.4, 7.4, 4.3, 3.4, 2.6, 1.3.
    • Step J. Preparation of ethyl cis-3-hydroxy-2-oxopiperidine-4-carboxylate (Int 11)
  • A mixture of Int 10 (15 g, 81 mmol) and 5% rhodium on carbon (2.0 g) in glacial acetic acid is placed under an atmosphere of hydrogen (52 psi). The mixture is shaken for 72 h. The mixture is filtered through Celite, and the filtrate is concentrated in vacuo to afford Int 11 as a white solid (98% yield): 1H NMR (CDCl3) δ 6.3, 4.2, 4.0-3.8, 3.4, 3.3-3.2, 2.2, 1.3.
    • Step K. Preparation of cis-4-(hydroxymethyl)piperidin-3-ol (Int 12)
  • Int 11 (3.7 g, 19.9 mmol) as a solid is added in small portions to a stirred solution of LiAlH4 in THF (80 mL of a 1.0 M solution) in an ice-water bath. The mixture is warmed to rt, and then the reaction is heated to reflux for 48 h. The mixture is cooled in an ice-water bath before water (3.0 mL, 170 mmol) is added dropwise, followed by the sequential addition of NaOH (3.0 mL of a 15% (w/v) solution) and water (9.0 mL, 500 mmol). Excess K2CO3 is added, and the mixture is stirred vigorously for 15 min. The mixture is filtered, and the filtrate is concentrated in vacuo to afford Int 12 as a yellow powder (70% yield): 1H NMR (DMSO-d6) δ 4.3, 4.1, 3.7, 3.5-3.2, 2.9-2.7, 2.5-2.3, 1.5, 1.3.
    • Step L. Preparation of benzyl cis-3-hydroxy-4-(hydroxymethyl)piperidine-1-carboxylate (Int 13)
  • N-(benzyloxy carbonyloxy)succinimide (3.04 g, 12.2 mmol) is added to a stirred solution of Int 12 (1.6 g, 12.2 mmol) in saturated aqueous NaHCO3 (15 mL) at rt. The mixture is stirred at rt for 18 h. The organic and aqueous layers are separated. The aqueous layer is extracted with ether (3×). The combined organic layers are dried over anhydrous K2CO3, filtered and concentrated in vacuo to afford Int 13 as a yellow oil (99% yield): 1H NMR (CDCl3) δ 7.4-7.3, 5.2, 4.3, 4.1, 3,8-3.7, 3.0-2.8, 2.1, 1.9-1.7, 1.4.
    • Step M. Preparation of benzyl cis-3-hydroxy-4-[(4-methylphenyl)sulfonyl oxymethyl]piperidine-1-carboxylate (Int 14)
  • Para-toluenesulfonyl chloride (1.0 g, 5.3 mmol) is added to a stirred solution of Int 13 (3.6 g, 5.3 mmol) in pyridine (10 mL) in a −15° C. bath. The mixture is stirred for 4 h, followed by addition of HCl (4.5 mL of a 6.0 M solution). CH2Cl2 (5 mL) is added. The organic and aqueous layers are separated. The aqueous layer is extracted with CH2Cl2. The combined organic layers are washed with brine, dried over MgSO4, filtered and concentrated in vacuo to afford Int 14 as a colorless oil (78% yield): 1H NMR (CDCl3) δ 7.8, 7.4-7.2, 5.1, 4.3-4.2, 4.1, 3.9-3.8, 2.9-2.7, 2.4, 1.9, 1.6-1.3.
    • Step N. Preparation of exo-1-azabicyclo[2.2.1]heptan-3-ol (Int 15)
  • A mixture of Int 14 (3.6 g, 8.6 mmol) and 10% Pd/C catalyst (500 mg) in EtOH (50 mL) is placed under an atmosphere of hydrogen. The mixture is shaken for 16 h. The mixture is filtered through Celite. Solid NaHCO3 (1.1 g, 13 mmol) is added to the filtrate, and the mixture is heated in an oil bath at 50° C. for 5 h. The solvent is removed in vacuo. The residue is dissolved in saturated aqueous K2CO3 solution. Continuous extraction of the aqueous layer using a liquid-liquid extraction apparatus (18 h), followed by drying the organic layer over anhydrous K2CO3 and removal of the solvent in vacuo affords Int 15 as a white solid (91% yield): 1H NMR δ 3.8, 3.0-2.8, 2.6-2.5, 2.4-2.3, 1.7, 1.1.
    • Step O. Preparation of endo-3-azido-1-azabicyclo[2.2.1]heptane (Int 16)
  • To a mixture of Int 15 (1.0 g, 8.9 mmol) and triphenyl phosphine (3.0 g, 11.5 mmol) in toluene-THF (50 mL, 3:2) in an ice-water bath are added sequentially a solution of hydrazoic acid in toluene (15 mL of ca. 2 M solution) and a solution of diethyl azadicarboxylate (1.8 mL, 11.5 mmol) in toluene (20 mL). The mixture is allowed to warm to rt and stir for 18 h. The mixture is extracted with aqueous 1.0M HCl solution. The aqueous layer is extracted with EtOAc, and the combined organic layers are discarded. The pH of the aqueous layer is adjusted to 9 with 50% aqueous NaOH solution. The aqueous layer is extracted with CH2Cl2 (3×), and the combined organic layers are washed with brine, dried over Na2SO4, filtered and concentrated in vacuo. The crude product is purified by flash chromatography on silica gel. Elution with CHCl3-MeOH—NH4OH (92:7:1) affords Int 16 as a colorless oil (41% yield): 1H NMR (CDCl3) δ 4.1, 3.2, 2.8, 2.7-2.5, 2.2, 1.9, 1.5.
    • Step P. Preparation of endo-3-amino-1-azabicyclo[2.2.1]heptane bis(hydro-para-toluenesulfonate)
  • A mixture of Int 16 (250 mg, 1.8 mmol) and 10% Pd/C catalyst (12 mg) in EtOH (10 mL) is placed under an atmosphere of hydrogen (15 psi). The mixture is stirred for 1 h at rt. The mixture is filtered through Celite, and the filtrate is concentrated in vacuo. The residue is dissolved in EtOH (10 mL) and para-toluenesulfonic acid monohydrate (690 mg, 3.7 mmol) is added. The mixture is stirred for 30 min, and the precipitate is filtered. The precipitate is washed sequentially with cold EtOH and ether. The precipitate is dried in vacuo to afford endo-[2.2.1]-Amine as a white solid (85% yield): 1H NMR (CD3OD) δ 7.7, 7.3, 4.2, 3.9, 3.6-3.4, 3.3-3.2, 2.4, 2.3, 2.1.
    • Preparation of tert-butyl (1S, 2R, 4R)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate
  • Figure US20060116395A1-20060601-C00042
  • Methyl propiolate (52 ml, 0.583 mol) is combined with recrystallized N-bromo-succinimide (120 g, 0.674 mol) in 1,700 ml acetone under nitrogen. The solution is treated with silver nitrate (9.9 g, 0.0583 mol) neat in a single lot and the reaction is stirred 6 h at RT. The acetone is removed under reduced pressure (25° C., bath temperature) to provide a gray slurry. The slurry is washed with 2×200 ml hexane, the gray solid is removed by filtration, and the filtrate is concentrated in vacuo to provide 95 g of a pale yellow oily residue. The crude material is distilled via short path under reduced pressure (65° C., about 25 mm Hg) into a dry ice/acetone cooled receiver to give 83.7 g (88%) of methyl-3-bromo-propiolate as a pale yellow oil. Anal. calc'd for C4H3BrO2: C, 29.48; H, 1.86. Found: C, 29.09; H, 1.97.
  • Methyl-3-bromo-propiolate (83.7 g, 0.513 mol) is added to N-t-butyloxy-pyrrole (430 ml, 2.57 mol) under nitrogen. The dark mixture is warmed in a 90° C. bath for 30 h, is cooled, and the bulk of the excess N-t-butyloxy-pyrrole is removed in vacuo using a dry ice/acetone condenser. The dark oily residue is chromatographed over 1 kg silica gel (230-400 mesh) eluting with 0-15% EtOAc/hexane. The appropriate fractions are combined and concentrated to afford 97 g (57%) of 7-tert-butyl 2-methyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate as a dark yellow oil. HRMS (FAB) calc'd for C13H16BrNO4+H, 330.0341, found 330.0335 (M+H)+.
  • 7-tert-Butyl 2-methyl 3-bromo-7-azabicyclo[2.2.1]hepta-2,5-diene-2,7-dicarboxylate (97 g, 0.294 mol) is added to 10% Pd/C (6.8 g) in 900 ml absolute EtOH in a PARR bottle. The suspension is diluted with a solution of NaHCO3 (25 g, 0.301 mol) in 250 ml water and the mixture is hydrogenated at 50 PSI for 2.5 h. The catalyst is removed by filtration, is washed with fresh EtOH, and the filtrate is concentrated in vacuo to give a residue. The residue is partitioned between 1×200 ml saturated NaHCO3 and CH2Cl2 (4×100 ml). The combined organic layer is dried over 1:1 K2CO3/MgSO4 and concentrated in vacuo to afford 72.8 g (98%) of (+/−) endo-7-tert-butyl 2-methyl 7-azabicyclo[2.2.1]heptane-2,7-dicarboxylate. MS (EI) for C14H22O4, m/z: 255 (M)+.
  • (+/−)Endo-7-tert-butyl 2-methyl 7-azabicyclo[2.2.1]heptane-2,7-dicarboxylate (72.8 g, 0.285 mol) is dissolved in 1000 ml dry MeOH in a dried flask under nitrogen. The solution is treated with solid NaOMe (38.5 g, 0.713 mol) neat, in a single lot and the reaction is warmed to reflux for 4 h. The mixture is cooled to 0° C., is treated with 400 ml water, and the reaction is stirred 1 h as it warms to RT. The mixture is concentrated in vacuo to about 400 ml and the pH of the aqueous residue is adjusted to 4.5 with 12N HCl. The precipitate is collected and dried. The tan, slightly tacky solid is washed with 2×100 ml 60% ether in hexane and is dried to provide 47 g (68%) of (+/−) exo-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]heptane-2-carboxylic acid as an off-white powder. HRMS (FAB) calc'd for C12H19NO4+H, 242.1392, found 242.1390 (M+H)+.
  • (+/−)Exo-7-(tert-butoxycarbonyl)-7-azabicyclo[2.2.1]heptane-2-carboxylic acid (103.9 g, 0.430 mol) is combined with TEA (60 ml, 0.430 mol) in 1200 ml dry toluene in a dry flask under nitrogen. The solution is treated drop-wise with diphenylphosphoryl azide (92.8 ml, 0.430 mol), and is allowed to stir for 20 min at RT. The mixture is treated with benzyl alcohol (47.9 ml, 0.463 mol), and the reaction is stirred overnight at 55° C. The mixture is cooled, is extracted successively with 2×500 ml 5% citric acid, 2×500 ml water, 2×500 ml saturated sodium bicarbonate, and 500 ml brine. The organic layer is dried over MgSO4 and concentrated in vacuo to an amber oil. The crude material is chromatographed over 900 g silica gel (230-400 mesh), eluting with 10-30% EtOAc/hexane. The appropriate fractions are combined and concentrated to give 106 g (71%) of (+/−) exo-tert-butyl 2-{[(benzyloxy)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate as a pale oil. 1H NMR (CDCl3) δ 1.29-1.60, 1.44, 1.62-2.01, 3.76-3.88, 4.10, 4.24, 5.10, 7.36 ppm.
  • (+/−) Exo-tert-Butyl 2-{[(benzyloxy)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate (1.5 g, 4.33 mmol) is combined with 10% Pd/C (150 mg) in 40 ml EtOH in a 250 ml Parr shaker bottle. The mixture is hydrogenated at 50 PSI for 1.5 h. The catalyst is removed by filtration and the filtrate is concentrated in vacuo. The crude material is chromatographed over 30 g silica gel (230-400 mesh), eluting with 7% MeOH/CH2Cl2+1% conc. NH4OH. The appropriate fractions are combined and concentrated to provide 606 mg (66%) of (+/−) exo-tert-butyl 2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate. HRMS (FAB) calcd for C11H20N2O2+H, 213.1603, found 213.1580 (M+H)+. This racemic mixture will be referenced as (+/−)-7-aza-[2.2.1]-Amine.
  • Resolution of Racemic Carboxylate Mixture:
  • The isolated (+/−) exo-tert-butyl 2-{[(benzyloxy)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate is resolved via preparative chiral HPLC (50×500 mm Chiralcel OJ column, 30 deg. C., 70 mL/min. 10/90 (v/v) isopropanol/heptane). The resolution affords 40 g of tert-butyl (1S, 2R, 4R)-(+)-2 {[(benzyloxy)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate and 42 g of tert-butyl-(1R, 2S, 4S)(−)-2 {[(benzyloxy)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate.
  • The 2R enantiomer is triturated with 40 ml ether followed by 40 ml hexane (to remove lingering diastereo and enantiomeric impurities) and is dried to afford 30 g (56%) of purified tert-butyl (1S, 2R, 4R)-(+)-2 {[(benzyloxy)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate with 99% enantiomeric excess. MS (EI) for C19H26N2O4, m/z: 346 (M)+. [α]25 D=22, (c 0.42, chloroform).
  • The 2S enantiomer is triturated with 40 ml ether followed by 40 ml hexane to give 35 g (66%) of purified tert-butyl (1R, 2S, 4S)-(−)-2 {[(benzyloxy)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate with 99% enantiomeric excess. MS (EI) for C19H26N2O4, m/z: 346 (M)+. [α]25 D=−23, (c 0.39, chloroform).
  • tert-Butyl (1S, 2R, 4R)-(+)-2 {[(benzyloxy)carbonyl]amino}-7-azabicyclo[2.2.1]heptane-7-carboxylate (9.5 g, 27.4 mmol) is combined with 950 mg 10% Pd/C in 75 ml absolute EtOH in a 500 ml Parr bottle. The reaction mixture is hydrogenated at 50 PSI for 3 h, the catalyst is removed by filtration, and the filter cake is washed with MeOH. The filtrate is concentrated in vacuo to give 6.4 g of a residue. The crude material is chromatographed over 200 g silica gel (230-400 mesh) eluting with 7% CH3OH/CHCl3 containing 1% conc. NH4OH. The appropriate fractions are combined and concentrated to give 5.61 g (96%) of tert-butyl-(1S, 2R, 4R)-(+)-2-amino-7-azabicyclo[2.2.1]heptane-7-carboxylate as a pale oil. MS (EI) for C11H20N2O2, m/z: 212 (M)+. [α]25 D=9, (c 0.67, CHCl3). This will be referenced as (2R)-7-aza-[2.2.1]-Amine.
    • Preparation of 1-azabicyclo[3.2.1]octan-3-amine Preparation of the 3R,5R-[3.2.1]-Amine
  • Figure US20060116395A1-20060601-C00043
    • (3S)-1-[(S)-1-Phenethyl]-5-oxo-3-pyrrolidine-carboxylic acid
  • Figure US20060116395A1-20060601-C00044
  • According to the literature procedure (Nielsen et al. J. Med. Chem 1990, 70-77), a mixture of itaconic acid (123.17 g, 946.7 mmol) and (S)-(−)-α-methyl benzylamine (122.0 mL, 946.4 mmol) were heated (neat) in a 160° C. oil bath for 4 h. Upon cooling, MeOH (˜200 mL) was added and the resulting solid collected by filtration. The solid was treated with EtOH (700 mL) and warmed using a steam bath until ˜450 mL solvent remained. After cooling to rt, the solid was collected and dried to afford 83.2 g as a white crystalline solid: [α]25 D=−80 (c 0.97, DMSO). MS (EI) m/z 233 (M+).
  • The lack of a resonance 3.59 indicates a single diastereomer. The other diastereomer can be retrieved from the initial MeOH triturant. Attempts to crystallize this material generally led to small quantities of (3RS)-1-[(S)-1-phenethyl]-5-oxo-3-pyrrolidine-carboxylic acid.
    • (3S)-1-[(S)-1-Phenethyl]-3-(hydroxymethyl)pyrrolidine
  • Figure US20060116395A1-20060601-C00045
    A suspension (3S)-1-[(S)-1-phenethyl]-5-oxo-3-pyrrolidine-carboxylic acid (82.30 g, 352.8 mmol) in Et2O (200 mL) was added in small portions to a slurry of LiAlH4 (17.41 g, 458.6 mmol) in Et2O (700 mL). The mixture began to reflux during the addition. The addition funnel containing the suspension was rinsed with Et2O (2×50 mL), and the mixture was heated in a 50° C. oil bath for an additional 2 h and first allowed to cool to rt and then further cooled using an ice bath. The mixture was carefully treated with H2O (62 mL). The resulting precipitate was filtered, rinsed with Et2O, and discarded. The filtrate was concentrated to a yellow oil. When EtOAc was added to the oil, a solid began to form. Hexane was then added and removed by filtration and dried to afford 43.3 g as a white solid. [α]25 D=−71 (c 0.94, CHCl3). MS (EI) m/z 205 (M+).
    • (3R)-1-[(S)-1-Phenethyl]-3-(cyanomethyl)pyrrolidine
  • Figure US20060116395A1-20060601-C00046
  • A solution of (3S)-1-[(S)-1-phenethyl]-3-(hydroxymethyl)pyrrolidine (42.75 g, 208.23 mmol) in chloroform (350 mL) was heated to reflux under N2. The solution was treated with a solution of thionyl chloride (41.8 mL, 573 mmol) in chloroform (40 mL) dropwise over 45 min. The mixture stirred for an additional 30 min, was cooled and concentrated. The residue was diluted with H2O (˜200 mL), 1 N NaOH was added until a pH ˜8 (pH paper). A small portion (˜50 mL) of sat. NaHCO3 was added and the basic mixture was extracted with EtOAc (3×400 mL), washed with brine, dried over MgSO4, filtered and concentrated to give 46.51 g of a red-orange oil for (3S)-1-[(S)-1-phenethyl]-3-(chloromethyl)pyrrolidine: Rf: 0.50 (EtOAc-hexane 1:1); MS (ESI+) m/z 224.2 (MH+). The chloride (46.35 g, 208.0 mmol) was transferred to a flask, dimethyl sulfoxide (200 mL) was added, and the solution was treated with NaCN (17.84 g, 363.9 mmol). The mixture was heated under N2 in a 100° C. oil bath overnight and was cooled. The brown mixture was poured into H2O (300 mL) and extracted with EtOAc (1000 mL in portions). The combined organic layer was washed with H2O (6ט50 mL), brine (˜100 mL), dried (MgSO4), filtered and concentrated to give 40.61 g as an orange-red oil: Rf: 0.40 (EtOAc-PhCH3 1:1). MS (ESI+) for m/z 215.2 (M+H+).
    • (3R)-Methyl 1-[(S)-1-phenylethly]pyrrolidine-3-acetate
  • Figure US20060116395A1-20060601-C00047
  • Acetyl chloride (270 mL, 3.8 mol) was carefully added to a flask containing chilled (0° C.) methanol (1100 mL). After the addition was complete, the acidic solution stirred for 45 min (0° C.) and then (3R)-1-[(S)-1-phenethyl]-3-(cyanomethyl)pyrrolidine (40.50 g, 189.0 mmol) in methanol (200 mL) was added. The ice bath was removed and the mixture stirred for 100 h at rt. The resulting suspension was concentrated. Water (600 mL) was added, the mixture stirred for 45 min and then the pH was adjusted (made basic) through the addition of 700 mL sat. aq. NaHCO3. The mixture was extracted with EtOAc (3×300 mL). The combined organics were washed with brine, dried (MgSO4), filtered through celite and concentrated to give 36.86 g as an orange-red oil. MS (ESI+) m/z 248.2 (M+H+).
    • (5R)-1-Azabicyclo[3.2.1]octan-3-one hydrochloride
  • Figure US20060116395A1-20060601-C00048
  • A solution of (3R)-methyl 1-[(S)-1-phenylethly]pyrrolidine-3-acetate (25.72 g, 104.0 mmol) in THF (265 mL) was cooled under N2 in a CO2/acetone bath. Next, ICH2Cl (22.7 mL, 312.0 mmol) was added, and the mixture stirred for 30 min. A solution of 2.0M lithium diisopropylamide (heptane/THF/ethylbenzene, 156 mL, 312 mmol) was added slowly over 30 min. The internal temperature reached a maximum of −40° C. during this addition. After 1 h, sat. NH4Cl (100 mL) was added and the mixture was allowed to warm to rt. The organic layer was separated, dried (MgSO4), filtered and concentrated. The resulting red-brown foam was chromatographed (300 g SiO2, CHCl3-MeOH—NH4OH (89:10:1) followed by CHCl3-MeOH (3:1). The product fractions were pooled and concentrated to afford (5R)-3-oxo-1-[(1S)-1-phenylethyl]-1-azoniabicyclo[3.2.1]octane chloride (10.12 g) as a tan foam (MS (ESI+) m/z 230.1 (M+H+). This foam (10.1 g, 38 mmol) was taken up in MeOH (500 mL), 10% Pd(C) (3.0 g) added and the mixture was hydrogenated (45 psi) overnight. The mixture was filtered and re-subjected to the reduction conditions (9.1 g, 10% Pd/C, 50 psi). After 5 h, TLC indicated the consumption of the (5R)-3-oxo-1-[(1S)-1-phenylethyl]-1-azoniabicyclo[3.2.1]octane chloride. The mixture was filtered, concentrated and triturated (minimal iPrOH) to give 3.73 g in two crops, as an off-white solid: [α]25 D=33 (c 0.97, DMSO). MS (EI) m/z 125 (M+).
    • (3R,5R)-1-azabicyclo[3.2.1]octan-3-amine dihydrochloride
  • Figure US20060116395A1-20060601-C00049
  • To a flask containing (5R)-1-azabicyclo[3.2.1]octan-3-one hydrochloride (3.64 g, 22.6 mmol), hydroxylamine hydrochloride (2.04 g, 29.4 mmol), and ethanol (130 mL) was added sodium acetate trihydrate (9.23 g, 67.8 mmol). The mixture stirred for 3 h and was filtered and concentrated. The resulting white solid was taken up in n-propanol (100 mL) and sodium (˜13.6 g, 618 mmol) was added over 20-25 portions. The reaction spontaneously began to reflux, and the reaction was heated in an oil bath (100° C.). The addition was complete in ˜20 min and the mixture had solidified after ˜40 min. The oil bath was removed and n-propanol (2×25 mL) was added dissolving the remaining sodium metal. The mixture was carefully quenched through the dropwise addition of H2O (100 mL). Saturated aq. NaCl (20 mL) was added, and the layers were separated. The organic layer was dried (MgSO4), filtered, treated with freshly prepared MeOH/HCl, and concentrated. The resulting solid was triturated with 30 mL EtOH, filtered and dried in vaccuo to afford 3.51 g as a white solid: [α]25 D=−3 (c 0.94, DMSO). MS (FAB) m/z 127 (MH+).
    • Preparation of endo-1-azabicyclo[3.2.1]octan-3-amine dihydrochloride (endo-[3.2.1]-Amine)
  • Figure US20060116395A1-20060601-C00050
  • A mixture of 1-azabicyclo[3.2.1]octan-3-one hydrochloride (2.80 g, 17.3 mmol), ethanol (25 mL), and hydroxylamine hydrochloride (1.56 g, 22.4 mmol) is treated with sodium acetate trihydrate (7.07 g, 51.2 mmol). The mixture is stirred for 3 h and evaporated in vacuo. The residue is diluted with CH2Cl2, treated with charcoal, filtered and evaporated. The resulting oxime (3.1 mmol) is treated with acetic acid (30 mL) and hydrogenated at 50 psi over PtO2 (50 mg) for 12 h. The mixture is then filtered and evaporated. The residue is taken up in a minimal amount of water (6 mL) and the pH is adjusted to >12 using solid NaOH. The mixture is then extracted with ethyl acetate (4×25 mL), dried over MgSO4, filtered, treated with ethereal HCl, and evaporated to give the give endo-[3.2.1]-Amine.
    • Preparation of the 3.2.2 Amines
  • Figure US20060116395A1-20060601-C00051
    • Preparation of tert-butyl 4-(2-oxopropylidene)piperidine-1-carboxylate (Int 101)
  • Sodium hydride (60% oil dispersion, 2.01 g, 50.2 mmol) is washed with pentane (3×) and suspended in dry THF (40 mL). The solution is cooled to 0° C. before diethyl (2-oxopropyl)phosphonate (9.75 g, 50.2 mmol) is added dropwise. After complete addition, the solution is warmed to rt and stirred for 30 min. tert-Butyl 4-oxo-1-piperidinecarboxylate (5.0 g, 25.1 mmol) is added in portions over 10 min, followed by stirring at rt for 2 h. A saturated aqueous solution of ammonium chloride is added, followed by dilution with ether. The organic layer is extracted with water. The organic layer is dried over anhydrous MgSO4, filtered and concentrated to a yellow oil. The crude product is purified by flash chromatography on silica gel. Elution with hexanes-ether (60:40) gave 4.5 g (75%) of Int 101 as a white solid: 1H NMR (CDCl3) δ 6.2, 3.5, 3.4, 2.9, 2.3, 2.2, 1.5.
    • Preparation of tert-butyl 4-(2-oxopropyl)piperidine-1-carboxylate (Int 102)
  • A mixture of Int 101 (4.5 g, 19 mmol) and 10% palladium on activated carbon (450 mg) in EtOH (150 mL) is placed in a Parr bottle and hydrogenated for 5 h at 50 psi. The mixture is filtered through Celite, and the filtrate is concentrated in vacuo to afford 4.3 g (94%) of Int 102 as a clear oil: 1H NMR (CDCl3) δ 4.1, 2.8, 2.4, 2.2, 2.0, 1.7, 1.5, 1.1.
    • Preparation of tert-butyl 4-(3-bromo-2-oxopropyl)piperidine-1-carboxylate (Int 103)
  • To a stirred solution lithium hexamethyldisilylamide in THF (20.0 mL, 1.0 M) in a −78° C. bath is added chlorotrimethylsilane (11.0 mL, 86.4 mmol) dropwise. The mixture is stirred at −78° C. for 20 min, followed by addition of Int 102 (3.21 g, 13.3 mmol) in a solution of THF (50 mL) dropwise. After complete addition, the mixture is stirred at −78° C. for 30 min. The mixture is warmed to 0° C. in an ice-water bath and phenyltrimethylammonium tribromide (5.25 g, 14.0 mmol) is added. The mixture is stirred in an ice-bath for 30 min, followed by the addition of water and ether. The aqueous layer is washed with ether, and the combined organic layers are washed with saturated aqueous sodium thiosulfate solution. The organic layer is dried over anhydrous MgSO4, filtered and concentrated in vacuo to afford a yellow oil. The crude product is purified by flash chromatography on silica gel. Elution with hexanes-ether (60:40) gave 2.2 g (52%) of Int 103 as a lt. yellow oil: 1H NMR (CDCl3) δ 4.2-4.1, 3.9, 2.8, 2.7, 2.6, 2.1-2.0, 1.7, 1.5, 1.2-1.1.2.
    • Preparation of 1-bromo-3-piperidin-4-ylacetone trifluoroacetate (Int 104)
  • To a stirred solution of Int 103 (2.2 g, 6.9 mmol) in CH2Cl2 (30 mL) in an ice-water bath is added trifluoroacetic acid (10 mL, 130 mmol). The mixture is stirred at 0° C. for 30 min. The volatiles are removed in vacuo to afford 2.0 g (87%) of Int 104 as a yellow residue: MS (ESI) for C8H15BrNO [M+H] m/e 220.
    • Preparation of 1-azabicyclo[3.2.2]nonan-3-one (Int 105)
  • To a stirred solution of DIEA (13 mL) in acetoniltrile (680 mL) at reflux temperature is added a solution of Int 104 (2.0 g, 6.0 mmol) in acetonitrile (125 mL) over a 4 h period via syringe pump. The mixture is kept at reflux temperature overnight. The mixture is concentrated in vacuo and the remaining residue is partitioned between a saturated aqueous potassium carbonate solution and CHCl3-MeOH (90:10). The aqueous layer is extracted with CHCl3-MeOH (90:10), and the combined organic layers are dried over MgSO4, filtered and concentrated in vacuo to a brown oil. The crude product is purified by flash chromatography on silica gel. Elution with CHCl3-MeOH—NH4OH (95:4.5:0.5) gives 600 mg (72%) of Int 105 as a clear solid: 1H NMR (CDCl3) δ 3.7, 3.3-3.2, 3.1-3.0, 2.7, 2.3, 2.0-1.8.
    • Preparation of 1-azabicyclo[3.2.2]nonan-3-amine bis(4-methylbenzenesulfonate) ([3.2.2]-Amine)
  • To a stirred mixture of Int 105 (330 mg, 2.4 mmol) and sodium acetate.trihydrate (670 mg, 4.8 mmol) in EtOH (6.0 mL) is added hydroxylamine.hydrochloride (200 mg, 2.8 mmol). The mixture is stirred at rt for 10 h. The mixture is filtered and the filtrate is concentrated in vacuo to a yellow solid. To a solution of the solid (350 mg, 2.3 mmol) in n-propanol (30 mL) at reflux temperature is added sodium metal (2.0 g, 87 mmol) in small portions over 30 min. Heating at reflux is continued for 2 h. The solution is cooled to rt and brine is added. The mixture is extracted with n-propanol, and the combined organic layers are concentrated in vacuo. The residue is taken up in CHCl3 and the remaining solids are filtered. The filtrate is dried over anhydrous MgSO4, filtered and concentrated in vacuo to a clear solid. To a stirred solution of the solid (320 mg, 2.3 mmol) in EtOH (4 mL) is added p-toluenesulfonic acid monohydrate (875 mg, 4.6 mmol). The solution is warmed in a water bath to 45° C. for 30 min, followed by concentration of the solvent to afford 710 mg (62%) of [3.2.2]-Amine as a white solid: 1H NMR (CD3OD) δ 7.7, 7.3, 4.1-3.9, 3.6-3.4, 2.6-2.5, 2.4, 2.2-2.1, 2.1-2.0, 1.9.
  • Resolution of Stereoisomers:
  • The amine can be coupled to form the appropriate amides or thioamides as a racemic mixture. The racemic mixture can then be resolved by chromatography using chiral columns or chiral HPLC, techniques widely known in the art, to provide the requisite resolved enantiomers 3(R) and 3(S) of said amides.
    • Couplings
  • The following examples are provided as examples and are not intended to limit the scope of this invention to only those provided examples and named compounds. Also, the salts made in the examples are only exemplary and are not intended to limit the invention. Any pharmaceutically acceptable salt can be made by one of ordinary skill in the art. Further, the naming of specific stereoisomers is for exemplification, and is not intended to limit in anyway the scope of the invention. The invention includes the following examples in pure stereoisomeric form or as racemic mixtures.
    • EXAMPLE 1 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-bromo-1H-pyrazole-1-carboxamide hydrochloride
  • Figure US20060116395A1-20060601-C00052
  • A solution of 4-bromopyrazole (0.52 g, 3.5 mmol) in 30 mL EtOAc is added to excess phosgene (10 mL, 20% solution in toluene) in EtOAc. After complete addition, the solution is refluxed for 1 h, cooled and concentrated in vacuo. EtOAc is added, and the mixture is concentrated again. The residue is treated with 20 mL THF, (R)-(+)-3-aminoquinuclidine dihydrochloride (0.71 g, 3.5 mmol) and excess TEA (5.0 mL, 68.1 mmol). After 60 h, 1N NaOH solution is added. The mixture is extracted with CHCl3, dried (MgSO4), filtered and concentrated. The residue is purified by flash chromatography (Biotage 40S, 90:9:1 CHCl3/MeOH/NH4OH). The hydrochloride salt is prepared and recrystallized from MeOH/EtOAc to afford 289 mg (25%) of a white solid. HRMS (FAB) calcd for C11H15BrN4O+H 299.0508, found 299.0516.
    • EXAMPLE 2 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-iodo-1H-pyrazole-1-carboxamide hydrochloride
  • Figure US20060116395A1-20060601-C00053
  • Phenyl chloroformate (0.75 mL, 6.0 mmol) is added dropwise to a solution of 4-iodopyrazole (1.05 g, 5.4 mmol) and triethylamine (0.9 mL, 6.5 mmol) in 15 mL CH2Cl2. The reaction is stirred at RT. After 60 h, water is added. The mixture is extracted with CH2Cl2, dried (MgSO4), filtered and concentrated. Hexane is added and the solvent is removed in vacuo. A white solid forms on standing to provide 1.6 g (95%) of phenyl 4-iodo-1H-pyrazole-1-carboxylate. MS (EI) m/z 315.1 (M+).
  • Phenyl 4-iodo-1H-pyrazole-1-carboxylate (1.6 g, 5.2 mmol) and (R)-(+)-3-aminoquinuclidine dihydrochloride (1.0 g, 5.2 mmol) are suspended in 10 mL DMF. DIEA (2.7 mL, 15.5 mmol) is added dropwise. After 36 h, the solvent is removed and the residue is taken up in 1N NaOH and CHCl3. The aqueous layer is extracted with CHCl3, dried (MgSO4), filtered and concentrated. The residue is purified by chromatography (Biotage 40S, 90:9:1 CHCl3/MeOH/NH4OH) to provide 1.66 g (93%) of the product as a white solid. A portion of the material is converted into the hydrochloride salt and recrystallized from MeOH/EtOAc. HRMS (FAB) calcd for C11H15IN4O+H 347.0370, found 347.0357.
    • EXAMPLE 3 N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide hydrochloride
  • Figure US20060116395A1-20060601-C00054
  • Hydrazine hydrate (0.55 mL, 11.3 mmol) is added to a suspension of 2-chlorophenylmalondialdehyde dissolved in 20 mL EtOH. The mixture is heated under reflux for 3 min, then allowed to stir at RT overnight. The solvent is removed in vacuo to provide 4-(2-chlorophenyl)-1H-pyrazole as a yellow solid. MS (EI) m/z 177.0 (M−).
  • 4-Nitrophenyl chloroformate (2.3 g, 11.5 mmol) and 4-(2-chlorophenyl)-1H-pyrazole (2.0 g, 11.0 mmol) are dissolved in 30 mL CH2Cl2 and cooled to 0° C. TEA (1.7 mL, 12.0 mmol) is added, and the reaction is allowed to warm to RT. After 30 min, additional 4-nitrophenyl chloroformate (0.25 g) and TEA are added. After 1 h, water is added. The mixture is extracted with CH2Cl2, dried (MgSO4), filtered and concentrated to give a solid. The solid is triturated with hexanes, filtered and dried to provide 1.7 g (45%) of the crude 4-nitrophenyl 4-(2-chlorophenyl)-1H-pyrazole-1-carboxylate.
  • A portion of 4-nitrophenyl 4-(2-chlorophenyl)-1H-pyrazole-1-carboxylate (0.34 g, 1.0 mmol) and (R)-(+)-3-aminoquinuclidine dihydrochloride (0.22 g, 1.1 mmol) are suspended in 5 mL DMF. TEA (0.4 mL, 3.0 mmol) is added dropwise. After 18 h, 1N NaOH is added, and the solvent is removed under reduced pressure. The residue is taken up in 1N NaOH and CHCl3. The aqueous layer is extracted with CHCl3, dried (MgSO4), filtered and concentrated. The residue is purified by chromatography (Biotage 40S, 90:9:1 CHCl3/MeOH/NH4OH). The hydrochloride salt is prepared and recrystallized from MeOH/EtOAc to provide 102 mg (28%) of the product. HRMS (FAB) calcd for C17H19ClN4O+H 331.1325, found 331.1312.
    • EXAMPLE 4 N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]4-iodo-1H-pyrazole-1-carboxamide
  • Figure US20060116395A1-20060601-C00055
  • A solution of 4-iodopyrazole (1.05 g, 5.4 mmol) in 15 mL CH2Cl2 is treated with triethyl amine (0.90 mL, 6.5 mmol) and phenylchloroformate (0.75 ml, 6.0 mmol). The mixture is stirred for 5 h and treated with H2O (1 mL). The aqueous layer is discarded and the organic dried (MgSO4). The mixture is filtered, and evaporated to a yellow oil which solidifies upon evaporation from hexane. A portion of this solid (0.628 g, 2.0 mmol) is added to DMF (10 ml) containing (3R,5R)-1-azabicyclo[3.2.1]octan-3-amine dihydrochloride (0.398 g, 2.0 mmol). Diisopropylethyl amine (1.1 mL, 6.0 mmol) is added and the mixture becomes nearly homogeneous. The mixture is extracted between EtOAc and H2O. The organic layer is washed with H2O (3×), brine, dried (MgSO4), and the mixture is evaporated. The resulting material is taken up in hot EtOAc, filtered through celite, and allowed to stand at RT. The resulting solid is collected and dried to afford Example 4 (0.142 g, 20%) as a white solid: HRMS (ESI) calcd for C11H15N4OI (MH+) 347.0370, found 347.0370. Anal. Calcd for C11H15IN4O: C, 38.17; H, 4.37; N, 16.18. Found: C, 38.43; H, 4.42; N, 16.11.
  • The acids are coupled with the other amines identified herein using the coupling methods described herein to make examples with the acids and corresponding amines.
    • Materials and Methods for Determining α7 nAChR Agonist Activity
  • Cell-Based Assay for Measuring the EC50 of α7 nAChR Agonists
  • Construction and Expression of the α7-5HT3 Receptor
  • The cDNA encoding the N-terminal 201 amino acids from the human α7 nAChR that contain the ligand binding domain of the ion channel was fused to the cDNA encoding the pore forming region of the mouse 5HT3 receptor as described by Eisele J L, et al., Chimaeric nicotinic-serotonergic receptor combines distinct ligand binding and channel specificities, Nature (1993), Dec. 2;366(6454):479-83, and modified by Groppi, et al., WO 00/73431. The chimeric α7-5HT3 ion channel was inserted into pGS175 and pGS179 which contain the resistance genes for G-418 and hygromycin B, respectively. Both plasmids were simultaneously transfected into SH-EP1 cells and cell lines were selected that were resistant to both G-418 and hyrgromycin B. Cell lines expressing the chimeric ion channel were identified by their ability to bind fluorescent α-bungarotoxin on their cell surface. The cells with the highest amount of fluorescent α-bungarotoxin binding were isolated using a Fluorescent Activated Cell Sorter (FACS). Cell lines that stably expressed the chimeric α7-5HT3 were identified by measuring fluorescent α-bungarotoxin binding after growing the cells in minimal essential medium containing nonessential amino acids supplemented with 10% fetal bovine serum, L-glutamine, 100 units/ml penicillin/streptomycin, 250 ng/mg fungizone, 400 μg/ml hygromycin B, and 400 μg/ml G-418 at 37° C. with 6% CO2 in a standard mammalian cell incubator for at least 4 weeks in continuous culture.
  • Assay of the Activity of the Chimeric α7-5HT3 Receptor
  • To assay the activity of the α7-5HT3 ion channel, cells expressing the channel were plated into each well of either a 96 or 384 well dish (Corning #3614) and grown to confluence prior to assay. On the day of the assay, the cells were loaded with a 1:1 mixture of 2 mM Calcium Green 1, AM (Molecular Probes) dissolved in anhydrous DMSO and 20% pluronic F-127 (Molecular Probes). This solution was added directly to the growth media of each well to achieve a final concentration 2 μM. The cells were incubated with the dye for 60 min at 37° C. and then washed with a modified version of Earle's balanced salt solution (MMEBSS) as described in WO 00/73431. The ion conditions of the MMEBSS was adjusted to maximize the flux of calcium ion through the chimeric α7-5HT3 ion channel as described in WO 00/73431. The activity of compounds on the chimeric α7-5HT3 ion channel was analyzed on FLIPR. The instrument was set up with an excitation wavelength of 488 nanometers using 500 milliwatts of power. Fluorescent emission was measured above 525 nanometers with an appropriate F-stop to maintain a maximal signal to noise ratio. Agonist activity of each compound was measured by directly adding the compound to cells expressing the chimeric α7-5HT3 ion channel and measuring the resulting increase in intracellular calcium that is caused by the agonist-induced activation of the chimeric ion channel. The assay is quantitative such that concentration-dependent increase in intracelluar calcium is measured as concentration-dependent change in Calcium Green fluorescence. The effective concentration needed for a compound to cause a 50% maximal increase in intracellular calcium is termed the EC50. The examples of the present invention have EC50 values between 171 nM and 366 nM.
  • Binding Constants:
  • Another way for measuring α7 nAChR agonist activity is to determine binding constants of a potential agonist in a competition binding assay. For α7 nAChR agonists, there is good correlation between functional EC50 values using the chimeric α7-5HT3 ion channel as a drug target and binding affinity of compounds to the endogenous α7 nAChR.
  • Membrane Preparation.
  • Male Sprague-Dawley rats (300-350 g) are sacrificed by decapitation and the brains (whole brain minus cerebellum) are dissected quickly, weighed and homogenized in 9 volumes/g wet weight of ice-cold 0.32 M sucrose using a rotating pestle on setting 50 (10 up and down strokes). The homogenate is centrifuged at 1,000×g for 10 minutes at 4° C. The supernatant is collected and centrifuged at 20,000×g for 20 minutes at 4° C. The resulting pellet is resuspended to a protein concentration of 1-8 mg/mL. Aliquots of 5 mL homogenate are frozen at −80° C. until needed for the assay. On the day of the assay, aliquots are thawed at rt and diluted with Kreb's-20 mM Hepes buffer pH 7.0 (at rt) containing 4.16 mM NaHCO3, 0.44 mM KH2PO4, 127 mM NaCl, 5.36 mM KCl, 1.26 mM CaCl2, and 0.98 mM MgCl2, so that 25-150 μg protein are added per test tube. Proteins are determined by the Bradford method (Bradford, M. M., Anal. Biochem., 72, 248-254, 1976) using bovine serum albumin as the standard.
  • Binding Assay.
  • For saturation studies, 0.4 mL homogenate are added to test tubes containing buffer and various concentrations of radioligand, and are incubated in a final volume of 0.5 mL for 1 hour at 25° C. Nonspecific binding was determined in tissues incubated in parallel in the presence of 0.05 mls MLA for a final concentration of 1 μM, added before the radioligand. In competition studies, drugs are added in increasing concentrations to the test tubes before addition of 0.05 mls [3H]-MLA for a final concentration 3.0 to 4.0 nM. The incubations are terminated by rapid vacuum filtration through Whatman GF/B glass filter paper mounted on a 48 well Brandel cell harvester. Filters are pre-soaked in 50 mM Tris HCl pH 7.0-0.05% polyethylenimine. The filters are rapidly washed two times with 5 mL aliquots of cold 0.9% saline and then counted for radioactivity by liquid scintillation spectrometry.
  • Data Analysis.
  • In competition binding studies, the inhibition constant (Ki) was calculated from the concentration dependent inhibition of [3H]-MLA binding obtained from non-linear regression fitting program according to the Cheng-Prusoff equation (Cheng, Y. C. and Prussoff, W. H., Biochem. Pharmacol., 22, p. 3099-3108, 1973). Hill coefficients were obtained using non-linear regression (GraphPad Prism sigmoidal dose-response with variable slope).

Claims (12)

1. A compound of the Formula I:
Figure US20060116395A1-20060601-C00056
wherein Azabicyclo is
Figure US20060116395A1-20060601-C00057
W is
Figure US20060116395A1-20060601-C00058
wherein W1 is N or CH;
X is O or S;
R0 is H, lower alkyl, substituted lower alkyl, or halogenated lower alkyl;
R1 is H, alkyl, halogenated alkyl, cycloalkyl, substituted phenyl, or substituted naphthyl;
R2 is F, Cl, Br, I, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, or aryl;
k1, k2, k5, k6, and k7 are independently 0, or 1;
k3, and k4 are independently 0, 1, or 2;
Each R3 is independently F, Cl, Br, I, —CN, —NO2, alkyl, halogenated alkyl, substituted alkyl, alkenyl, halogenated alkenyl, substituted alkenyl, alkynyl, halogenated alkynyl, substituted alkynyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocyloalkyl, substituted heterocycloalkyl, lactam heterocyclcoalkyl, aryl, R7, R9, —OR10, —SR10, —SOR10, —SO2R10, —SCN, —S(O)N(R10)2, —S(O)2N(R10)2, —C(O)R10, —C(O)2R10, —C(O)N(R10)2, C(R10)═N—OR10, —NC(O)R7, —NC(O)R8, —NC(O)R9, —N(R10)2, —NR10C(O)R10, —NR10S(O)2R10, or two R3 on adjacent carbon atoms may fuse to form a 6-membered ring to give a 5-6 fused, bicyclic moiety where the 6-membered ring is optionally substituted with 1-3 substitutents selected from R4;
m is 0, 1, or 2;
R4 is alkyl, alkenyl, alkynyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated alkenyl, halogenated alkynyl, halogenated cycloalkyl, halogenated heterocycloalkyl, —OR8, —SR8, —S(O)2R8, —S(O)R8, —OS(O)2R8, —N(R8)2, —C(O)R8, —C(S)R8, —C(O)OR8, —CN, —C(O)N(R8)2, —NR8C(O)R8, —S(O)2N(R8)2, —NR8S(O)2R8, —NO2, —N(R8)C(O)N(R8)2, substituted alkyl, substituted alkenyl, substituted alkynyl, substituted cycloalkyl, substituted heterocycloalkyl, lactam heterocycloalkyl, phenyl, phenyl having 0-4 substituents independently selected from F, Cl, Br, I and R15, naphthyl, naphthyl having 0-4 substituents independently selected from F, Cl, Br, I, or R15, or two R4 on adjacent carbon atoms may combine to form a three-ring-fused-5-6-6 system optionally substituted with up to 3 substituents independently selected from Br, Cl, F, I, —CN, —NO2, —CF3, —N(R8)2, —N(R8)C(O)R8, alkyl, alkenyl, and alkynyl;
Each R5 is independently H, alkyl, or substituted alkyl;
R6 is H, alkyl, an amino protecting group, or an alkyl group having 1-3 substituents selected from F, Cl, Br, I, —OH, —CN, —NH2, —NH(alkyl), or —N(alkyl)2;
R7 is 5-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms independently selected from the group consisting of —O—, ═N—, —N(R14)—, and —S—, and having 0-1 substituent selected from R15, and further having 0-3 substituents independently selected from F, Cl, Br, or I, or R7 is 9-membered fused-ring moieties having a 6-membered ring fused to a 5-membered ring and having the formula
Figure US20060116395A1-20060601-C00059
wherein A1 is O, S, or NR14,
Figure US20060116395A1-20060601-C00060
wherein A is CR17 or N, and each A2 or A3 is independently selected from CR17, O, S, N, or NR14, or
Figure US20060116395A1-20060601-C00061
wherein A is CR17 or N, and each A2 or A3 is independently selected from CR17, O, S, N, or NR14, and, each 9-membered fused-ring moiety having 0-1 substituent selected from R15, and further having 0-3 substituent(s) independently selected from F, Cl, Br, or I, and having a bond directly or indirectly attached to the core molecule where valency allows in either the 6-membered or the 5-membered ring of the fused-ring moiety;
Each R8 is independently H, alkyl, halogenated alkyl, substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, substituted heterocycloalkyl, phenyl, or phenyl substituted with 0-4 independently selected from F, Cl, Br, I, or R15;
R9 is 6-membered heteroaromatic mono-cyclic moieties containing within the ring 1-3 heteroatoms selected from ═N— and having 0-1 substituent selected from R15 and 0-3 substituent(s) independently selected from F, Cl, Br, or I, or R9 is 10-membered heteroaromatic bi-cyclic moieties containing within one or both rings 1-3 heteroatoms selected from ═N—, including, but not limited to, quinolinyl or isoquinolinyl, each 10-membered fused-ring moiety having 0-1 substituent selected from R15, and 0-3 substituent(s) independently selected from F, Cl, Br, or I and having a bond directly or indirectly attached to the core molecule where valency allows;
Each R10 is independently H, alkyl, cycloalkyl, heterocycloalkyl, alkyl substituted with 1 substituent selected from R13, cycloalkyl substituted with 1 substituent selected from R13, heterocycloalkyl substituted with 1 substituent selected from R13, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, phenyl, or substituted phenyl;
Each R11 is independently H, alkyl, cycloalkyl, heterocyclo-alkyl, halogenated alkyl, halogenated cycloalkyl, or halogenated heterocycloalkyl;
R12 is —NO2, —CN, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, substituted alkyl, substituted cycloalkyl, substituted heterocycloalkyl, —OR11, —SR11, —N(R11)2, —C(O)R11, —C(O)N(R11)2, —NR11C(O)R11, —S(O)2N(R11)2, or —NR11S(O)2R11;
R13 is —OR11, —SR11, —N(R11)2, —C(O)R11, —SOR11, —SO2R11, —C(O)N(R11)2, —CN, —CF3, —NR11C(O)R11, —S(O)2N(R11)2, —NR11S(O)2R11, or —NO2;
R14 is independently H, alkyl, halogenated alkyl, limited substituted alkyl, cycloalkyl, halogenated cycloalkyl, substituted cycloalkyl, heterocycloalkyl, halogenated heterocycloalkyl, or substituted heterocycloalkyl;
R15 is alkyl, substituted alkyl, halogenated alkyl, —OR11, —CN, —NO2, —N(R10)2;
R17 is H, alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R18, —OR11, —SR11, —N(R11)2, —NR11S(O)2R11, F, Cl, Br, or I, or a bond directly or indirectly attached to the core molecule, provided that there is only one said bond to the core molecule within the 9-membered fused-ring moiety, further provided that the fused-ring moiety has 0-1 substituent selected from alkyl, cycloalkyl, heterocycloalkyl, halogenated alkyl, halogenated cycloalkyl, halogenated heterocycloalkyl, R18, —OR11, —SR11, —NR11R11, —C(O)R11, —NO2, —C(O)NR11R11, —CN, —NR11C(O)R1, —S(O)2NR11R11, or —NR11S(O)2R11, and further provided that the fused-ring moiety has 0-3 substituent(s) selected from F, Cl, Br, or I;
R18 is alkyl, cycloalkyl, heterocycloalkyl, any of which is substituted with 0-3 substituents independently selected from F, Cl, Br, or I and further substituted with 1 substituent selected from —NO2, —CN, —OR10, —SR10, —NR10R10, —C(O)R10, —C(O)NR10R10, —NR10C(O)R10, —S(O)2NR10R10, —NR10S(O)2R10, phenyl, or phenyl having 1 substituent selected from R15 and further having 0-3 substituents independently selected from F, Cl, Br, or I;
or pharmaceutically acceptable salt, racemic mixture, or pure enantiomer thereof.
2. The compound of claim 1, wherein X is O.
3. The compound of claim 2, wherein R0 is H, lower alkyl, substituted lower alkyl, or halogenated lower alkyl, wherein R1 is H, alkyl, or cycloalkyl, and wherein k1, k2, k3 and k4 are each 0 or 1, provided that when k1, k2, k3 or k4 is 1, each R2 is independently lower alkyl, substituted lower alkyl, or halogenated lower alkyl.
4. The compound of claim 3, wherein m is 0 or 1.
5. The compound of claim 4, wherein Azabicyclo is I, II, III, or IV.
6. The compound of claim 5, where R2 is lower alkyl, provided that k1, k2, k3 or k4 is 1, or kl, k2, k3 and k4 is 0.
7. The compound of claim 6, wherein W1 is N.
8. The compound of claim 7, wherein the compound is
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-chloro-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-bromo-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-iodo-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-methyl-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-cyano-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(methylthio)-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-thien-2-yl-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-thien-3-yl-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-pyridin-2-yl-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-phenyl-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(3-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-chloro-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-bromo-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-iodo-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-methyl-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-cyano-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(methylthio)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-thien-2-yl-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-4-thien-3-yl-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-pyridin-2-yl-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-phenyl-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(3-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-chloro-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-bromo-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-iodo-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-methyl-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-cyano-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(methylthio)-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-thien-2-yl-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-thien-3-yl-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-pyridin-2-yl-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-phenyl-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(3-methoxyphenyl)-H-pyrazole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-chloro-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-bromo-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2. I]hept-3-yl)-4-iodo-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-methyl-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-cyano-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(methylthio)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-thien-2-yl-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-thien-3-yl-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-pyridin-2-yl-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-phenyl-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(3-methoxyphenyl)-1H-pyrazole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-chloro-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-bromo-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-iodo-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-methyl-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-cyano-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(methylthio)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-thien-2-yl-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-thien-3-yl-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-pyridin-2-yl-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-phenyl-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(3-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-chloro-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-bromo-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-iodo-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-methyl-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-cyano-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(methylthio)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-thien-2-yl-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-thien-3-yl-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-pyridin-2-yl-1H-pyrazole-1-carboxamide;
N−1-azabicyclo[3.2.2]non-3-yl-4-pyridin-3-yl-1H-pyrazole-1-carboxamide;
N−1-azabicyclo[3.2.2]non-3-yl-4-phenyl-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(2-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(3-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(4-fluorophenyl)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(3-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(4-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(2-methylphenyl)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(3-methylphenyl)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(4-methylphenyl)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(2-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(3-methoxyphenyl)-1H-pyrazole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-4-(4-methoxyphenyl)-1H-pyrazole-1-carboxamide; or
a pharmaceutically acceptable salt thereof.
9. The compound of claim 8, wherein the compound is
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-bromo-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-iodo-1H-pyrazole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]4-(2-chlorophenyl)-1H-pyrazole-1-carboxamide;
N-[(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl]4-iodo-1H-pyrazole-1-carboxamide; or
pharmaceutically acceptable salt thereof.
10. The compound of claim 6, wherein W1 is CH.
11. The compound of claim 9, wherein the compound is
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-chloro-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-iodo-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(methylthio)-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-thien-2-yl-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-thien-3-yl-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-phenyl-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-chloro-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-iodo-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(methylthio)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-thien-2-yl-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-thien-3-yl-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-phenyl-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-[(2S,3R)-2-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-chloro-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-bromo-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-iodo-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-methyl-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-cyano-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(methylthio)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-thien-2-yl-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-thien-3-yl-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-phenyl-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-[(3R)-6-methyl-1-azabicyclo[2.2.2]oct-3-yl]-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-chloro-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-bromo-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-iodo-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-methyl-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-cyano-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(methylthio)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-thien-2-yl-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-thien-3-yl-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-phenyl-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide;
Exo-4(S)-N-(1-azabicyclo[2.2.1]hept-3-yl)-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-chloro-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-bromo-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-iodo-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-methyl-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-cyano-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(methylthio)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-thien-2-yl-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-thien-3-yl-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-phenyl-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-(3R,5R)-1-azabicyclo[3.2.1]oct-3-yl-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-chloro-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-bromo-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-iodo-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-methyl-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-cyano-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(methylthio)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-thien-2-yl-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-thien-3-yl-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-pyridin-2-yl-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-pyridin-3-yl-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-phenyl-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(2-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(3-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(4-fluorophenyl)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(2-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(3-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(4-chlorophenyl)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(2-methylphenyl)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(3-methylphenyl)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(4-methylphenyl)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(2-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(3-methoxyphenyl)-1H-pyrrole-1-carboxamide;
N-1-azabicyclo[3.2.2]non-3-yl-3-(4-methoxyphenyl)-1H-pyrrole-1-carboxamide; or a pharmaceutically acceptable salt thereof.
12. A pharmaceutical composition comprising a compound of claim 1 and a pharmaceutically acceptable excipient.
US11/329,475 2002-08-01 2006-01-11 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease Abandoned US20060116395A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US11/329,475 US20060116395A1 (en) 2002-08-01 2006-01-11 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US40033902P 2002-08-01 2002-08-01
US10/627,140 US7176198B2 (en) 2002-08-01 2003-07-25 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
US11/329,475 US20060116395A1 (en) 2002-08-01 2006-01-11 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/627,140 Division US7176198B2 (en) 2002-08-01 2003-07-25 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease

Publications (1)

Publication Number Publication Date
US20060116395A1 true US20060116395A1 (en) 2006-06-01

Family

ID=31495812

Family Applications (2)

Application Number Title Priority Date Filing Date
US10/627,140 Expired - Fee Related US7176198B2 (en) 2002-08-01 2003-07-25 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease
US11/329,475 Abandoned US20060116395A1 (en) 2002-08-01 2006-01-11 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease

Family Applications Before (1)

Application Number Title Priority Date Filing Date
US10/627,140 Expired - Fee Related US7176198B2 (en) 2002-08-01 2003-07-25 1H-pyrazole and 1H-pyrrole-azabicyclic compounds for the treatment of disease

Country Status (5)

Country Link
US (2) US7176198B2 (en)
EP (1) EP1542999A1 (en)
JP (1) JP2005537297A (en)
AU (1) AU2003253686A1 (en)
WO (1) WO2004013137A1 (en)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153812A1 (en) * 2006-12-21 2008-06-26 Astrazeneca Ab Novel compounds
US20090318468A1 (en) * 2008-06-19 2009-12-24 Astrazeneca Ab Pyrazole compounds 436
US10183938B2 (en) 2014-12-16 2019-01-22 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors
US10370370B2 (en) 2015-06-10 2019-08-06 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
US10420764B2 (en) 2012-12-21 2019-09-24 Astrazeneca Ab Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10164139A1 (en) 2001-12-27 2003-07-10 Bayer Ag 2-heteroaryl carboxamides
WO2006001894A1 (en) * 2004-04-22 2006-01-05 Memory Pharmaceutical Corporation Indoles, 1h-indazoles, 1,2-benzisoxazoles, 1,2-benzoisothiazoles, and preparation and uses thereof
GB0424564D0 (en) * 2004-11-05 2004-12-08 Novartis Ag Organic compounds
CL2008000119A1 (en) 2007-01-16 2008-05-16 Wyeth Corp COMPOUNDS DERIVED FROM PIRAZOL, ANTAGONISTS OF THE NICOTINIC ACETILCOLINE RECEIVER; PHARMACEUTICAL COMPOSITION; AND USE IN THE TREATMENT OF DISEASES SUCH AS SENILE DEMENTIA, ALZHEIMER AND SCHIZOPHRENIA.
SA08290475B1 (en) 2007-08-02 2013-06-22 Targacept Inc (2S,3R)-N-(2-((3-pyrdinyl)methyl)-1-aza bicyclo[2,2,2]oct-3-yl)benzofuran-2-carboxamide, its new salt forms and methods of use
US8697722B2 (en) * 2007-11-02 2014-04-15 Sri International Nicotinic acetylcholine receptor modulators
TW201031664A (en) 2009-01-26 2010-09-01 Targacept Inc Preparation and therapeutic applications of (2S,3R)-N-2-((3-pyridinyl)methyl)-1-azabicyclo[2.2.2]oct-3-yl)-3,5-difluorobenzamide
CN102905527B (en) 2010-01-11 2016-08-24 阿斯特来亚治疗有限责任公司 Nicotinic acetylcholine receptor modulators
SMT201700549T1 (en) 2010-05-17 2018-03-08 Forum Pharmaceuticals Inc Pharmaceutical formulations comprising crystalline forms of (r)-7-chloro-n-(quinuclidin-3-yl)benzo(b)thiophene-2-carboxamide hydrochloride monohydrate
BR112013000925A2 (en) * 2010-07-15 2020-12-01 Bayer Intellectual Property Gmbh heterocyclic compounds as pesticides
KR101928505B1 (en) * 2011-01-28 2018-12-12 에스케이바이오팜 주식회사 Pharmaceutical composition comprising pyridone derivatives
EP3666272A1 (en) 2012-05-08 2020-06-17 Forum Pharmaceuticals Inc. Use of encenicline in the treatment of cognitive impairment, alzheimer's disease, memory deficit
WO2014069554A1 (en) * 2012-10-31 2014-05-08 東レ株式会社 Quinuclidine amide derivative and medicinal use of same
KR20250005197A (en) * 2022-05-05 2025-01-09 필립모리스 프로덕츠 에스.에이. Nicotinic acetylcholine receptor ligand

Family Cites Families (50)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3702324A (en) 1970-06-24 1972-11-07 Stanford Research Inst 3,4,5-trimethoxybenzamides of substituted anilines and of alkylpiperidines
FR2531083B1 (en) 1982-06-29 1986-11-28 Sandoz Sa NOVEL PIPERIDINE DERIVATIVES, THEIR PREPARATION AND THEIR USE AS MEDICINES
FR2529548A1 (en) 1982-07-02 1984-01-06 Delalande Sa NOVEL DERIVATIVES OF AMINO-3 QUINUCLIDINE, THEIR PROCESS AND THEIR THERAPEUTIC APPLICATION
JPS5936675A (en) 1982-07-13 1984-02-28 サンド・アクチエンゲゼルシヤフト Cyclic carboxylic acid piperidyl ester and amide derivative
US5175173A (en) 1983-12-22 1992-12-29 Sun Jung Hui Carboxamides useful as antiemetic or antipsychotic agents
US4605652A (en) 1985-02-04 1986-08-12 A. H. Robins Company, Inc. Method of enhancing memory or correcting memory deficiency with arylamido (and arylthioamido)-azabicycloalkanes
DE3688296T2 (en) 1985-03-14 1993-11-04 Beecham Group Plc MEDICINES FOR TREATING EMERGENCY.
GB8520616D0 (en) 1985-08-16 1985-09-25 Beecham Group Plc Compounds
EP0247266B1 (en) 1986-01-07 1993-03-10 Beecham Group Plc Indole derivatives having an azabicyclic side chain, process for their preparation, intermediates, and pharmaceutical compositions
DE3782107T2 (en) 1986-07-25 1993-04-01 Beecham Group Plc AZABICYCLIC COMPOUNDS, METHOD FOR THEIR PRODUCTION AND THEIR PHARMACEUTICAL USE.
HU202108B (en) 1986-07-30 1991-02-28 Sandoz Ag Process for producing pharmaceutical compositions containing serotonine antqgonistic derivatives of indol-carboxylic acid or imidazolyl-methyl-carbazol
US5237066A (en) 1987-02-04 1993-08-17 Delande S.A. Enantiomers of absolute configuration S of amide derivatives of 3-aminoquinuclidine, the process for preparing them and their application in therapy
US4835162A (en) 1987-02-12 1989-05-30 Abood Leo G Agonists and antagonists to nicotine as smoking deterents
DE3822792C2 (en) 1987-07-11 1997-11-27 Sandoz Ag New use of 5HT¶3¶ antagonists
US5364863A (en) 1987-09-08 1994-11-15 Eli Lilly And Company Specific 5-HT3 antagonists
US4921982A (en) 1988-07-21 1990-05-01 Eli Lilly And Company 5-halo-2,3-dihydro-2,2-dimethylbenzofuran-7-carboxylic acids useful as intermediates for 5-HT3 antagonists
US5206246A (en) 1987-10-16 1993-04-27 A. H. Robins Company, Incorporated Anxiolytic-R-n(1-azabicyclo[2.2.2]oct-3-yl) benzamides and thiobenzamides
IE63474B1 (en) 1987-12-24 1995-04-19 Wyeth John & Brother Ltd Heterocyclic compounds
FR2625678B1 (en) 1988-01-13 1991-06-07 Delalande Sa ANOREXIGENAL AGENTS BASED ON N- (QUINUCLIDIN-3-YL) -BENZAMIDES OR THIOBENZAMIDES
US4863919A (en) 1988-02-01 1989-09-05 A. H. Robins Company, Incorporated Method of enhancing memory or correcting memory deficiency with arylamido(and arylthiomido)-azabicycloalkanes
DE3810552A1 (en) 1988-03-29 1989-10-19 Sandoz Ag Esters and amides of indole-, benzo[b]thiophene or benzo[b]furancarboxylic acids or 4-amino-2-methoxybenzoic acids with N-heterocyclic or N-heterobicyclic alcohols or amines, processes for their preparation, pharmaceutical compositions containing them and applicator for administration thereof
US5246942A (en) 1988-04-27 1993-09-21 Rhone-Poulenc Rorer Pharmaceuticals Inc. Pharmaceutically useful dibenzofurancarboxamides of specific stereo-configuration
ATE85217T1 (en) 1988-08-04 1993-02-15 Synthelabo ANTI-SCHIZOPHRENIC S-N-(1-AZABICYCLO (2.2.2.>OCT-3-YL)BENZAMIDES AND THIOBENZAMIDES.
EP0353371A1 (en) 1988-08-04 1990-02-07 Synthelabo Memory enhancing-R-N-(1-azabicyclo[2.2.2] oct-3-yl) benzamides and thiobenzamides
IT1228288B (en) 1989-01-09 1991-06-07 Zambon Spa COMPOUNDS WITH ANTI-SEROTONIN ACTIVITY
WO1990014347A1 (en) 1989-05-24 1990-11-29 Nippon Shinyaku Co., Ltd. Indole derivatives and medicine
EP0402056A3 (en) 1989-06-06 1991-09-04 Beecham Group p.l.c. Azabicyclic compounds, process for their preparation and pharmaceutical compositions containing them
EP0436245A1 (en) 1989-12-27 1991-07-10 Duphar International Research B.V Substituted 3,4-annelated benzimidazol-2(1H)-ones
US5057519A (en) 1990-06-11 1991-10-15 Bristol-Myers Squibb Company 5-HT3 antagonists: use in reducing opiate tolerance
DE69111816D1 (en) 1990-08-31 1995-09-07 Nippon Shinyaku Co Ltd INDOLEDERIVATIVES AND THEIR USE AS A SEROTONIN ANTAGONISTE.
US5070095A (en) 1990-12-12 1991-12-03 A. H. Robins Company, Incorporated Substituted 4-(amidino)benzamides of 1-azabicyclo[2.2.2]octan-3- and -4-amine as gastric prokinetic, antiemetic, and anxiolytic agents
GB9027487D0 (en) 1990-12-19 1991-02-06 Beecham Group Plc Pharmaceuticals
JPH04247081A (en) 1991-02-01 1992-09-03 Takeda Chem Ind Ltd 5-membered heterocyclic acid amide
AU1752792A (en) 1991-03-08 1992-10-06 Rhone-Poulenc Rorer International (Holdings) Inc. Multicyclic tertiary amine polyaromatic squalene synthetase inhibitors
DE4115215A1 (en) 1991-05-10 1992-11-12 Merck Patent Gmbh INDOLDER DERIVATIVES
US5273972A (en) 1992-03-26 1993-12-28 A. H. Robins Company, Incorporated [(2-diakylaminomethyl)-3-quinuclidinyl]-benzamides and benzoates
US5236931A (en) 1992-03-26 1993-08-17 A. H. Robins Company, Incorporated 2-substituted benzamide and benzoate derivatives of 3-aminoquinuclidine and 3-quinuclidinol
FR2692575B1 (en) 1992-06-23 1995-06-30 Sanofi Elf NOVEL PYRAZOLE DERIVATIVES, PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM.
US5977144A (en) 1992-08-31 1999-11-02 University Of Florida Methods of use and compositions for benzylidene- and cinnamylidene-anabaseines
ES2229216T3 (en) 1993-03-08 2005-04-16 MERCK & CO., INC. COMPOSITIONS OF HUMAN NEURAL NICOTINIC RECEPTORS OF ACETILCOLINE AND PROCEDURES THAT USE THE SAME.
US5510478A (en) 1994-11-30 1996-04-23 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
US5712270A (en) 1995-11-06 1998-01-27 American Home Products Corporation 2-arylamidothiazole derivatives with CNS activity
SE9600683D0 (en) 1996-02-23 1996-02-23 Astra Ab Azabicyclic esters of carbamic acids useful in therapy
NZ500643A (en) 1997-05-30 2001-12-21 Neurosearch As Spiro-quinuclidine derivatives and their use in treating conditions responsive to nicotinic ACh receptor modulators
JP2003501022A (en) 1999-05-27 2003-01-14 ファルマシア・アンド・アップジョン・カンパニー Method for measuring ion channel conductance and composition thereof
SE9904176D0 (en) 1999-11-18 1999-11-18 Astra Ab New use
SE0000540D0 (en) 2000-02-18 2000-02-18 Astrazeneca Ab New compounds
US6500840B2 (en) * 2000-08-21 2002-12-31 Pharmacia & Upjohn Company Quinuclidine-substituted heteroaryl moieties for treatment of disease
CZ2004408A3 (en) * 2001-10-02 2005-03-16 Pharmacia & Upjohn Company Azabicyclic substituted condensed heteroaryl compounds
EP1442041A1 (en) * 2001-11-08 2004-08-04 PHARMACIA & UPJOHN COMPANY Azabicyclic-substituted-heteroaryl compounds for the treatment of disease

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20080153812A1 (en) * 2006-12-21 2008-06-26 Astrazeneca Ab Novel compounds
US7737149B2 (en) 2006-12-21 2010-06-15 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-yl]-4-(3,5-dimethylpiperazin-1-yl)benzamide and salts thereof
US20100273811A1 (en) * 2006-12-21 2010-10-28 Astrazeneca Ab N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and Salts Thereof
US8129391B2 (en) 2006-12-21 2012-03-06 Astrazeneca Ab N-[5-[2-(3,5-Dimethoxyphenyl)ethyl]-1H-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof
US8604022B2 (en) 2006-12-21 2013-12-10 Astrazeneca Ab N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-1h-pyrazol-3-yl]-4-(3,4-dimethylpiperazin-1-yl)benzamide and salts thereof
US9688640B2 (en) 2006-12-21 2017-06-27 Astrazeneca Ab Methods of treating cancer with a pyrazole derivative
US10301267B2 (en) 2006-12-21 2019-05-28 Astrazeneca Ab Compounds
US20090318468A1 (en) * 2008-06-19 2009-12-24 Astrazeneca Ab Pyrazole compounds 436
US10420764B2 (en) 2012-12-21 2019-09-24 Astrazeneca Ab Pharmaceutical formulation of N-[5-[2-(3,5-dimethoxyphenyl)ethyl]-2H-pyrazol-3-YL]-4-[(3R,5S)-3 ,5-dimethylpiperazin-1-YL] benzamide
US10183938B2 (en) 2014-12-16 2019-01-22 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of α-7 nicotonic acetylcholine receptors
US10370370B2 (en) 2015-06-10 2019-08-06 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors

Also Published As

Publication number Publication date
JP2005537297A (en) 2005-12-08
US20040087616A1 (en) 2004-05-06
US7176198B2 (en) 2007-02-13
AU2003253686A1 (en) 2004-02-23
EP1542999A1 (en) 2005-06-22
WO2004013137A1 (en) 2004-02-12

Similar Documents

Publication Publication Date Title
US20060116395A1 (en) 1H-pyrazole and 1h-pyrole-azabicyclic compounds for the treatment of disease
US7001900B2 (en) Azabicyclic compounds for the treatment of disease
US6858613B2 (en) Fused bicyclic-N-bridged-heteroaromatic carboxamides for the treatment of disease
US6919359B2 (en) Azabicyclic-substituted-heteroaryl compounds for the treatment of disease
US6894042B2 (en) Azabicyclic compounds for the treatment of disease
US6492386B2 (en) Quinuclidine-substituted aryl compounds for treatment of disease
US6951868B2 (en) Azabicyclic-phenyl-fused-heterocyclic compounds for treatment of disease
US6849620B2 (en) N-(azabicyclo moieties)-substituted hetero-bicyclic aromatic compounds for the treatment of disease
US20040147522A1 (en) Compounds having both alpha7 nicotinic agonist activity and 5HT3 antagonist activity for the treatment of CNS diseases
WO2003037896A1 (en) N-azabicyclo-substituted hetero-bicyclic carboxamides as nachr agonists
US6852716B2 (en) Substituted-aryl compounds for treatment of disease
US20030069296A1 (en) Substituted-aryl 7-aza[2.2.1]bicycloheptanes for the treatment of disease

Legal Events

Date Code Title Description
STCB Information on status: application discontinuation

Free format text: ABANDONED -- FAILURE TO RESPOND TO AN OFFICE ACTION

点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载